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Duchenne  muscular  dystrophy  (DMD)  is  a  severe  hereditary  disorder  caused  by  
a  loss  of  dystrophin,  an  essential  musculoskeletal  protein.  Decades  of  promising  
research  have  yielded  only  modest  gains  in  survival  and  quality  of  life  for  these  patients  
and  there  have  been  no  approved  gene  therapies  for  DMD  to  date.  There  are  two  
significant  hurdles  to  creating  effective  gene  therapies  for  DMD;  it  is  difficult  to  deliver  a  
replacement  dystrophin  gene  due  to  its  large  size  and  current  strategies  to  restore  the  
native  dystrophin  gene  likely  require  life-­‐‑long  administration  of  a  gene-­‐‑modifying  drug.  
This  thesis  presents  a  novel  method  to  address  these  challenges  through  restoring  
dystrophin  expression  by  genetically  correcting  the  native  dystrophin  gene  using  
engineered  nucleases  that  target  one  or  more  exons  in  a  mutational  hotspot  in  exons  45-­‐‑
55  of  the  dystrophin  gene.  Importantly,  this  hotspot  mutational  region  collectively  
represents  approximately  62%  of  all  DMD  mutations.  In  this  work,  we  utilize  various  
engineered  nuclease  platforms  to  create  genetic  modifications  that  can  correct  a  variety  
of  DMD  patient  mutations.  
Initially,  we  demonstrate  that  genome  editing  can  efficiently  correct  the  
dystrophin  reading  frame  and  restore  protein  expression  by  introducing  micro-­‐‑
frameshifts  in  exon  51,  which  is  adjacent  to  a  hotspot  mutational  region  in  the  
dystrophin  gene.  Transcription  activator-­‐‑like  effector  nucleases  (TALENs)  were  
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engineered  to  mediate  highly  efficient  gene  editing  after  introducing  a  single  TALEN  
pair  targeted  to  exon  51  of  the  dystrophin  gene.  This  led  to  restoration  of  dystrophin  
protein  expression  in  cells  from  DMD  patients,  including  skeletal  myoblasts  and  dermal  
fibroblasts  that  were  reprogrammed  to  the  myogenic  lineage  by  MyoD.  We  show  that  
our  engineered  TALENs  have  minimal  cytotoxicity  and  exome  sequencing  of  cells  with  
targeted  modifications  of  the  dystrophin  locus  showed  no  TALEN-­‐‑mediated  off-­‐‑target  
changes  to  the  protein  coding  regions  of  the  genome,  as  predicted  by  in  silico  target  site  
analysis.    
In  an  alternative  approach,  we  capitalized  on  the  recent  advances  in  genome  
editing  to  generate  permanent  exclusion  of  exons  by  using  zinc-­‐‑finger  nucleases  (ZFNs)  
to  selectively  remove  sequences  important  in  specific  exon  recognition.  This  strategy  has  
the  advantage  of  creating  predictable  frame  restoration  and  protein  expression,  although  
it  relies  on  simultaneous  nuclease  activity  to  generate  genomic  deletions.  ZFNs  were  
designed  to  remove  essential  splicing  sequences  in  exon  51  of  the  dystrophin  gene  and  
thereby  exclude  exon  51  from  the  resulting  dystrophin  transcript,  a  method  that  can  
potentially  restore  the  dystrophin  reading  frame  in  up  to  13%  of  DMD  patients.  
Nucleases  were  assembled  by  extended  modular  assembly  and  context-­‐‑dependent  
assembly  methods  and  screened  for  activity  in  human  cells.  Selected  ZFNs  had  
moderate  observable  cytotoxicity  and  one  ZFN  showed  off-­‐‑target  activity  at  two  
chromosomal  loci.  Two  active  ZFN  pairs  flanking  the  exon  51  splice  acceptor  site  were  
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transfected  into  DMD  patient  cells  and  a  clonal  population  was  isolated  with  this  region  
deleted  from  the  genome.  Deletion  of  the  genomic  sequence  containing  the  splice  
acceptor  resulted  in  the  loss  of  exon  51  from  the  dystrophin  mRNA  transcript  and  
restoration  of  dystrophin  expression  in  vitro.  Furthermore,  transplantation  of  corrected  
cells  into  the  hind  limb  of  immunodeficient  mice  resulted  in  efficient  human  dystrophin  
expression  localized  to  the  sarcolemma.    
Finally,  we  exploited  the  increased  versatility,  efficiency,  and  multiplexing  
capabilities  of  the  CRISPR/Cas9  system  to  enable  a  variety  of  otherwise  challenging  gene  
correction  strategies  for  DMD.  Single  or  multiplexed  sgRNAs  were  designed  to  restore  
the  dystrophin  reading  frame  by  targeting  the  mutational  hotspot  at  exons  45-­‐‑55  and  
introducing  either  intraexonic  small  insertions  and  deletions,  or  large  deletions  of  one  or  
more  exons.  Significantly,  we  generated  a  large  deletion  of  336  kb  across  the  entire  exon  
45-­‐‑55  region  that  is  applicable  to  correction  of  approximately  62%  of  DMD  patient  
mutations.  We  show  that,  for  selected  sgRNAs,  CRISPR/Cas9  gene  editing  displays  
minimal  cytotoxicity  and  limited  aberrant  mutagenesis  at  off-­‐‑target  chromosomal  loci.  
Following  treatment  with  Cas9  nuclease  and  one  or  more  sgRNAs,  dystrophin  
expression  was  restored  in  Duchenne  patient  muscle  cells  in  vitro.  Human  dystrophin  
was  detected  in  vivo  following  transplantation  of  genetically  corrected  patient  cells  into  
immunodeficient  mice.    
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In  summary,  the  objective  of  this  work  was  to  develop  methods  to  genetically  
correct  the  native  dystrophin  as  a  potential  therapy  for  DMD.  These  studies  integrate  the  
rapid  advances  in  gene  editing  technologies  to  create  targeted  frameshifts  that  restore  
the  dystrophin  gene  around  patient  mutations  in  non-­‐‑essential  coding  regions.  
Collectively,  this  thesis  presents  several  gene  editing  methods  that  can  correct  patient  
mutations  by  modification  of  specific  exons  or  by  deletion  of  one  or  more  exons  that  
results  in  restoration  of  the  dystrophin  reading  frame.  Importantly,  the  gene  correction  
methods  described  here  are  compatible  with  leading  cell-­‐‑based  therapies  and  in  vivo  
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NHEJ  DNA  repair  in  exon  51  using  the  CR3  sgRNA.  (c)  Schematic  of  multiplex  sgRNA  
targets  designed  to  delete  exon  51  and  restore  the  dystrophin  reading  frame  in  a  patient  
mutation  with  the  deletion  of  exons  48-­‐‑50.  (d)  Schematic  of  multiplex  sgRNA  targets  
designed  to  delete  the  entire  exon  45-­‐‑55  region  to  address  a  variety  of  DMD  patient  
mutations.  ...................................................................................................................................  100	  
Figure  19:  Fluorescence-­‐‑activated  flow  sorting  to  enrich  genetically  modified  DMD  
myoblasts.  (a)  A  plasmid  expressing  a  human-­‐‑codon  optimized  SpCas9  protein  linked  to  
a  GFP  marker  using  a  T2A  ribosomal  skipping  peptide  sequence  was  co-­‐‑electroporated  
into  human  DMD  myoblasts  with  one  or  two  plasmids  carrying  sgRNA  expression  
cassettes.  (b)  The  indicated  sgRNA  expression  cassettes  were  independently  co-­‐‑
transfected  into  HEK293Ts  with  a  separate  plasmid  expressing  SpCas9  with  (bottom)  or  
without  (top)  a  GFP  marker  linked  to  SpCas9  by  a  T2A  ribosomal  skipping  peptide  
sequence.  Gene  modification  frequencies  were  assessed  at  3  days  post-­‐‑transfection  by  
the  Surveyor  assay.  (c)  DMD  myoblasts  with  deletions  of  exons  48-­‐‑50  in  the  dystrophin  
gene  were  treated  with  sgRNAs  that  correct  the  dystrophin  reading  frame  in  these  
patient  cells.  Gene  modification  was  assessed  at  20  days  post-­‐‑electroporation  in  unsorted  
(bulk)  or  GFP+  sorted  cells.  (d)  GFP  expression  in  DMD  myoblasts  3  days  after  
electroporation  with  indicated  expression  plasmids.  Transfection  efficiencies  and  sorted  
cell  populations  are  indicated  by  the  gated  region.  .............................................................  104	  
Figure  20:  Targeted  frameshifts  to  restore  the  dystrophin  reading  frame  using  
CRISPR/Cas9.  (a)  The  5’  region  of  exon  51  was  targeted  using  a  sgRNA,  CR3,  that  binds  
immediately  upstream  of  the  first  out-­‐‑of-­‐‑frame  stop  codon.  PAM:  protospacer-­‐‑adjacent  
motif.  (b)  The  exon  51  locus  was  PCR  amplified  from  HEK293T  cells  treated  with  SpCas9  
and  CR3  expression  cassettes.  Sequences  of  individual  clones  were  determined  by  
Sanger  sequencing.  The  top  sequence  (bolded,  exon  in  red)  is  the  native,  unmodified  
sequence.  The  number  of  clones  for  each  sequence  is  indicated  in  parentheses.  (c)  
Summary  of  total  gene  editing  efficiency  and  reading  frame  conversions  resulting  from  
gene  modification  shown  in  (b).  (d)  Western  blot  for  dystrophin  expression  in  human  
DMD  myoblasts  treated  with  SpCas9  and  the  CR3  sgRNA  expression  cassette  (Figure  
19c)  to  create  targeted  frameshifts  to  restore  the  dystrophin  reading  frame.  Dystrophin  
expression  was  probed  using  an  antibody  against  the  rod-­‐‑domain  of  the  dystrophin  
protein  after  6  days  of  differentation.  ....................................................................................  106	  
Figure  21: Deletion  of  exon  51  from  the  human  genome  using  multiplex  CRISPR/Cas9  
gene  editing.  (a)  End-­‐‑point  genomic  PCR  across  the  exon  51  locus  in  human  DMD  
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myoblasts  with  a  deletion  of  exons  48-­‐‑50.  The  top  arrow  indicates  the  expected  position  
of  full-­‐‑length  PCR  amplicons  and  the  two  lower  arrows  indicate  the  expected  position  of  
PCR  amplicons  with  deletions  caused  by  the  indicated  sgRNA  combinations.  (b)  PCR  
products  from  (a)  were  cloned  and  individual  clones  were  sequenced  to  determine  
insertions  and  deletions  present  at  the  targeted  locus.  The  top  row  shows  the  wild-­‐‑type  
unmodified  sequence  and  the  triangles  indicate  SpCas9  cleavage  sites.  At  the  right  are  
representative  chromatograms  showing  the  sequences  of  the  expected  deletion  
junctions.  (c)  End-­‐‑point  RT-­‐‑PCR  analysis  of  dystrophin  mRNA  transcripts  in  
CRISPR/Cas9-­‐‑modified  human  Δ48-­‐‑50  DMD  myoblasts  treated  with  the  indicated  
sgRNAs.  A  representative  chromatogram  of  the  expected  deletion  PCR  product  is  
shown  at  the  right.  Asterisk:  band  resulting  from  hybridization  of  the  deletion  product  
strand  to  the  unmodified  strand.  (d)  Rescue  of  dystrophin  protein  expression  by  
CRISPR/Cas9  genome  editing  was  assessed  by  western  blot  for  the  dystrophin  protein  
with  GAPDH  as  a  loading  control.  The  arrow  indicates  the  expected  restored  dystrophin  
protein  band.  ..............................................................................................................................  108	  
Figure  22:  Deletion  of  the  entire  exon  45-­‐‑55  region  in  human  DMD  myoblasts  by  
multiplex  CRISPR/Cas9  gene  editing.  (a)  End-­‐‑point  genomic  PCR  of  genomic  DNA  to  
detect  deletion  of  the  region  between  intron  44  and  intron  55  after  treating  HEK293Ts  or  
DMD  myoblasts  with  the  indicated  sgRNAs.  (b)  Individual  clones  of  PCR  products  of  
the  expected  size  for  the  deletions  from  DMD  myoblasts  in  (a)  were  analyzed  by  Sanger  
sequencing  to  determine  the  sequences  of  genomic  deletions  present  at  the  targeted  
locus.  Below  is  a  representative  chromatograms  showing  the  sequence  of  the  expected  
deletion  junctions.  (c)  End-­‐‑point  RT-­‐‑PCR  analysis  of  dystrophin  mRNA  transcripts  in  
CRISPR/Cas9-­‐‑modified  human  Δ48-­‐‑50  DMD  myoblasts  treated  with  the  indicated  
sgRNAs.  A  representative  chromatogram  of  the  expected  deletion  PCR  product  is  
shown  at  the  right.  (d)  Analysis  of  restored  dystrophin  protein  expression  by  western  
blot  following  electroporation  of  DMD  myoblasts  with  sgRNAs  targeted  to  intron  44  
and/or  intron  55.  ........................................................................................................................  110	  
Figure  23:  Verification  of  flow  cytometry-­‐‑based  enrichment  of  gene-­‐‑modified  DMD  
myoblasts  used  for  in  vivo  cell  transplantation  experiment.  DMD  myoblasts  were  treated  
with  Cas9  with  or  without  sgRNA  expression  vectors  for  CR1  and  CR5  and  sorted  for  
GFP+  cells  by  flow  cytometry.  Deletions  at  the  exon  51  locus  were  detected  by  end-­‐‑point  
PCR  using  primers  flanking  the  locus.  Neg  ctrl:  DMD  myoblasts  treated  with  Cas9  only  
and  sorted  for  GFP+  cells.  ........................................................................................................  112	  
Figure  24:  Expression  of  restored  human  dystrophin  in  vivo  following  transplantation  of  
CRISPR/Cas9-­‐‑treated  human  DMD  myoblasts  into  immunodeficient  mice.  Human  Δ48-­‐‑
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50  DMD  myoblasts  were  treated  with  SpCas9,  CR1,  and  CR5  to  delete  exon  51  and  
sorted  for  GFP  expression  as  shown  in  Figure  19.  These  sorted  cells  and  untreated  
control  cells  were  injected  into  the  hind  limbs  of  immunodeficient  mice  and  assessed  for  
human-­‐‑specific  protein  expression  in  muscle  fibers  after  4  weeks  post-­‐‑transplantation.  
Cryosections  were  stained  with  anti-­‐‑human  spectrin,  which  is  expressed  by  both  
uncorrected  and  corrected  myoblasts  that  have  fused  into  mouse  myofibers,  or  anti-­‐‑
human  dystrophin  antibodies  as  indicated.  White  arrows  indicate  muscle  fibers  positive  
for  human  dystrophin.  .............................................................................................................  113	  
Figure  25: Additional  immunofluorescence  images  probing  human  dystrophin  
expression.  Serial  sections  from  regions  stained  with  anti-­‐‑human  spectrin  are  shown  
inset  in  top  left.  (a-­‐‑c)  Sections  from  muscles  injected  with  untreated  human  DMD  
myoblasts.  (d-­‐‑f)  Sections  from  muscles  injected  with  CR1/5  treated  human  DMD  
myoblasts  enriched  by  flow  cytometry.  White  arrows  indicate  dystrophin  positive  fibers.
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Figure  26: Evaluation  of  CRISPR/Cas9  toxicity  and  off-­‐‑target  effects  for  CR1/CR5-­‐‑
mediated  deletion  of  exon  51  in  human  cells.  (a)  Results  of  a  cytotoxicity  assay  in  
HEK293T  cells  treated  with  human-­‐‑optimized  SpCas9  and  the  indicated  sgRNA  
constructs.  Cytotoxicity  is  based  on  survival  of  GFP-­‐‑positive  cells  that  are  co-­‐‑transfected  
with  the  indicated  nuclease.  I-­‐‑SceI  is  a  well-­‐‑characterized  non-­‐‑toxic  meganuclease  and  
GZF3  is  a  known  toxic  zinc  finger  nuclease.  (b)  Surveyor  analysis  at  off-­‐‑target  sites  in  
sorted  hDMD  cells  treated  with  expression  cassettes  encoding  Cas9  the  indicated  
sgRNAs.  These  three  off-­‐‑target  sites  tested  in  hDMD  cells  were  identified  from  a  panel  
of  50  predicted  sites  tested  in  HEK293T  cells  (Table  4).  TGT:  on-­‐‑target  locus  for  indicated  
sgRNA.  OT:off-­‐‑target  locus.  (c,  d)  End-­‐‑point  nested  PCR  to  detect  chromosomal  
translocations  in  (c)  HEK293T  cells  treated  with  Cas9  and  CR1  or  (d)  sorted  hDMD  cells  
treated  with  Cas9,  CR1,  and  CR5.  The  schematic  depicts  the  relative  location  of  nested  
primer  pairs  customized  for  each  translocation  event.  The  expected  size  of  each  band  
was  estimated  based  on  the  primer  size  and  the  location  of  the  predicted  sgRNA  cut  site  
at  each  locus.  Asterisks  indicate  bands  detected  at  the  expected  size.  The  identities  of  the  
bands  in  (c)  were  verified  by  Sanger  sequencing  from  each  end  (Figure  29).  A  
representative  chromatogram  for  the  P2/P5  translocation  in  HEK293T  cells  is  shown.   117	  
Figure  27:  End-­‐‑point  nested  PCR  to  detect  chromosomal  translocations  caused  by  
CRISPR/Cas9  off-­‐‑target  activity  for  CR3  and  CR6/CR36  in  human  cells.  Nested  end-­‐‑point  
PCR  analysis  was  used  to  detect  translocations  in  (a)  HEK293T  or  sorted  hDMD  cells  
treated  with  Cas9  and  CR3  as  indicated,  (b)  HEK293T  cells  treated  with  Cas9  and  CR36  
alone,  or  (c)  sorted  hDMD  cells  treated  with  Cas9,  CR6,  and  CR36  expression  cassettes.  
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The  second  nested  PCR  reaction  for  translocation  was  amplified  using  custom  primers  
for  each  predicted  translocation  locus  to  maximize  specificity  (See  Appendix  C).  The  
schematic  depicts  the  relative  location  of  nested  primer  pairs  used  to  probe  for  the  
presence  of  translocations.  Each  possible  translocation  event  was  first  amplified  from  
genomic  DNA  isolated  from  cells  treated  with  or  without  the  indicated  sgRNA(s).  A  
second  nested  PCR  reaction  was  performed  using  primers  within  the  predicted  PCR  
amplicons  that  would  result  from  translocations.  Expected  size  was  estimated  based  on  
the  indicated  primer  binding  site  and  the  predicted  sgRNA  cut  site  at  each  locus.  
*indicates  bands  detected  at  the  expected  size  and  verified  by  Sanger  sequencing  from  
each  end.  #indicates  amplicons  in  which  Sanger  sequencing  showed  sequences  other  
than  the  predicted  translocation,  likely  a  result  of  mispriming  during  the  nested  PCR.122	  
Figure  28:  Sanger  sequencing  chromatograms  for  bands  detected  in  Figure  27  resulting  
from  translocations  between  CR3  and  CR3-­‐‑OT1,  on  chromosomes  X  and  1,  respectively,  
in  HEK293T  cells  treated  with  Cas9  and  CR3  gene  cassettes.  Arrows  show  regions  of  
homology  to  the  indicated  chromosome  nearby  the  expected  break  points  caused  by  the  
appropriate  sgRNAs.  Note  that  sequencing  reads  become  out  of  phase  near  the  break  
point  due  to  the  error-­‐‑prone  nature  of  DNA  repair  by  non-­‐‑homologous  end-­‐‑joining.  ..  124	  
Figure  29:  Sanger  sequencing  chromatograms  for  bands  detected  in  Figure  26c  resulting  
from  translocations  between  CR1  and  CR1-­‐‑OT1,  on  chromosomes  X  and  16,  respectively,  
in  HEK293T  cells  treated  with  Cas9  and  CR1  gene  cassettes.  Arrows  show  regions  of  
homology  to  the  indicated  chromosome  nearby  the  expected  break  points  caused  by  the  
appropriate  sgRNAs.  Note  that  sequencing  reads  become  out  of  phase  near  the  break  
point  due  to  the  error-­‐‑prone  nature  of  DNA  repair  by  non-­‐‑homologous  end-­‐‑joining.  ..  126	  
Figure  30:  Surveyor  analysis  of  Rosa26  ZFN  activities  in  skeletal  muscle  in  vitro  and  in  
vivo  following  delivery  of  AAV-­‐‑SASTG-­‐‑ROSA.  Arrows  indicate  expected  bands  
resulting  from  Surveyor  cleavage.  n.d.:  not  detected.  (a)  Proliferating  C2C12s  were  
transduced  with  the  indicated  amount  of  virus  and  harvested  at  4  days  post-­‐‑infection.  
Arrows  indicate  expected  bands  sizes  resulting  from  Surveyor  cleavage.  (b)  C2C12s  
were  incubated  in  differentiation  medium  for  5  days  and  then  transduced  with  the  
indicated  amount  of  AAV-­‐‑SASTG-­‐‑ROSA  virus  in  24  well  plates.  Samples  were  collected  
at  10  days  post-­‐‑transduction.  (c)  The  indicated  amount  of  AAV-­‐‑SASTG-­‐‑ROSA  was  
injected  directly  into  the  tibialis  anterior  of  C57BL/6J  mice  and  muscles  were  harvested  4  
weeks  post-­‐‑infection.  The  harvested  TA  muscles  were  partitioned  into  8  separate  pieces  
for  genomic  DNA  analysis,  each  shown  in  a  separate  lane.  ...............................................  145	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Figure  31:  TALEN  mediated  integration  of  minidystrophin  at  the  5’UTR  of  the  Dp427m  
skeletal  muscle  isoform  of  dystrophin  in  skeletal  myoblast  cell  lines  derived  from  
human  DMD  patients  carrying  different  deletions  in  the  dystrophin  gene.  DMD  patient  
cells  were  electroporated  with  constructs  encoding  a  TALEN  pair  active  at  the  5’UTR  
locus  and  a  donor  template  carrying  the  minidystrophin  gene.  (a)  Schematic  showing  
how  minidystrophin  is  integrated  into  the  5’UTR.  (b)  Hygromycin-­‐‑resistant  clonal  cell  
lines  were  isolated  and  screened  by  PCR  for  successful  site-­‐‑specific  integrations  at  the  
5’UTR  using  the  primers  shown  in  (a).  Asterisks  indicate  clones  selected  for  further  
analysis  in  (c).  (c)  Clonally  isolated  DMD  myoblasts  with  detected  integration  events  
were  differentiated  for  6  days  and  assessed  for  expression  of  an  HA  tag  fused  to  the  C  
terminus  of  minidystrophin.  ...................................................................................................  147	  
Figure  32:  Images  of  TBE-­‐‑PAGE  gels  used  to  quantify  Surveyor  assay  results  to  measure  
day  3  gene  modification  in  Table  3.  Asterisks  mark  expected  sizes  of  bands  indicative  of  
nuclease  activity.  .......................................................................................................................  156	  
Figure  33:  Images  of  TBE-­‐‑PAGE  gels  used  to  quantify  Surveyor  assay  results  to  measure  
day  10  gene  modification  in  Table  3.  Asterisks  mark  expected  sizes  of  bands  indicative  of  
nuclease  activity.  .......................................................................................................................  157	  
Figure  34:  Images  of  TBE-­‐‑PAGE  gels  used  to  quantify  Surveyor  assay  results  to  measure  
on-­‐‑target  and  off-­‐‑target  gene  modification  in  Table  4.  Asterisks  mark  expected  sizes  of  
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Chapter 1. Introduction and Specific Aims 
1.1 Rationale and Objectives 
Duchenne  muscular  dystrophy  (DMD)  is  a  severe  X-­‐‑linked  hereditary  disease  for  
which  no  effective  treatments  exist.  The  molecular  basis  of  DMD  is  a  deleterious  
mutation  in  the  dystrophin  gene,  discovered  over  25  years  ago  [1,  2],  that  leads  to  the  
complete  absence  of  this  essential  skeletal  muscle  protein.  DMD  presents  with  
progressive  muscle  wasting  that  leads  to  death  within  the  third  decade  of  life  due  to  
respiratory  or  heart  failure.  The  current  standard  of  care  for  DMD  is  palliative  and  has  
focused  on  managing  respiratory  and  cardiac  failure  with  steroid  and  ACE  inhibitor  
therapy  [3].  Despite  significantly  increasing  the  life  span  of  these  patients,  most  patients  
do  not  live  beyond  early  adulthood  and  are  increasingly  dying  of  cardiac  complications.  
There  have  been  various  novel  approaches  to  treating  DMD  that  focus  on  transiently  
restoring  the  mutant  dystrophin  gene  [4]  or  replacing  it  using  gene  therapy  to  deliver  a  
functional  dystrophin  gene  [5]  to  muscle  tissue.  However,  significant  challenges  
associated  with  these  strategies  include  insertional  mutagenesis,  the  use  of  synthetic  
promoters,  and  transient  gene  restoration.    
Recent  advances  have  enabled  targeted  genetic  therapies  based  on  engineered  
enzymes  that  exploit  cellular  DNA  repair  pathways  to  create  site-­‐‑specific,  predefined  
genetic  modifications  in  complex  genomes  [6].  These  synthetic  enzymes  are  commonly  
based  on  meganucleases  [7],  zinc  finger  nucleases  (ZFNs)  [6],  transcription  activator-­‐‑like  
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effector  nucleases  (TALENs)  [8,  9],  and  more  recently  the  RNA-­‐‑guided  CRISPR/Cas  
system  [10,  11].  These  nucleases  create  site-­‐‑specific  double-­‐‑strand  breaks  (DSBs)  at  
predefined  sites  to  stimulate  endogenous  DNA  repair  pathways  that  are  used  to  achieve  
desired  genetic  changes.    
The  overall  objective  of  this  thesis  work  is  to  develop  engineered  nucleases  that  
can  specifically  edit  and  correct  the  human  dystrophin  gene.  The  central  hypothesis  is  that  
genetic  correction  of  the  dystrophin  gene  will  restore  the  dystrophin  reading  frame  and  
rescue  dystrophin  expression.  
1.2 Specific Aims 
Aim  1:  Engineer  nucleases  to  introduce  targeted  micro-­‐‑frameshifts  in  exon  51  to  
restore  the  dystrophin  reading  frame.  
TALE  nucleases  were  engineered  to  generate  small  insertions  and  deletions  in  
exon  51  of  the  dystrophin  gene  to  restore  aberrant  dystrophin  reading  frames.  The  
working  hypothesis  was  that  micro-­‐‑frameshifts  in  exon  51  that  corrected  the  dystrophin  
reading  frame  would  result  in  restored  dystrophin  protein  expression.  TALENs  targeted  
to  exon  51  were  delivered  to  cell  lines  from  DMD  patients  with  mutations  correctable  by  
exon  51  modification.  Dystrophin  gene  correction  was  assessed  at  the  genomic  and  
protein  levels  in  vitro.  Nuclease-­‐‑related  toxicity  was  monitored  by  measuring  
cytotoxicity  in  human  cells,  exome  sequencing  of  genetically  modified  cell  populations,  
and  in  silico  prediction  of  potential  off-­‐‑target  sites  in  the  human  genome.  
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Aim  2:  Engineer  nucleases  to  delete  exon  51  from  the  genome  to  restore  the  
dystrophin  reading  frame.  
A  panel  of  zinc-­‐‑finger  nucleases  was  engineered  to  target  genomic  loci  flanking  
exon  51  of  the  dystrophin  gene.  The  working  hypothesis  was  that  co-­‐‑expression  of  two  
nucleases  would  result  in  genetic  deletion  of  essential  exon  51  splicing  sequences,  
resulting  in  the  loss  of  exon  51  from  the  dystrophin  transcript  and  restoration  of  
dystrophin  protein  expression.  Dozens  of  zinc-­‐‑finger  nucleases  were  created  and  
screened  for  activity  against  episomal  and  chromosomal  targets.  Two  selected  ZFN  pairs  
flanking  the  exon  51  splice  acceptor  were  delivered  to  skeletal  myoblasts  from  DMD  
patients  and  a  clonal  population  of  genetically  corrected  cells  was  isolated.  Changes  to  
the  dystrophin  gene  and  mRNA  transcript  were  monitored  in  vitro,  and  restoration  of  
dystrophin  protein  expression  was  assessed  both  in  vitro  and  in  vivo.  Off-­‐‑target  activity  
of  selected  ZFNs  was  assessed  in  human  cells  by  measuring  ZFN-­‐‑specific  cytotoxicity  
and  off-­‐‑target  mutagenesis. 
Aim  3:  Develop  broad  patient-­‐‑specific  and  universal  gene  correction  strategies  to  
correct  the  dystrophin  gene.  
CRISPR/Cas9  gene  correction  can  utilize  single  and  multiplex  gene  editing  to  
introduce  small  insertions  and  deletions  within  exons  or  to  efficiently  delete  targeted  
regions  of  the  dystrophin  gene.  The  working  hypothesis  is  that  targeting  the  dystrophin  
gene  across  the  hotspot  mutational  region  in  exons  45-­‐‑55  will  enable  patient-­‐‑specific  or  
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universal  gene  editing  approaches  that  can  address  up  to  62%  of  DMD  patient  
mutations.  The  S.  pyogenes  CRISPR/Cas9  system  was  utilized  to  introduce  targeted  
micro-­‐‑frameshifts  in  specific  exons  across  exons  45-­‐‑55,  to  delete  the  entire  exon  51  locus,  
or  to  delete  the  entire  region  containing  exons  45-­‐‑55.  Modification  of  the  dystrophin  
gene  was  monitored  at  the  DNA  and  RNA  level  in  vitro,  and  protein  levels  in  vitro  and  
following  in  vivo  transplantation  of  a  bulk  population  of  CRISPR/Cas9  treated  cells.  Off-­‐‑
target  effects  for  selected  CRISPR/Cas9  targets  were  monitored  by  cytotoxicity  assays  
and  direct  interrogation  of  predicted  off-­‐‑target  chromosomal  loci  by  PCR.  
1.3. Significance 
This  approach  builds  on  the  promise  of  genome  editing  heralded  by  the  recent  
entrance  of  ZFNs  into  clinical  trials  for  disruption  of  the  HIV-­‐‑1  co-­‐‑receptor  CCR5  [12,  13]  
and  disruption  of  the  glucocorticoid  receptor  in  T  cells  for  glioblastoma  treatment.  
Importantly,  the  genetic  correction  methods  presented  in  this  thesis  could  be  expanded  
to  a  range  of  diseases  that  are  correctable  by  restoring  disrupted  reading  frames  
introduced  by  intragenic  insertions,  deletions  or  aberrant  stop  codons  in  non-­‐‑essential  
coding  regions,  including  Collagen  type  VII-­‐‑associated  dystrophic  epidermolysis  bullosa  
[14],  Fukuyama  congenital  muscular  dystrophy  [15],  and  Limb-­‐‑girdle  muscular  
dystrophy  type  2B  [15].    
We  propose  that  genome  editing  is  a  promising  method  that  addresses  many  of  
the  present  challenges  for  effective  long-­‐‑term  correction  of  the  genetic  defects  causing  
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DMD.  In  particular,  genome  editing  provides  a  solution  that  is  permanent  and  may  
require  as  little  as  one  treatment  to  achieve  therapeutic  effect.  Moreover,  genome  editing  
strategies  for  DMD  are  compatible  with  existing  cell-­‐‑based  therapies  and  gene  transfer  
modalities  for  skeletal  muscle  gene  therapy,  such  as  adeno-­‐‑associated  virus  gene  
transfer.  This  thesis  analyzes  a  diverse  range  of  gene  editing  platforms  to  implement  
gene  correction  strategies  that  restore  the  reading  frame  within  the  native  dystrophin  
gene  and  presents  genome  editing  as  a  unique  method  to  permanently  address  the  
genetic  basis  of  DMD.    
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Chapter 2. Literature Review 
2.1. Duchenne muscular dystrophy and the dystrophin gene 
Duchenne  muscular  dystrophy  (DMD)  is  a  severe  monogenic  X-­‐‑linked  
hereditary  disease  that  occurs  in  about  1  in  3500  male  births  in  the  United  States  [16].  
The  pathogenesis  of  DMD  manifests  during  the  first  decade  of  life  and  results  in  
progressive  weakness  and  muscle  degeneration  leading  to  death.  Typically,  most  DMD  
patients  die  in  the  third  decade  of  life  due  to  respiratory  and/or  cardiac  complications.  
Dystrophic  muscle  tissue  is  characterized  by  continuous  cycles  of  necrosis  and  
regeneration,  resulting  in  centrally  nucleated  fibers  with  increased  permeability  and  
abnormally  high  adipose  and  fibrotic  tissue  content  [16].  The  causative  agent  of  DMD  is  
a  defect  in  the  gene  encoding  dystrophin,  an  essential  musculoskeletal  protein  that  is  
completely  absent  in  these  patients.  Dystrophin  is  a  large,  rod-­‐‑shaped  protein  with  four  
major  domains:  the  N-­‐‑terminus,  rod-­‐‑domain,  cysteine-­‐‑rich  domain,  and  C-­‐‑terminus  [17].  
The  C-­‐‑terminus  of  dystrophin  associates  with  numerous  other  proteins  to  form  the  
dystrophin  glycoprotein  complex  (DGC),  a  complex  that  acts  as  a  linker  between  the  
cytoskeleton  (via  actin  bound  at  the  N-­‐‑terminus  of  dystrophin)  and  laminin  in  the  
extracellular  matrix  (bound  through  the  DGC).  It  has  been  hypothesized  that  the  DGC,  
and  dystrophin  specifically,  protects  the  sarcolemma  from  excessive  force  during  muscle  
contraction  and  relaxation  [18].  Frame-­‐‑disrupting  or  premature  stop-­‐‑codon  truncations  
of  dystrophin  break  this  mechanical  link.  The  loss  of  this  link  results  in  sarcolemma  
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instability  and  muscle  necrosis  that  eventually  results  in  fibrosis  and  loss  of  muscle  
function  [19].  
The  dystrophin  locus  is  the  largest  identified  gene  in  the  human  genome  at  
approximately  2.4Mb.  The  primary  skeletal  muscle  isoform,  Dp427m,  results  in  a  13,993  
base  pair  mRNA  encoding  79  exons  that  produce  a  3,685  amino  acid  protein  (~427  kDa  
in  size)  with  an  isoform-­‐‑specific  N-­‐‑terminus  [20].  The  majority  of  dystrophin  mutations  
that  cause  DMD  are  deletions  of  exons  that  result  in  reading  frame  disruption  [5].  
However,  the  loss  of  internal  dystrophin  exons  that  retain  the  proper  reading  frame  
cause  the  less  severe  Becker  muscular  dystrophy  (BMD).  This  has  led  to  efforts  create  
internally  minimized  dystrophin  proteins  that  can  be  packaged  into  small  viruses,  such  
as  the  AAV,  or  to  restore  the  disrupted  native  dystrophin  reading  frame  in  Duchenne  
patients,  thereby  producing  internally  deleted,  but  functional  dystrophin  proteins  [4].  
Deletions  that  occur  in  the  exon  45-­‐‑55  region,  contained  within  the  rod  domain,  and  
leave  the  rest  of  the  protein  intact  generally  produce  highly-­‐‑functional  proteins,  and  
many  carriers  of  this  mutation  are  asymptomatic  [4].  An  interesting  phenomenon  
observed  in  BMD  patients  are  divergent  observed  phenotypic  outcomes  in  Becker  
muscular  dystrophy  (BMD)  patient  siblings  with  the  same  underlying  mutations  in  the  
dystrophin  gene  [21,  22].  This  suggests  that  there  are  other  unknown  factors  that  may  
alter  disease  progression  and  severity  in  patients  with  internal  dystrophin  deletions.  
Despite  this  uncertainty,  deletions  in  the  exon  45-­‐‑55  region  that  disrupt  the  dystrophin  
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protein  are  an  attractive  class  of  DMD  mutations  to  target,  since  correction  would  
presumably  result  in  functional  dystrophin  and  improve  the  DMD  phenotype  [22].  
Furthermore,  it  is  estimated  that  up  to  62%  of  patients  with  DMD  could  benefit  from  
correction  in  exons  45-­‐‑55  [4].  Notably,  exon  51  is  frequently  adjacent  to  frame-­‐‑disrupting  
deletions  in  DMD  patients,  account  for  nearly  13%  of  all  DMD  mutations,  and  has  been  
targeted  in  clinical  trials  for  oligonucleotide-­‐‑based  exon  skipping  with  promising  early  
therapeutic  results  [4,  23,  24].  Thus,  exon  51  is  of  particular  interest  in  designing  genetic  
therapies  for  DMD.  
This  thesis  takes  advantage  of  the  highly  defined  genetic  basis  of  DMD  as  it  is  
especially  amenable  to  the  gene  correction  methods  presented  in  this  work.  In  particular,  
deletion  of  exon  51  is  ideally  suited  for  exploring  permanent  correction  of  the  native  
dystrophin  gene  by  genome  editing  because  it  is  an  established  therapeutic  target  in  
current  exon-­‐‑skipping  clinical  trials  and  is  likely  to  produce  highly  functional  proteins.  
Moreover,  deletion  of  the  entire  exon  45-­‐‑55  region  could  potentially  address  62%  of  
patient  mutations  and  generate  a  dystrophin  protein  that  retains  a  high  level  of  
functionality,  based  on  similar  proteins  found  in  asymptomatic  carriers  or  the  mild  
disease  Becker  muscular  dystrophy.  
2.2. Cell-based therapies for DMD 
Cell-­‐‑based  therapies  for  DMD  aim  to  introduce  functional  dystrophin  expression  
in  patient  muscle  by  genetically  correcting  autologous  patient  cells  or  by  isolating  
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healthy  allogeneic  cells  that  can  be  used  to  repopulate  and  replace  dystrophic  tissue  in  a  
DMD  patient.  Initially,  cell-­‐‑based  therapy  focused  on  transplantation  of  allogeneic  
healthy  donor  muscle  progenitors  directly  into  DMD  patient  muscle  by  injection  and  
was  combined  with  immunosuppression  [25].  Several  early  clinical  trials  explored  
combining  different  methods  of  immune  suppression  in  tandem  with  transplantation  of  
donor  allogeneic  myoblasts.  These  early  trials  had  varied  success,  but  at  best  only  a  few  
patients  had  meaningful  donor  engraftment  and  restored  dystrophin  expression  [25].  
Some  of  the  challenges  associated  with  these  therapies  included  immune  rejection  [26],  
insufficient  donor  engraftment  [27],  and  poor  migration  from  the  injection  site  [28].  
Therefore,  while  conceptually  simple,  these  methods  are  technically  difficult  and  require  
numerous  injections  directly  into  target  tissue  and  poor  engraftment  of  donor  tissue  has  
precluded  meaningful  clinical  results.    
New  approaches  based  on  genetic  engineering  of  autologous  cells  have  led  to  
renewed  interest  in  cell-­‐‑based  therapies  for  DMD.  It  has  been  shown  previously  that  
autologous  patient  cells  can  be  genetically  modified  to  stably  express  full-­‐‑length  
dystrophin  [29,  30]  or  minidystrophin  [31].  A  notable  and  innovative  approach  
introduced  a  human  artificial  chromosome  (HAC)  containing  an  entire  intact  DMD  locus  
that  successfully  restored  dystrophin  expression  in  a  progenitor  cell  population.  These  
cells  could  home  to  and  repopulate  dystrophic  tissue  in  an  animal  model  of  DMD  [30].  
However,  isolation  of  these  progenitor  cell  populations,  as  well  as  the  subsequent  
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genetic  engineering  and  identification  of  appropriately  corrected  cells,  is  technically  
difficult  and  time  consuming.  In  contrast,  genome  editing  offers  a  streamlined,  highly  
efficient  approach  to  directly  correct  the  dystrophin  gene  in  situ,  thereby  obviating  the  
need  for  extensive  genetic  engineering  required  for  modifying  and  characterizing  
autologous  cells  containing  HACs.  More  recently,  site-­‐‑specific  integration  of  a  
minidystrophin  gene  cassette  into  a  nonessential  genetic  locus  was  used  to  restore  
dystrophin  expression  in  human  myoblasts  [31].  However,  a  major  concern  for  this  
approach  is  the  possibility  of  off-­‐‑target  integration  of  the  gene  cassette  that  may  
potentially  interfere  with  oncogenes  and  tumor  suppressors.  
Site-­‐‑specific  genome  engineering  is  rapidly  becoming  a  robust,  easy-­‐‑to-­‐‑use  
platform  for  creating  desired  genetic  changes  or  additions.  The  correction  of  the  native  
gene  or  site-­‐‑specific  replacement  of  the  entire  dystrophin  gene  may  offer  a  superior  
method  to  restore  the  dystrophin  gene  in  autologous  patient  cell  lines.  These  methods  
are  compatible  with  a  myriad  of  cell  types  currently  under  investigation  for  cell-­‐‑based  
therapies  for  muscular  dystrophies,  including  induced  pluripotent  stem  cells  [29,  32],  
bone  marrow-­‐‑derived  progenitors  [33],  skeletal  muscle  progenitors  [34],  
mesoangioblasts  [30],  CD133+  cells  [35],  and  dermal  fibroblasts  [36].  Additionally,  
advances  in  immortalization  of  human  myogenic  cells  may  greatly  simplify  clonal  
derivation  of  genetically  corrected  myogenic  cells  [37,  38].  These  cell  types  can  be  
modified  by  genome  editing  tools  in  vitro  by  transfection  or  electroporation  of  plasmid  
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or  mRNA,  transduction  by  integrase-­‐‑deficient  lentivirus  [39],  or  treatment  with  cell-­‐‑
permeable  nucleases  [40,  41].  Of  these,  one  notable  approach  is  to  create  iPSCs  from  
autologous  patient  cells,  correct  the  dystrophin  gene  ex  vivo,  differentiate  the  iPSCs  
towards  the  myogenic  lineage,  and  inject  the  cells  to  repopulate  dystrophic  tissue  [29-­‐‑32,  
42,  43].  
This  work  will  focus  on  genetic  correction  of  the  native  gene  using  non-­‐‑
homologous  end-­‐‑joining  DNA  repair  that,  as  discussed  below  in  Chapter  2.4,  requires  
only  delivery  of  the  gene  editing  nucleases  and  is  an  excellent  candidate  for  highly  
efficient  delivery  to  and  gene  modification  of  cell  types  that  can  be  utilized  to  
reconstitute  dystrophin  expression  in  skeletal  muscle    
2.3. Gene and molecular therapies for DMD 
2.3.1. Gene transfer to skeletal muscle 
Traditionally,  gene  therapy  aims  to  deliver  functional  replacement  proteins  
either  directly  or  by  gene  transfer  to  a  target  tissue.  Gene  transfer  vectors  for  skeletal  
muscle  include  lentivirus  [44,  45],  adeno-­‐‑associated  virus  [46-­‐‑56],  adenovirus  [57],  and  
non-­‐‑viral  methods.  One  of  the  leading  gene  transfer  vectors  for  in  vivo  gene  therapy  is  
adeno-­‐‑associated  virus  (AAV),  which  is  a  small,  non-­‐‑pathogenic  dependovirus  that  
typically  encodes  a  single-­‐‑strand  DNA  genome  with  a  maximum  packaging  capacity  of  
~4.7kb  [58].  AAV  vectors  based  on  AAV2  pseudotyped  with  alternative  muscle-­‐‑tropic  
AAV  capsids,  such  as  AAV2/1,  AAV2/6,  AAV2/7,  AAV2/8,  AAV2/9,  and  the  more  recent  
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AAV2.5  and  AAV/SASTG  vectors  have  been  shown  to  efficiently  transduce  skeletal  
muscle  by  systemic  and  local  delivery  [46-­‐‑56]  with  sustained  gene  transfer  measuring  at  
least  several  months.  More  recently,  the  first  AAV-­‐‑based  gene  therapy  was  approved  as  
a  product  in  Europe  and  is  also  administered  by  intramuscular  delivery  [59].  However,  
the  large  size  of  dystrophin  (>11kb  cDNA)  complicates  gene  transfer  strategies,  in  
particular  with  the  use  of  adeno-­‐‑associated  virus,  due  to  its  limited  packaging  capacity  
of  approximately  4.7kb  [49].  This  led  to  the  development  of  novel  minidystrophin  genes  
[60],  which  can  be  packaged  into  adeno-­‐‑associated  virus  vectors  to  deliver  a  functional,  
but  truncated,  dystrophin  gene  [5]  to  muscle  tissue  [49].  These  miniaturized  dystrophin  
proteins  (“minidystrophins”)  may  be  sufficient  to  ameliorate  the  symptoms  of  DMD  
[60],  though  careful  selection  of  appropriate  minimal  dystrophin  proteins  is  still  under  
investigation  [61].  One  minidystrophin,  termed  Δ3990,  has  shown  favorable  functional  
profiles  [60,  61]  and  was  investigated  in  Phase  I  clinical  trials  for  AAV-­‐‑based  gene  
transfer  [48].  However,  AAV  gene  transfer  is  generally  limited  to  postmitotic  skeletal  
muscle  fibers  and  thus  far  no  study  has  demonstrated  sustained  gene  transfer  in  
progenitor  cell  populations.  This  is  an  important  aspect  of  potential  DMD  therapies  to  
ensure  that  corrected  genomes  are  not  lost  during  tissue  regeneration  following  normal  
muscle  damage  and  repair.  The  non-­‐‑integrative  nature  of  AAV  also  means  that  gene  
transfer  vectors  in  progenitor  cell  populations  in  vivo  would  be  quickly  diluted  out  from  
transduced  progenitor  populations.  Therefore,  it  is  likely  that  prolonged  clinical  efficacy  
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would  require  intermittent  readministration  of  the  gene  transfer  vector,  which  presents  
significant  challenges  in  overcoming  primary  immunity  to  the  vector  after  initial  
treatment.  However,  AAV-­‐‑based  gene  transfer  is  still  an  attractive  method  for  long-­‐‑term  
expression  of  a  minidystrophin  transgene  and  methods  to  overcome  vector  immunity  
are  an  area  of  active  investigation  [15].  Therefore,  AAV  remains  a  valuable  tool  for  
systemic  delivery  of  transgenes,  such  as  gene  editing  enzymes,  to  skeletal  muscle.  
Non-­‐‑viral  methods  are  also  an  attractive  method  for  efficient,  tissue-­‐‑specific  gene  
transfer,  though  their  efficiency  in  skeletal  muscle  expression  is  limited.  Skeletal  muscle  
has  been  shown  to  readily  take  up  plasmid  DNA  [62],  which  would  greatly  simplify  
gene  transfer  to  skeletal  muscle  at  low  cost.  These  methods  were  expanded  upon  to  
increase  efficiency  by  electroporation  [63],  hydrostatic  pressure  [64],  ultrasound  [65],  
and  non-­‐‑ionic  carriers  [66].  Nanoparticles  can  also  be  programmed  to  deliver  a  payload  
to  specific  tissues  by  conjugating  targeting  peptides  to  the  nanoparticle  complex,  
enabling  versatile  control  over  delivery  of  gene  editing  therapeutics  [67].  Moreover,  
these  complexes  can  be  used  to  deliver  therapeutic  peptides  or  RNA  in  addition  to  
conventional  gene  transfer  via  DNA.  Notably,  it  has  been  demonstrated  that  
nanoparticles  can  mediate  in  vivo  gene  editing  by  simultaneously  delivering  both  the  
gene  editing  agent  and  a  suitable  donor  template  [68].  Thus,  non-­‐‑viral  methods  may  be  a  
promising  method  to  deliver  short  bursts  of  gene  editing  drugs.  
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There  is  a  significant  opportunity  to  combine  these  rapid  advances  in  gene  
transfer  to  skeletal  muscle  with  genome  editing  strategies  to  achieve  in  situ  gene  
correction  in  vivo.  This  work  aims  to  develop  novel  genome  editing  technologies  that  are  
compatible  with  many  of  the  leading  gene  therapy  vectors,  including  AAV.  Importantly,  
genome  editing  would  also  enable  permanent  gene  correction  following  transient  
delivery  of  targeted  nucleases,  in  contrast  to  the  transient  delivery  of  replacement  
dystrophin  genes  that  relies  on  exogenous  expression  to  achieve  therapeutic  effect.  
Correction  of  the  native  genome  directly  also  ensures  physiologic  expression  and  
expression  of  all  dystrophin  isoforms.  Therefore,  genome  editing  would  be  an  important  
advance  in  treating  DMD  that  is  compatible  with  established  gene  transfer  vectors,  such  
as  AAV,  integrase-­‐‑deficient  lentivirus,  or  other  non-­‐‑viral  DNA  delivery  methods.  
2.3.2. Oligonucleotide-mediated exon skipping 
Restoration  of  the  native  dystrophin  gene  product  may  lead  to  improved  clinical  
outcomes  by  salvaging  the  maximum  amount  of  protein  functionality  [69].  This  is  a  
relatively  new  area  of  the  gene  and  molecular  therapy  field  that  has  seen  new  strategies  
developed  to  selectively  exclude  portions  of  a  damaged,  out-­‐‑of-­‐‑frame  gene  or  to  force  
read-­‐‑through  of  aberrant  stop  codons.  The  most  successful  approach  to  date  is  based  on  
small  oligonucleotides  that  transiently  and  selectively  remove  exons  (“exon  skipping”)  
from  dystrophin  mRNA  to  restore  the  reading  frame  of  dystrophin  [4].  This  approach  
has  led  to  several  successful  Phase  I/II  clinical  trials  [24,  70,  71],  including  a  recent  trial  
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that  demonstrated  a  significant  increase  in  mean  walking  distance  in  patients  
continuously  treated  for  48  weeks  by  intravenous  injection  with  the  exon  skipping  
compound  eteplirsen  (previously  AVI-­‐‑4658),  which  acts  to  selectively  skip  exon  51  [23].  
However,  delivery  of  exon  skipping  molecules  at  sufficient  therapeutic  concentrations  
remains  a  significant  challenge  for  some  tissue  types,  especially  cardiac  tissue  [5].  
Additionally,  some  exons  cannot  be  skipped  exclusively,  and  must  be  skipped  along  
with  other  exons  (i.e.  exon  44),  which  may  further  impact  the  resulting  functionality  of  
the  truncated  protein  [69],  as  well  as  the  therapeutic  efficacy  given  the  requirement  for  
sufficient  intracellular  levels  of  more  than  one  compound.  Finally,  small  molecules  that  
can  force  ribosomal  stop  codon  read-­‐‑through  [72]  have  been  investigated  as  possible  
agents  to  restore  truncated  dystrophin  proteins,  including  PTC124  [73]  (rebranded  as  
Ataluren)  and  gentamicin  [74].  However,  these  compounds  have  shown  little,  if  any,  
therapeutic  benefit  for  treating  DMD,  perhaps  due  to  insufficient  induction  of  full-­‐‑length  
dystrophin  expression.    
Genome  editing  is  a  valuable  approach  to  permanently  recapitulate  all  of  the  
above  methods  to  restore  dystrophin  expression  by  rewriting  the  dystrophin  gene.  
Genomic  therapies  for  DMD  would  be  a  significant  benefit  over  transient  therapies  that  
must  be  continuous  for  the  life  of  the  patient  to  maintain  therapeutic  efficacy.  These  
continuous  therapies  also  require  inconvenient  weekly  injections  of  large  quantities  of  
expensive  therapeutic  agents.  Importantly,  genome  editing  can  theoretically  accomplish  
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therapeutic  gene  correction  in  a  single  dose  since  genetic  modifications  result  in  
permanent  genetic  changes  that  last  for  the  life  of  a  modified  cell  and  its  progeny.  
2.4. Targeted genome editing 
Genome  editing  with  engineered  site-­‐‑specific  endonucleases  has  emerged  as  a  
new  technology  to  selectively  replace  or  correct  disrupted  genes,  in  contrast  to  
conventional  gene  therapy  methods  of  gene  addition  [75].  These  engineered  nucleases  
act  by  creating  a  targeted  double-­‐‑strand  break  in  the  genome  that  stimulates  cellular  
DNA  repair  through  either  homology-­‐‑directed  repair  (HDR)  or  non-­‐‑homologous  end-­‐‑
joining  (NHEJ)  (Figure  1).  HDR  uses  a  designed  synthetic  donor  DNA  template  to  guide  
repair  and  can  be  used  to  create  specific  sequence  changes  to  genome,  including  the  
targeted  addition  of  whole  genes.  HDR  has  enabled  integration  of  gene  cassettes  of  up  to  
8kb  in  the  absence  of  selection  at  high  frequency  (~6%)  in  human  cells  [76].  Generally,  
gene  correction  strategies  have  been  based  solely  on  HDR,  the  efficiency  of  which  is  
dependent  on  cell-­‐‑cycle  state  and  delivery  of  an  exogenous  DNA  template  [77-­‐‑81].  In  
many  cases,  antibiotic  selection  is  used  in  tandem  with  genome  editing  for  gene  
correction  in  cell  types  with  low  levels  of  HDR  repair  [78-­‐‑80].  Gene  targeting  may  also  
be  enhanced  by  using  AAV-­‐‑based  delivery  of  donor  templates  and  gene  editing  
enzymes  [82-­‐‑86].  Moreover,  AAV  delivery  of  zinc  finger  nucleases  (ZFNs)  with  a  donor  
template  has  been  shown  to  mediate  efficient  gene  targeting  in  vivo  [71,  87].  HDR-­‐‑based  
genome  editing  is  a  valuable  strategy  to  introduce  a  functional  dystrophin  gene  cassette  
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at  a  predefined  point  of  the  genome  [31],  offering  controlled  expression  and  minimizing  
the  potential  deleterious  effects  of  random  integration.  Moreover,  some  patient  deletions    
may  necessitate  addition  of  absent  essential  coding  regions  to  the  dystrophin  gene  to  
restore  function.  
  
Figure  1:  Mechanisms  of  DNA  repair  following  the  creation  of  a  double-­‐‑strand  
break  by  an  engineered  nuclease.  
Although  HDR  is  extremely  valuable  for  restoring  the  complete  coding  sequence  
of  the  mutant  gene,  evidence  from  studies  investigating  transient  exon  skipping  [88]  and  
premature  stop  codon  read-­‐‑through  [72]  demonstrate  that  restoring  partially  truncated  
proteins  may  also  provide  therapeutic  benefit  in  a  large  fraction  of  DMD  patients.  The  
template-­‐‑independent  re-­‐‑ligation  of  DNA  ends  by  NHEJ  is  a  stochastic,  error-­‐‑prone  
repair  process  that  introduces  random  small  insertions  and  deletions  at  the  DNA  
breakpoint.  Small  insertions  and  deletions  resulting  from  NHEJ  repair  could  
permanently  restore  a  disrupted  reading  frame  or  remove  a  premature  stop  codon,  
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current  transient  methods  [89,  90].  Traditionally,  gene  editing  by  NHEJ  has  been  used  in  
mammalian  cells  to  disrupt  genes  [6]  or  delete  chromosomal  segments  [91,  92],  but  it  has  
been  proposed  that  genetic  mutations  created  by  endonucleases  could  be  utilized  to  
restore  an  aberrant  reading  frame  [36,  89].  Moreover,  the  NHEJ  gene  repair  pathway  
operates  in  all  cell  cycle  states,  while  the  efficiency  of  HDR  is  cell  cycle-­‐‑dependent.  
Given  the  high  number  of  patient  mutations  correctable  by  frame  restoration  alone,  
NHEJ  presents  an  optimal  DNA  repair  pathway  to  efficiently  correct  the  dystrophin  
gene.  Thus,  this  thesis  explores  this  opportunity  to  develop  NHEJ-­‐‑based  gene  correction  
strategies  to  restore  the  native  dystrophin  reading  frame  without  the  need  for  exogenous  
DNA  to  replace  a  defective  gene.  
2.5. Genome editing platforms 
2.5.1. Overview 
There  are  numerous  platforms  for  generating  site-­‐‑specific  gene  modifications  in  a  
human  genome,  but  to  date  the  most  successful  have  been  based  on  ZFNs  [93],  TALENs  
[75,  94]  and  more  recently,  the  RNA-­‐‑guided  CRISPR/Cas  system  [10,  11]  (Figure  2).  
These  systems  are  at  present  the  most  developed  publicly  available  platforms  for  robust  
and  efficient  targeted  gene  editing.  In  particular,  the  recent  development  of  TALENs  
and  CRISPR/Cas9  has  dramatically  advanced  genome  editing  due  to  their  high  rate  of  
successful  and  efficient  genetic  modification  [8-­‐‑11,  75,  95-­‐‑103].  In  addition,  there  are  
several  others  gene  editing  systems  available,  including  oligonucleotide-­‐‑mediated  exon  
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skipping  [4,  70],  meganucleases  [104],  triplex-­‐‑forming  oligonucleotide  (TFO)  complexes  
[105,  106],  integrases  [107,  108]  and  programmable  recombinases  based  on  zinc  finger  
[109-­‐‑111]  or  TALE  DNA-­‐‑binding  domains  [112].  However,  meganucleases  have  proven  
to  be  difficult  to  engineer  due  to  interdependence  of  the  DNA-­‐‑binding  and  cleavage  
domains,  while  TFO  complexes  have  demonstrated  relatively  low  levels  of  gene  
modification.  Programmable  recombinases  are  a  promising  next-­‐‑generation  gene  editing  
technology,  but  target  site  requirements,  overall  efficiency,  and  unknown  off-­‐‑target  
effects  are  still  major  challenges  to  the  widespread  adoption  of  this  technology.  
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Figure  2:  Schematic  of  nuclease-­‐‑based  genome  editing  technologies,  including  
(a)  ZFNs,  (b)  TALENs,  and  (c)  CRISPR/Cas9,  with  the  DNA  target  in  black,  the  gRNA  
in  blue,  and  the  Cas9  nuclease  in  green.  
2.5.2. Chimeric nucleases based on the FokI domain 
ZFNs  and  TALENs  are  chimeric  nucleases  that  utilize  an  independent,  
programmable  DNA-­‐‑binding  domain  fused  to  the  non-­‐‑specific  catalytic  domain  of  the  
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5’-TATTTTAGCTCCTACTCAGACTGTTACTCTGGTGACACAACCTGTGGTTACTAAGGAAACTG!











independent  nucleases  bind  to  adjacent  target  DNA  sequences,  thereby  permitting  
dimerization  of  FokI  and  cleavage  of  the  target  DNA.  Thus,  since  FokI  acts  as  a  dimer,  
these  nucleases  are  designed  in  pairs  to  guide  each  half  of  FokI  to  a  desired  target  site.  
Several  improvements  have  been  made  to  enhance  the  specificity  of  these  chimeric  
nucleases.  The  first  major  advance  was  the  identification  of  mutations  that  require  left  
and  right  obligate  heterodimerization  [114,  115],  thereby  preventing  potential  
homodimerization  of  nuclease  monomers  at  unintended  target  loci.  Several  groups  also  
created  nuclease  pairs  that  simply  nick  DNA  by  introducing  inactivating  mutations  to  
the  FokI  domain  on  one  of  the  nucleases  in  each  pair,  thereby  retaining  high  
recombinogenic  activity  while  drastically  reducing  error-­‐‑prone  NHEJ  repair  [116,  117].  
Directed  evolution  of  the  FokI  domain  identified  highly  active  variants  that  significantly  
increase  chimeric  nuclease  activity  in  a  target  site-­‐‑independent  manner  [118].  
2.5.2.1.  Zinc  Finger  Nucleases  (ZFNs)    
ZFNs  are  polydactyl  proteins  that  recognize  DNA  by  linking  individual  zinc-­‐‑
finger  (ZF)  motifs,  with  each  motif  recognizing  3bp  of  DNA,  in  tandem  [6] (Figure 2a). 
The  zinc-­‐‑finger  DNA  binding  domains  are  engineered  based  on  the  Cys2-­‐‑His2  zinc  
finger  domain,  the  most  common  DNA-­‐‑binding  motif  in  the  human  proteome.  The  
DNA-­‐‑binding  specificity  of  synthetic  zinc  finger  domains  has  been  extensively  altered  to  
recognize  almost  any  DNA  target  through  site-­‐‑directed  mutagenesis  and  rational  design  
or  the  selection  of  large  combinatorial  libraries  [6].  This  work  led  to  the  establishment  of  
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ZFNs  as  one  of  the  earliest  and  most  widely  used  genome  editing  tools  [77,  119-­‐‑122].  
Custom  ZFNs  can  be  assembled  by  a  variety  of  publicly  available  techniques,  including  
assembly  from  a  predefined  library  of  zinc-­‐‑finger  modules  [123-­‐‑126],  selection-­‐‑based  
assembly  [122,  127],  a  library  of  prevalidated  zinc-­‐‑finger  arrays  [128],  and  commercial  
synthesis.  Despite  the  difficulty  of  engineering  new  arrays,  ZFNs  have  had  success  in  
the  clinic  [13]  and  are  therefore  a  promising  technology  for  manipulating  the  human  
genome.  
2.5.2.2.  TALENs  
TALENs  recognize  DNA  through  a  set  of  linked  protein  repeats,  with  the  DNA  
preference  of  each  repeat  dictated  by  a  unique  repeat  variable  diresidue  (RVD)  in  each  
repeat  that  makes  base-­‐‑specific  DNA  contacts  (Figure  2b).  The  DNA  binding  domain  for  
TALENs  was  adapted  from  the  DNA  binding  domain  of  a  plant  pathogen  protein  and  
consists  of  an  array  of  RVD  modules,  each  of  which  specifically  recognizes  a  single  base  
pair  of  DNA  [97,  98].  RVD  modules  can  be  arranged  in  any  order  to  assemble  an  array  
that  recognizes  a  defined  sequence,  requiring  only  that  each  target  site  be  immediately  
preceded  by  a  5’-­‐‑thymine  for  efficient  DNA  recognition  [113,  129,  130].  The  resulting  
engineered  TALE  DNA  binding  domain  is  then  fused  to  the  FokI  domain  to  form  a  
nuclease.  Several  studies  have  shown  that  appropriate  truncation  of  the  C-­‐‑terminus  of  
TALEs  enhances  nuclease  activity  when  fused  to  the  FokI  domain  [96,  113,  131].  Custom  
TALENs  can  be  rapidly  created  from  a  relatively  small  library  of  plasmids  using  
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publicly  available  reagents  utilizing  ‘Golden  Gate’  molecular  cloning  techniques  to  
assemble  new  arrays  within  days  [8,  132]  or  high-­‐‑throughput  methods  that  utilize  solid-­‐‑
phase  assembly  [9,  133]  or  ligation-­‐‑independent  cloning  techniques  [134].  The  apparent  
ease  of  engineering  TALENs  to  novel  targets  is  attractive  for  engineering  novel  
molecular  therapies  for  DMD.  
2.5.3. CRISPR/Cas9 
Recently,  a  new  class  of  DNA  editing  enzymes  was  adapted  from  an  innate  
bacterial  defense  system,  CRISPR/Cas9,  for  use  in  mammalian  cells.  Unlike  ZFNs  or  
TALENs,  CRISPR/Cas9  recognizes  a  target  DNA  sequence  through  the  RNA-­‐‑DNA  
interaction  of  a  guide  RNA  sequence  that  tethers  to  and  guides  a  nuclease  protein  
domain  to  cleave  a  predefined  DNA  sequence  (Figure  2c).  CRISPR/Cas9  has  been  
successfully  adapted  to  work  in  mammalian  cells  by  co-­‐‑expression  of  a  Cas9  nuclease  
that  pairs  with  a  guide  RNA  (gRNA)  molecule  that  targets  the  Cas9  nuclease  to  a  
predefined  DNA  target  matching  the  5’  end  of  the  gRNA  sequence.  The  adapted  
systems  consist  of  a  Cas9  nuclease  that  is  co-­‐‑expressed  with  a  single  guide  RNA  
(sgRNA)  molecule.  The  Cas9  nuclease  forms  a  complex  with  the  3’  end  of  the  sgRNA,  
and  the  protein-­‐‑RNA  pair  recognizes  its  genomic  target  by  complementary  base  pairing  
between  the  5’  end  of  the  sgRNA  sequence  and  a  predefined  20  bp  DNA  sequence,  
known  as  the  protospacer.  By  simply  exchanging  the  20  bp  recognition  sequence  of  the  
expressed  sgRNA,  the  Cas9  nuclease  can  be  directed  to  new  genomic  targets.  The  only  
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restriction  for  protospacer  targeting  is  that  the  sequence  must  be  immediately  followed  
by  the  protospacer-­‐‑adjacent  motif  (PAM),  a  short  sequence  recognized  by  the  Cas9  
nuclease  that  is  required  for  DNA  cleavage.  A  unique  capability  of  the  CRISPR/Cas9  
system  is  the  straightforward  ability  to  simultaneously  target  multiple  distinct  genomic  
loci  by  co-­‐‑expressing  a  single  Cas9  protein  with  two  or  more  sgRNAs  [10,  11,  135].  
Several  orthogonal  Cas9  nucleases  have  been  identified  from  a  range  of  bacterial  
species,  including  S.  pyogenes,  S.  thermophilus,  N.  meningitidis  and  T.  denticola  [11,  100,  
136].  These  CRISPR/Cas9  systems  operate  similarly,  but  with  each  utilizing  distinct  Cas9  
with  unique  PAM  recognition  sequence  and  guide  RNA  molecules  [100,  136].  The  
CRISPR  system  adapted  from  S.  pyogenes  has  a  well-­‐‑defined  the  PAM  sequence  for  its  
Cas9  nuclease  (SpCas9)  as  5’-­‐‑NRG-­‐‑3’,  where  R  is  either  A  or  G  [137].  The  on-­‐‑target  
specificity  of  this  gene  editing  system  has  been  extensively  characterized  in  human  cells  
[137-­‐‑143],  observing  positional  dependence  of  mismatches  in  the  protospacer  on  
specificity  and  unexpected  recognition  of  degenerate  PAM  sequences.  Because  nickase  
activity  alone  greatly  reduces  NHEJ  mutagenesis  [116,  117],  target  site  specificity  can  be  
greatly  increased  by  utilizing  off-­‐‑set  sgRNAs  and  CRISPR/Cas9  nickases  [142].  In  this  
method,  two  sgRNAs  are  designed  to  bind  to  and  nick  opposite  strand  DNA  targets  
immediately  adjacent  to  each  other.  The  two  nicks  on  opposite  strands  results  in  a  
double-­‐‑strand  break  and  NHEJ  mutagenesis  and  decreases  the  likelihood  that  both  
sgRNAs  will  bind  opposite  strands  at  off-­‐‑target  loci.  Another  simple  method  to  increase  
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sgRNA  specificity  of  the  S.  pyogenes  CRISPR/Cas9  system  is  to  truncate  the  length  of  the  
protospacer  in  sgRNAs  [143],  presumably  reducing  the  tolerance  of  mismatches.  
Collectively,  these  studies  demonstrate  that  SpCas9  system  is  an  exciting  new  advance  
towards  specific  and  highly  efficient  gene  editing  applications.  However,  CRISPR/Cas  
specificity  may  yet  be  further  enhanced  through  novel  Cas9  nucleases,  longer  and  more  
stringent  PAM  sequences,  and/or  alterations  to  sgRNA  structure  that  limit  off-­‐‑target  
recognition.  
2.6. Therapeutic applications of genome editing 
Genome  editing  transitioned  from  bench  to  bedside  with  the  entrance  of  ZFNs  
into  Phase  I/II  clinical  trials  for  disruption  of  the  HIV-­‐‑1  co-­‐‑receptor  CCR5  [12,  144].  
Additionally,  there  are  ongoing  Phase  I  trials  for  ZFN-­‐‑mediated  disruption  of  the  
glucocorticoid  receptor  in  T  cells  for  glioblastoma  treatment,  demonstrating  the  
therapeutic  potential  of  this  emergent  technology.  Notably,  both  of  these  clinical  trials  
utilize  ZFN-­‐‑mediated  genetic  disruption  by  error-­‐‑prone  NHEJ  to  abolish  expression  of  
specific  receptors,  rather  than  as  a  tool  for  genetic  correction.  A  landmark  study  
demonstrated  in  vivo  genome  editing  to  correct  mutations  causing  hemophilia  B  in  a  
mouse  model  [81].  The  investigators  achieved  phenotypic  correction  of  hemophilia  B  in  
a  transgenic  mouse  model  of  hemophilia,  carrying  a  disrupted  human  factor  IX  gene,  
after  in  vivo  delivery  of  a  ZFN  that  enabled  site-­‐‑specific  integration  of  a  gene  targeting  
construct  to  replace  the  factor  IX  gene  in  situ.  This  work  demonstrated  that  adeno-­‐‑
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associated  virus  gene  transfer  for  in  vivo  delivery  of  ZFNs  could  be  used  for  both  
homology-­‐‑independent  (i.e.,  NHEJ)  and  homology-­‐‑directed  gene  modification.  A  
following  study  demonstrated  that  in  vivo  gene  editing  is  efficient  in  the  quiescent  livers  
of  adult  mice  as  well  [87].  Together,  these  studies  suggest  that  gene  editing  in  non-­‐‑
dividing  tissues,  such  as  skeletal  muscle,  may  be  feasible.  Other  preclinical  studies  have  
utilized  nucleases  to  correct  several  other  human  genetic  mutations  associated  with  
sickle  cell  anemia  [78,  79],  X-­‐‑linked  SCID  [77],  and  alpha-­‐‑1-­‐‑antitrypsin  deficiency  [80,  
145],  epidermolysis  bullosa  [146],  xeroderma  pigmentosum  [147],  and  mitochondrial  
DNA  disorders  [148].  Therefore,  we  propose  that  genome  editing  is  a  promising  
technology  to  address  mutations  in  the  human  dystrophin  gene.  Furthermore,  this  
technology  has  the  potential  to  be  delivered  in  vivo  to  correct  dystrophin  mutations  in  
situ  in  non-­‐‑dividing  skeletal  muscle.  
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Chapter 3. Reading Frame Correction by Targeted 
Genome Editing Restores Dystrophin Expression in 
Cells from Duchenne Muscular Dystrophy Patients 
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3.1. Synopsis  
Genome  editing  with  engineered  nucleases  has  recently  emerged  as  an  approach  
to  correct  genetic  mutations  by  enhancing  homologous  recombination  with  a  DNA  
repair  template.  However  many  genetic  diseases,  such  as  Duchenne  muscular  
dystrophy,  can  be  treated  simply  by  correcting  a  disrupted  reading  frame.  We  show  that  
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genome  editing  with  TALENs,  without  a  repair  template,  can  efficiently  correct  the  
reading  frame  and  restore  the  expression  of  a  functional  dystrophin  protein  that  is  
mutated  in  Duchenne  muscular  dystrophy.  TALENs  were  engineered  to  mediate  highly  
efficient  gene  editing  at  exon  51  of  the  dystrophin  gene.  This  led  to  restoration  of  
dystrophin  protein  expression  in  cells  from  Duchenne  patients,  including  skeletal  
myoblasts  and  dermal  fibroblasts  that  were  reprogrammed  to  the  myogenic  lineage  by  
MyoD.  Finally,  exome  sequencing  of  cells  with  targeted  modifications  of  the  dystrophin  
locus  showed  no  TALEN-­‐‑mediated  off-­‐‑target  changes  to  the  protein-­‐‑coding  regions  of  
the  genome,  as  predicted  by  in  silico  target  site  analysis.  This  strategy  integrates  the  
rapid  and  robust  assembly  of  active  TALENs  with  an  efficient  gene  editing  method  for  
the  correction  of  genetic  diseases  caused  by  mutations  in  non-­‐‑essential  coding  regions  
that  cause  frameshifts  or  premature  stop  codons.  
3.2. Introduction 
Genome  editing  with  engineered  site-­‐‑specific  endonucleases  has  emerged  as  a  
new  technology  to  selectively  replace  or  correct  disrupted  genes,  in  contrast  to  
conventional  gene  therapy  methods  of  gene  addition  [6,  75].  The  recent  development  of  
TALENs  has  dramatically  advanced  genome  editing  due  to  their  high  rate  of  successful  
and  efficient  genetic  modification  [8,  9,  75,  95-­‐‑98,  113,  134,  149-­‐‑151].  TALENs  are  
engineered  fusion  proteins  of  the  catalytic  domain  of  the  endonuclease  FokI  and  a  
designed  TALE  DNA-­‐‑binding  domain  that  can  be  targeted  to  a  custom  DNA  sequence  
  29  
[113,  149].  The  TALE  domain  consists  of  an  array  of  repeat  variable  diresidue  (RVD)  
modules,  each  of  which  specifically  recognizes  a  single  base  pair  of  DNA  [97,  98].  RVD  
modules  can  be  arranged  in  any  order  to  assemble  an  array  that  recognizes  a  defined  
sequence  [97,  98].  Site-­‐‑specific  double-­‐‑strand  breaks  are  created  when  two  independent  
TALENs  bind  to  adjacent  DNA  sequences,  thereby  permitting  dimerization  of  FokI  and  
cleavage  of  the  target  DNA  [75].  This  targeted  double-­‐‑strand  break  stimulates  cellular  
DNA  repair  through  either  homology-­‐‑directed  repair  (HDR)  or  the  non-­‐‑homologous  
end  joining  (NHEJ)  pathway.  HDR  uses  a  donor  DNA  template  to  guide  repair  and  can  
be  used  to  create  specific  sequence  changes  to  the  genome,  including  the  targeted  
addition  of  whole  genes.  In  contrast,  the  template-­‐‑independent  re-­‐‑ligation  of  DNA  ends  
by  NHEJ  is  a  stochastic,  error-­‐‑prone  repair  process  that  introduces  random  micro-­‐‑
insertions  and  micro-­‐‑deletions  (indels)  at  the  DNA  breakpoint.    
Thus  far,  strategies  for  the  correction  of  human  genes  have  been  based  primarily  
on  HDR,  the  efficiency  of  which  is  dependent  on  cell-­‐‑cycle  state  and  delivery  of  an  
exogenous  DNA  template  [77-­‐‑81].  In  many  cases,  antibiotic  selection  is  used  in  tandem  
with  genome  editing  for  gene  correction  in  cell  types  with  low  levels  of  HDR  repair  [78-­‐‑
80].  Although  HDR  is  extremely  valuable  for  restoring  the  complete  coding  sequence  of  
the  mutant  gene,  evidence  from  studies  investigating  oligonucleotide-­‐‑mediated  exon  
skipping  and  pharmacologic  read-­‐‑through  of  premature  stop  codons  demonstrates  that  
restoring  expression  of  fully  or  partially  functional  truncated  proteins  can  provide  
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therapeutic  benefit  for  many  diseases  [4,  5].  Therefore  indels  resulting  from  NHEJ-­‐‑
mediated  gene  repair  could  restore  a  disrupted  reading  frame  or  remove  a  premature  
stop  codon  and  ameliorate  the  symptoms  of  these  genetic  diseases.  This  approach  would  
result  in  permanent  gene  correction,  in  contrast  to  pharmacologic  approaches  that  act  
transiently  at  the  level  of  mRNA  splicing  or  translation.  
NHEJ  has  been  used  in  human  cells  to  disrupt  genes  [6,  12]  or  delete  
chromosomal  segments  [91,  92],  although  it  has  been  proposed  that  genetic  mutations  
created  by  endonucleases  could  be  used  to  restore  an  aberrant  reading  frame  [89,  90].  In  
this  study,  we  provide  the  first  example  of  the  restoration  of  protein  expression  from  an  
endogenous  mutated  gene  through  template-­‐‑free  NHEJ-­‐‑mediated  DNA  repair.  
Duchenne  muscular  dystrophy  (DMD),  the  most  common  monogenic  hereditary  
disease,  is  caused  by  defects  in  the  gene  encoding  dystrophin.  The  majority  of  
dystrophin  mutations  that  cause  DMD  are  deletions  of  exons  that  disrupt  the  reading  
frame  [5].  However,  deletion  of  internal  dystrophin  exons  that  retain  the  proper  reading  
frame  causes  the  less  severe  Becker  muscular  dystrophy.  This  has  led  to  efforts  to  restore  
the  disrupted  dystrophin  reading  frame  in  DMD  patients  by  skipping  non-­‐‑essential  
exons  during  mRNA  splicing,  thereby  producing  internally  deleted,  but  still  partially  or  
fully  functional,  dystrophin  proteins  [4,  70,  71].  In  contrast  to  a  transient  method  
targeting  the  dystrophin  mRNA,  the  correction  of  the  dystrophin  reading  frame  in  the  
genome  by  transiently  expressed  TALENs  would  lead  to  permanently  restored  
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dystrophin  expression  by  each  modified  cell  and  all  of  its  progeny.  Notably,  exon  51  is  
frequently  adjacent  to  frame-­‐‑disrupting  deletions  in  DMD  patients  and  has  been  
targeted  in  clinical  trials  for  oligonucleotide-­‐‑based  exon  skipping  with  promising  early  
therapeutic  results  [4,  70,  71].  An  ongoing  clinical  trial  for  the  exon  51  skipping  
compound  eteplirsen  recently  reported  a  significant  functional  benefit  across  48  weeks,  
with  an  average  of  47%  dystrophin  positive  fibers  compared  to  baseline.  Therefore,  this  
class  of  DMD  mutations  is  ideally  suited  for  permanent  correction  by  NHEJ-­‐‑based  
genome  editing.    
This  study  investigates  template-­‐‑free  gene  correction  by  using  TALENs  to  restore  
aberrant  reading  frames  through  the  introduction  of  indels  into  exon  51  of  the  
dystrophin  gene.  Accordingly,  we  designed  and  validated  an  optimized  TALEN  that  
targets  exon  51.  The  optimized  TALEN  was  transfected  into  human  DMD  cells  and  
shown  to  mediate  efficient  gene  modification  and  conversion  to  the  correct  reading  
frame.  Furthermore,  protein  restoration  was  concomitant  with  frame  restoration  and  
could  be  detected  in  a  bulk  population  of  TALEN-­‐‑treated  cells.  The  high  specificity  of  
the  optimized  TALEN  was  demonstrated  by  in  silico  analysis,  cytotoxicity  assays,  and  
exome  sequencing  of  clonally-­‐‑derived  modified  cells.    
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3.3. Materials and Methods  
3.3.1. Cell culture and transfection 
HEK293T  cells  were  obtained  from  the  American  Tissue  Collection  Center  
(ATCC)  through  the  Duke  Cell  Culture  Facility  and  were  maintained  in  DMEM  
supplemented  with  10%  bovine  calf  serum  and  1%  penicillin/streptomycin.  
Immortalized  myoblasts  [152]  (one  from  a  wild-­‐‑type  donor,  and  two  Δ48-­‐‑50  DMD  
patient  derived  lines)  were  maintained  in  skeletal  muscle  media  (PromoCell)  
supplemented  with  20%  bovine  calf  serum  (Sigma),  50  µμg/ml  fetuin,  10  ng/ml  human  
epidermal  growth  factor  (Sigma),  1  ng/ml  human  basic  fibroblast  growth  factor  (Sigma),  
10  µμg/ml  human  insulin  (Sigma),  1%  GlutaMAX  (Invitrogen),  and  1%  
penicillin/streptomycin  (Invitrogen).  Primary  DMD  dermal  fibroblasts  were  obtained  
from  the  Coriell  Cell  repository  (GM05162A,  Δ46-­‐‑50)  and  maintained  in  DMEM  
supplemented  with  10%  fetal  bovine  serum,  1  ng/mL  human  basic  fibroblast  growth  
factor,  and  1%  penicillin/streptomycin.  All  cell  lines  were  maintained  at  37°C  and  5%  
CO2.  HEK293T  cells  were  transfected  with  Lipofectamine  2000  (Invitrogen)  according  to  
the  manufacturer’s  protocol  in  24  well  plates.  Immortalized  myoblasts  and  primary  
fibroblasts  were  transfected  by  electroporation  using  the  Gene  Pulser  XCell  (BioRad)  
with  PBS  as  an  electroporation  buffer  using  optimized  conditions  for  each  line  (Figure  
3).  Transfection  efficiencies  were  measured  by  delivering  an  EGFP  expression  plasmid  
and  using  flow  cytometry.  These  efficiencies  were  routinely  ≥95%  for  HEK293T  and  
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≥70%  for  the  primary  fibroblasts  and  immortalized  myoblasts.  For  all  experiments,  the  
indicated  mass  of  electroporated  plasmid  corresponds  to  the  amount  used  for  each  
TALEN  monomer.  
  
Figure  3:  Optimization  of  electroporation  conditions  for  myoblasts.  (a)  DMD  
myoblast  cells  (cell  line  1)  were  electroporated  using  BioRad  Gene  Pulser  Xcell  or  
amaxa  Nucleofector  IIb  devices  using  the  indicated  programs.  Several  different  
buffers  were  tested,  including  BioRad  electroporation  solution,  Sigma  phosphate-­‐‑
buffered  saline  product  #D8537  (PBS),  Invitrogen  OptiMEM  I  (OM),  or  amaxa  
Nucleofector  solution  V  (N.V.).  Conditions  using  the  GenePulser  device  used  infinite  
resistance.  For  nucleofection,  1M  cells/100  µμL  nucleofection  solution  and  2  µμg  of  GFP  
vector  were  used  according  to  the  manufacturer’s  specifications.  Electroporation  using  
the  GenePulser  device  with  program  O  in  PBS  solution  was  selected  as  the  optimal  
conditions  for  electroporating  myoblasts.  (b)  Conditions  used  to  optimize  BioRad  








! B! C! D
! E! F! G
!
H



































A 1000uF, 120V, 1M cells/200uL, 10ug GFP + 10ug empty vector 
B 500uF, 120V, 1M cells/200uL, 10ug GFP + 10ug empty vector 
C 300uF, 120V, 1M cells/200uL, 10ug GFP + 10ug empty vector 
D 500uF, 100V, 1M cells/200uL, 10ug GFP + 10ug empty vector 
E 500uF, 150V, 1M cells/200uL, 10ug GFP + 10ug empty vector 
F 500uF, 200V, 1M cells/200uL, 10ug GFP + 10ug empty vector 
G 1000uF, 100V, 1M cells/200uL, 10ug GFP + 10ug empty vector 
H 1000uF, 150V, 1M cells/200uL, 10ug GFP + 10ug empty vector 
I 1000uF, 100V, 0.2M cells/200uL, 10ug GFP + 10ug empty vector 
J 1000uF, 100V, 0.4M cells/200uL, 10ug GFP + 10ug empty vector 
K 1000uF, 100V, 1M cells/200uL, 10ug GFP + 10ug empty vector 
L 950uF, 190V, 0.5M cells/150uL, 5ug GFP 
M 950uF, 190V, 1M cells/200uL, 10ug GFP 
N 950uF, 160V, 0.5M cells/150uL, 5ug GFP 
O 950uF, 160V, 1M cells/200uL, 10ug GFP 
P 950uF, 220V, 2M cells/300uL, 10ug GFP 
Q 950uF, 100V, 1M cells/200uL, 10ug GFP 
R 950uF, 190V, 1M cells/200ul, 2ug pmaxGFP 





3.3.2. TALE nuclease assembly and off-target site prediction 
TALENs  targeted  to  exon  51  of  the  human  dystrophin  gene  were  designed  in  
silico  using  the  TALE-­‐‑NT  webserver  [8].  TALEN  target  sites  were  chosen  to  include  half-­‐‑
site  targets  approximately  15-­‐‑19  bp  in  length,  preceded  by  a  5’-­‐‑T  [113].  Plasmids  
encoding  these  TALENs  were  assembled  using  the  Golden  Gate  assembly  method  [8]  
and  standard  cloning  techniques  into  a  modified  pcDNA3.1  (Invitrogen)  destination  
vector  containing  the  Δ152/+63  TALEN  architecture  [113]  derived  from  the  pTAL3  
expression  vector  provided  in  the  Golden  Gate  kit  from  Addgene.  The  FokI  
endonuclease  domains  were  codon  optimized  and  contained  the  ELD/KKR  obligate  
heterodimer  [115]  and  Sharkey  mutations  [118]  as  described  previously  [153].  Potential  
off-­‐‑target  sites  for  TALEN  pair  TN3/8  in  the  human  genome  were  predicted  in  silico  
using  the  Paired  Target  Finder  tool  on  the  TALE-­‐‑NT  2.0  webserver  [154].  All  predicted  
off-­‐‑target  sites  were  scanned  using  the  following  parameters:  recommended  score  cutoff  
(3.0),  spacers  of  range  12-­‐‑23  bp,  and  upstream  base  set  to  “T  only”.  Valid  likely  potential  
off-­‐‑target  sites  were  only  considered  as  those  with  up  to  4  mismatches  per  TALEN  half-­‐‑
site  binding  sequence  (maximum  of  8  mismatches  per  TALEN  pair  target  site).  
3.3.3. Cel-I quantification of endogenous gene modification 
TALEN-­‐‑induced  lesions  at  the  endogenous  target  site  were  quantified  using  the  
Surveyor  nuclease  assay,  which  can  detect  mutations  characteristic  of  nuclease-­‐‑mediated  
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NHEJ.  After  electroporation,  cells  were  incubated  for  3  or  10  days  at  37°C  and  genomic  
DNA  was  extracted  using  the  DNeasy  Blood  and  Tissue  kit  (QIAGEN).  The  target  locus  
was  amplified  by  30  cycles  of  PCR  with  the  AccuPrime  High  Fidelity  PCR  kit  
(Invitrogen)  using  primers  5’-­‐‑GAGTTTGGCTCAAATTGTTACTCTT-­‐‑3’  and  5’-­‐‑
GGGAAATGGTCTAGGAGAGTAAAGT-­‐‑3’.  The  resulting  PCR  products  were  
randomly  melted  and  reannealed  in  a  PCR  machine  with  the  program:  95°C  for  240  s,  
followed  by  85°C  for  60  s,  75°C  for  60s,  65°C  for  60s,  55°C  for  60  s,  45°C  for  60  s,  35°C  for  
60  s,  and  25°C  for  60s  with  a  -­‐‑0.3°C/s  rate  between  steps.  Following  reannealing,  8  µμl  of  
PCR  product  was  mixed  with  1  µμl  of  Surveyor  Nuclease  S  and  1  µμl  of  Enhancer  S  
(Transgenomic)  and  incubated  at  42°C  for  1  hour.  After  incubation,  6  µμl  of  digestion  
product  was  loaded  onto  a  10%  TBE  polyacrylamide  gel  and  run  at  200V  for  30  min.  The  
gels  were  stained  with  ethidium  bromide  and  quantified  using  ImageLab  (Bio-­‐‑Rad)  by  
densitometry  as  previously  described  [153].  
3.3.4. Cytotoxicity assay 
To  quantitatively  assess  potential  TALEN  cytotoxicity,  HEK293T  cells  were  
transfected  with  10  ng  of  a  GFP  reporter  and  100  ng  of  each  nuclease  using  
Lipofectamine  2000  according  to  the  manufacturer’s  instructions  (Invitrogen).  The  
percentage  of  GFP  positive  cells  was  assessed  at  2  and  5  days  by  flow  cytometry.  The  
survival  rate  was  calculated  as  the  decrease  in  GFP  positive  cells  from  days  2  to  5  and  
  36  
normalized  to  cells  transfected  with  an  empty  nuclease  expression  vector  as  described  
[155].  
3.3.5. Clone isolation procedure 
Immortalized  DMD  myoblasts  were  electroporated  with  10  µμg  of  each  TALEN  
plasmid  (20  µμg  total).  After  7  days,  isogenic  clones  were  isolated  by  clonal  dilution  in  
hypoxic  conditions  (5%  O2)  to  accelerate  myoblast  growth.  Genomic  DNA  was  extracted  
from  clones  using  the  QuickExtract  Kit  (Epicentre)  and  the  target  locus  amplified  by  
PCR  using  the  Cel-­‐‑I  primers  and  conditions  above.  The  resulting  PCR  products  were  
either  mixed  with  equal  amounts  of  PCR  product  from  untreated  cells  and  analyzed  by  
the  Surveyor  assay  (Figure  7a)  and/or  directly  submitted  for  conventional  Sanger  
sequencing  (Figure  7c)  to  identify  modified  clones.  
3.3.6. Viral transduction and forced MyoD overexpression in primary 
fibroblasts 
300,000  fibroblasts  were  plated  transduced  in  10  cm  plates  with  a  lentiviral  vector  
encoding  a  full-­‐‑length  human  MyoD  cDNA  under  the  control  of  a  dox-­‐‑inducible  
promoter  and  a  constitutive  puromycin  resistance  cassette.  Two  days  post-­‐‑transduction,  
fibroblasts  were  selected  for  6  days  in  1  µμg/mL  puromycin  (Sigma)  to  enrich  for  
transduced  cells.  Fibroblasts  were  then  plated  at  a  density  of  200,000  cells  in  10  cm  
dishes  and  MyoD  expression  was  induced  by  adding  3  µμg/mL  doxycycline  (Fisher  
Scientific)  to  the  media,  which  was  exchanged  every  two  days.  
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3.3.7. Western blot analysis 
To  assess  dystrophin  expression,  immortalized  myoblasts  were  differentiated  
into  myofibers  by  replacing  the  growth  medium  with  DMEM  supplemented  with  1%  
insulin-­‐‑transferrin-­‐‑selenium  (Invitrogen)  and  1%  antibiotic/antimycotic  (Invitrogen)  for  
4-­‐‑7  days.  Fibroblasts  were  transdifferentiated  into  myoblasts  by  inducing  MyoD  
overexpression  and  incubating  the  cells  in  DMEM  supplemented  with  1%  insulin-­‐‑
transferrin-­‐‑selenium  (Invitrogen),  1%  antibiotic/antimycotic  (Invitrogen)  and  3  µμg/mL  
doxycycline  for  15  days.  TALEN  expression  was  assessed  at  3  days  after  transfecting  
HEK293T  cells.  Cells  were  collected  and  lysed  in  RIPA  buffer  (Sigma)  supplemented  
with  a  protease  inhibitor  cocktail  (Sigma)  and  the  total  protein  amount  was  quantified  
using  the  bicinchoninic  acid  assay  according  to  the  manufacturer’s  instructions  (Pierce).  
Samples  were  then  mixed  with  NuPAGE  loading  buffer  (Invitrogen)  and  5%  β-­‐‑
mercaptoethanol  and  heated  to  85°C  for  10  minutes.  Twenty-­‐‑five  micrograms  of  protein  
were  separated  on  4-­‐‑12%  NuPAGE  Bis-­‐‑Tris  gels  (Invitrogen)  with  MES  buffer  
(Invitrogen).  Proteins  were  transferred  to  nitrocellulose  membranes  for  1-­‐‑2  hours  in  
transfer  buffer  containing  10-­‐‑20%  methanol  and  0.01%  SDS.  The  blot  was  then  blocked  
for  1  hour  with  5%  milk-­‐‑TBST  at  room  temperature.  Blots  were  probed  with  the  
following  primary  antibodies:  NCL-­‐‑Dys2  (1:25,  Leica),  MANDYS8  (1:100,  Sigma),  
GAPDH  (1:5000,  Cell  Signaling),  anti-­‐‑FLAG-­‐‑HRP  (1:2000,  Cell  Signaling),  or  anti-­‐‑
myogenin  F5D  (1:200,  Santa  Cruz).  Dystrophin  expression  was  detected  using  
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MANDYS8  in  DMD  myoblast  line  2  and  the  DMD  fibroblast  line  or  NCL-­‐‑Dys2  in  DMD  
myoblast  line  1.  TALEN  expression  was  detected  using  anti-­‐‑FLAG.  Blots  were  then  
incubated  with  mouse  or  rabbit  horseradish  peroxidase-­‐‑conjugated  secondary  
antibodies  (Santa  Cruz)  and  visualized  using  the  ChemiDoc  chemilumescent  system  
(BioRad)  and  Western-­‐‑C  ECL  substrate  (BioRad).  
3.3.8. Immunofluorescence 
Fibroblasts  were  plated  on  cover  slips  in  24  well  plates  at  a  density  of  30,000  
cells/well  and  MyoD  expression  was  induced  for  15  days  as  described  above.  Cells  were  
then  fixed  in  4%  paraformaldehyde  and  blocked  for  1  hour  at  room  temperature  with  
PBS  containing  5%  BSA,  2%  goat  serum  and  0.2%  Triton  X-­‐‑100.  Cells  were  then  stained  
overnight  at  4°C  with  MF20  (1:200,  Developmental  Studies  Hybridoma  Bank)  primary  
antibody  and  then  for  1  hour  at  room  temperature  with  anti-­‐‑mouse  AlexaFluor  488  
(Molecular  Probes)  secondary  antibody.  Cover  slips  were  mounted  with  ProLong  Gold  
antifade  (Molecular  Probes).  
3.3.9. Exome sequencing and analysis 
We  analyzed  the  exomes  of  four  clonally  derived  DMD  myoblast  lines  carrying  
known  TALEN-­‐‑mediated  deletions  in  exon  51  of  the  dystrophin  gene,  as  well  as  the  
parent  line  for  these  cells.  Genomic  DNA  was  isolated  using  the  DNeasy  Blood  and  
Tissue  Kit  (QIAGEN)  and  3  µμg  of  DNA  were  submitted  to  the  Duke  Institute  for  
Genome  Sciences  and  Policy’s  Genome  Sequencing  &  Analysis  Core.  Illumina-­‐‑
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compatible  libraries  were  made  and  enriched  for  exonic  regions  using  the  SureSelect  
Human  All  Exon  V4  Kit  (Agilent).  Five  total  libraries  were  prepared  from  the  four  
treatment  samples  and  one  parental  line  reference  sample.  The  libraries  were  indexed  
and  sequenced  on  one  lane  of  Illumina  HiSeq2000  (100-­‐‑bp  paired-­‐‑end  sequencing).  
Bioinformatics  analyses  were  performed  by  Duke  Genome  Sequencing  &  Analysis  Core.  
The  analysis  pipeline  includes  the  initial  QC  to  remove  sequencing  adaptors  and  low  
quality  bases  to  facilitate  mapping.  Sequence  depth  of  targeted  regions  was  calculated  as  
>97%  at  10x  coverage,  >91%  at  20x  coverage,  and  >82%  for  30x  coverage  (Appendix  A).  
Each  sequencing  reaction  generated  >64  million  reads  with  >93%  of  reads  above  a  
quality  score  of  30  and  an  overall  mean  quality  score  of  >36.4.  High  quality  reads  were  
mapped  to  the  human  reference  genome  (hg19)  using  bwa  0.5.9.  An  exome  capture  
pipeline  developed  at  the  Duke  Sequencing  Core  was  used  to  assess  the  exome  capture  
efficiency.  Picard  v1.74  is  used  for  removing  PCR  duplicates.  The  GATK  (v1.6-­‐‑13)  toolkit  
is  used  for  variant  calling,  read  realignment  around  INDELs,  quality  score  recalibration  
and  QC  filtering.  The  filtering  step  discards  the  variants  with  1)  low  coverage  (coverage  
(<30x),  2)  strand-­‐‑bias,  3)  low  SNP  quality  score  (<  50)  and  4)  low  allelic  frequency  (<0.5).  
Each  candidate  point  mutation  or  INDEL  were  reviewed  manually  by  IGV  to  identify  
false  negative  artifacts  due  to  insufficient  coverage  of  the  parental  line.  Identical  point  
mutations  and  INDELs  that  occurred  in  more  than  two  of  the  four  clones  were  verified  
as  artifacts  due  to  coverage  of  the  reference  parent  cell  line  and  were  discarded.  
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Common  point  mutations  and  INDELs  were  removed  by  comparing  to  human  
dbSNP135.  The  remaining  point  mutations  and  INDELs  were  annotated  using  Annovar  
(May  25,  2012  version)  and  classified  using  a  perl  script  written  by  the  Duke  Sequencing  
Core.  The  non-­‐‑exonic  point  mutations  were  not  considered.  All  point  mutations  and  
INDELs  were  individually  visualized  and  validated  on  IGV.  The  flanking  100bp  of  each  
validated  mutation  was  screened  for  any  potential  sequence  similarity  to  the  TN3/8  
target  site  using  the  Paired  Target  Finder  tool  on  the  TALE-­‐‑NT  2.0  webserver  [154]  using  
the  parameters:  recommended  score  cutoff  (3.0),  spacers  of  range  1-­‐‑30bp,  and  upstream  
base  set  to  “T  only”.  
3.4. Results 
3.4.1. Design and validation of TALENs targeted to the dystrophin 
gene 
To  evaluate  TALEN-­‐‑mediated  genetic  correction  by  NHEJ,  several  TALENs  were  
designed  to  target  exon  51  in  the  dystrophin  gene.  TALEN  target  sites  were  chosen  
immediately  upstream  of  the  two  possible  out-­‐‑of-­‐‑frame  stop  codons  (Figure  4),  such  that  
insertions  or  deletions  could  restore  the  dystrophin  reading  frame  in  either  disrupted  
frame.  Variable  lengths  of  spacers  between  TALEN  monomers  and  TALEN  RVD  array  
lengths  were  tested  to  optimize  nuclease  activity  (Appendix  A),  as  done  previously  
[113].  Western  blots  confirmed  full-­‐‑length  and  robust  expression  of  the  TALENs  
following  transfection  of  TALEN-­‐‑encoding  plasmids  into  HEK293T  cells  (Figure  5a).  All  
combinations  of  left  and  right  TALENs  were  then  transfected  into  HEK293T  cells  and  
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the  genomic  DNA  was  assessed  for  modification  by  the  Surveyor  assay,  which  can  
detect  the  frequency  of  allelic  modifications  with  a  dynamic  range  of  ~1-­‐‑50%.  Several  
TALENs  with  spacers  of  14-­‐‑19  bp  were  highly  active  with  gene  editing  efficiencies  
exceeding  modification  of  10%  of  total  alleles  (Figure  5b-­‐‑d),  consistent  with  previous  
observations  [9,  96,  113].  The  gene  editing  frequencies  were  stable  from  day  3  to  day  10  
(Figure  5b,  e),  confirming  that  these  TALENs  are  well  tolerated  in  human  cells  [9,  96,  
113].  Furthermore,  the  engineered  TALENs  showed  minimal  cytotoxicity  in  human  cells  
similar  to  the  well-­‐‑characterized  non-­‐‑cytotoxic  homing  endonuclease  I-­‐‑SceI  (Figure  5f,  
Figure  6)  [96,  155].  TN3/8  was  the  most  highly  active  and  well-­‐‑tolerated  TALEN  pair  
and  therefore  was  used  for  subsequent  experiments.    
  
Figure  4: Design  of  TALENs  targeted  to  exon  51  of  the  human  dystrophin  gene.  
(a)  The  possible  reading  frames  of  human  dystrophin  exon  51  and  expected  amino  
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acid  sequences  after  genome  editing.  (b)  Combinations  of  TALEN  pairs  were  
designed  to  target  immediately  upstream  of  either  out-­‐‑of-­‐‑frame  stop  codon  
(underline)  in  exon  51  (bold)  of  the  human  dystrophin  gene.    
  
Figure  5: Validation  and  characterization  of  TALENs.  (a)  Each  TALEN  
construct  was  transfected  independently  into  HEK293T  cells  to  confirm  full-­‐‑length  
expression.  All  TALENs  were  the  expected  size  of  ~95-­‐‑110kDa.  (b)  Combinations  of  
TALENs  were  co-­‐‑transfected  into  HEK293T  cells  to  screen  for  highly  active  TALEN  
pairs.  Gene  modification  frequency  was  monitored  at  day  3  and  day  10  to  assess  
stable  gene  modification.  Arrows  denote  expected  cleavage  band  sizes  indicative  of  
NHEJ  activity.  (c)  Summary  of  TALEN  spacer  lengths.  (d)  Measured  gene  
modification  rates  detected  by  the  Surveyor  assay  from  day  3  data  in  (b).  (e)  Measured  
indel  signal  changes  between  day  3  and  day  10  from  the  data  in  (b).  (f)  Cytotoxicity  
assay  in  HEK293T  cells  for  all  TALEN  combinations.  I-­‐‑SceI  is  a  non-­‐‑toxic  
meganuclease  and  GZF3  is  a  zinc-­‐‑finger  nuclease  known  to  be  cytotoxic  to  human  
cells.  n.d.,  not  detected.  
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Figure  6:  Optimization  of  cytotoxicity  assay  using  Lipofectamine  2000  in  293T  
cells.  Varying  amounts  of  the  non-­‐‑toxic  endonuclease  I-­‐‑SceI  and  toxic  zinc-­‐‑finger  
nuclease  GZF3  were  transfected  into  293T  cells  and  assessed  for  relative  survival  rates  
post-­‐‑transfection.  Based  on  these  data,  100  ng  of  nuclease  was  used  for  the  cytotoxicity  
studies.  
3.4.2. TN3/8 mediates high efficiency conversion to all three reading 
frames 
NHEJ-­‐‑based  gene  modification  is  expected  to  create  indels  of  random  length  and  
therefore  should  cause  conversion  to  any  of  the  three  reading  frames  in  an  exonic  
sequence.  In  order  to  validate  the  overall  gene  modification  rate  and  possible  reading  
frames  generated  following  TALEN-­‐‑induced  NHEJ,  clonal  cell  populations  were  
derived  from  human  skeletal  myoblasts  that  had  been  electroporated  with  TN3/8-­‐‑
encoding  plasmids.  These  clones  were  assayed  for  NHEJ  events  occurring  at  the  
dystrophin  exon  51  locus  using  the  Surveyor  assay  to  detect  sequence  differences  
relative  to  untreated  cells  (Figure  7a).  Eleven  of  twenty-­‐‑eight  (39%)  clonal  cell  
populations  were  modified  and  subsequent  sequencing  of  the  alleles  from  these  clones  
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confirmed  indels  characteristic  of  NHEJ  (Figure  7b).  Similar  to  other  studies  with  
TALENs,  deletions  were  heavily  favored  [156].  The  random  length  of  these  indels  
verifies  that  conversion  to  any  of  the  three  reading  frames  is  possible.  The  conversion  
rate  to  any  one  of  the  three  reading  frames  was  observed  to  be  roughly  proportional  to  
the  expected  1/3  of  the  total  NHEJ  events  (Figure  7b).  Interestingly,  several  small  
deletions  were  observed  that  did  not  alter  the  original  reading  frame,  demonstrating  
that  this  approach  could  be  used  to  delete  aberrant  stop-­‐‑codons  (Figure  7b).  
3.4.3. Reading frame correction leads to restored protein expression 
We  next  assessed  whether  correction  of  the  dystrophin  reading  frame  by  
TALEN-­‐‑mediated  NHEJ  results  in  restored  dystrophin  protein  expression.  Immortalized  
human  myoblasts  derived  from  DMD  patients  with  a  frame-­‐‑disrupted  dystrophin  gene  
caused  by  deletion  of  exons  48-­‐‑50  (Δ48-­‐‑50)  were  electroporated  with  plasmids  encoding  
TN3/8.  Clonal  cell  populations  were  isolated  and  screened  by  PCR  amplification  of  
genomic  DNA  and  Sanger  sequencing  to  identify  indels  characteristic  of  NHEJ.  In  this  
experiment,  approximately  5%  of  clones  contained  modifications  in  exon  51,  including  
one  clone  with  an  NHEJ  event  expected  to  correct  the  dystrophin  reading  frame  (Figures  
7c,  8).  Following  myogenic  differentiation,  restored  dystrophin  protein  expression  was  
detected  by  western  blot  at  its  predicted  size  (~412  kDa)  only  in  the  corrected  clone,  and  
not  in  clones  with  non-­‐‑corrective  NHEJ  events  (Figure  7d).  These  data  demonstrate  that  
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NHEJ  events  that  restore  the  dystrophin  reading  frame  also  rescue  dystrophin  protein  
expression.  
  
Figure  7: Genetic  correction  of  aberrant  dystrophin  reading  frames  by  TALEN-­‐‑
mediated  genome  editing.  (a)  Isogenic  clones  were  derived  from  human  skeletal  
myoblasts  treated  with  ten  micrograms  of  each  plasmid  encoding  TN3/8  and  screened  
using  the  Surveyor  assay  to  detect  mutant  alleles  in  reference  to  the  parent  (untreated)  
genomic  DNA  .  Arrows  denote  expected  cleavage  band  sizes  indicative  of  NHEJ  
activity.  (b)  Sanger  sequencing  of  the  TALEN  target  site  in  exon  51  in  mutant  clones  
identified  in  (a).  (c)  DMD  human  myoblast  cell  line  1  was  treated  with  ten  
micrograms  of  each  plasmid  encoding  the  TN3/8  TALEN  pair  and  isogenic  clones  
were  subsequently  derived.  Sanger  sequencing  was  used  to  identify  clones  with  small  
insertion  or  deletion  mutations  at  the  exon  51  genomic  locus  characteristic  of  NHEJ.  
Clone  106  had  a  5  bp  deletion  expected  to  restore  the  reading  frame  (boxed).  All  other  
clones  had  deletions  that  were  not  expected  to  result  in  corrective  frameshift  events.  
(d)  Clonal  cell  populations  with  NHEJ  events  detected  at  exon  51  were  cultured  in  
differentiation  conditions  for  7  days  and  analyzed  by  western  blot  for  dystrophin  
expression  at  the  expected  molecular  weight  (412  kDa).    
  46  
  
Figure  8:  Chromatograms  of  clones  from  Figure  7.  
3.4.4. TALEN-mediated genetic correction in bulk-treated DMD 
myoblasts 
Efficient  in  situ  frame  correction  in  the  absence  of  selection  is  a  powerful  use  of  
NHEJ-­‐‑based  gene  correction.  Accordingly,  we  investigated  the  restoration  of  dystrophin  
expression  in  TALEN-­‐‑treated  bulk  populations  of  DMD  myoblast  lines  derived  from  
two  different  patients  containing  different  deletions  of  exons  48-­‐‑50  in  the  dystrophin  
gene.  As  expected,  the  frequency  of  gene  modification  increased  with  the  dose  of  
electroporated  TN3/8-­‐‑encoding  plasmids  with  indels  detected  in  up  to  12.7%  and  6.8%  
of  alleles,  in  the  two  patient  lines  as  measured  by  the  Surveyor  assay  (Figures  9a,  b).  
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Following  7  days  of  myogenic  differentiation  induced  by  serum  removal,  restored  
dystrophin  expression  was  detected  in  the  bulk  cell  populations  at  the  predicted  size  
(~412  kDa)  relative  to  expression  from  wild-­‐‑type  cells  (427  kDa)  (Figures  9c,  d).  The  
increase  in  dystrophin  protein  expression  with  TALEN  dose  was  concomitant  with  the  
level  NHEJ  events  detected  by  the  Surveyor  assay.    
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Figure  9:  Efficient  genetic  modification  and  protein  restoration  in  a  bulk  
population  of  cells  treated  with  TN3/8.  (a,b)  Dose-­‐‑dependent  response  of  NHEJ  
activity  with  increasing  amounts  of  TALEN  pair  TN3/8  measured  by  the  Surveyor  
assay  after  transfection  of  the  indicated  amount  of  each  TALEN  plasmid  into  two  
different  DMD  myoblast  lines,  each  carrying  a  novel  deletion  of  exons  48-­‐‑50  (Δ48-­‐‑50).  
Arrows  denote  expected  cleavage  band  sizes  indicative  of  NHEJ  activity.  (c)  DMD  
myoblast  line  1  was  treated  with  five  micrograms  of  each  TALEN  plasmid  and  
dystrophin  expression  was  assessed  after  7  days  of  differentiation  by  western  blot  
using  the  NCL-­‐‑Dys2  antibody.  (d)  DMD  myoblast  2  was  treated  with  the  indicated  
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amount  of  each  TALEN  plasmid  and  dystrophin  expression  was  assessed  after  7  days  
of  differentiation  by  western  blot  using  the  MANDYS8  antibody.  Protein  from  wild-­‐‑
type  human  myoblasts  differentiated  in  parallel  was  diluted  1:100  and  loaded  as  a  
positive  control  for  full-­‐‑length  dystrophin  expression  (427  kDa)  relative  to  the  
truncated  Δ48-­‐‑50  product  (412  kDa).  
3.4.5. Gene restoration in primary DMD dermal fibroblasts 
The  simplicity  of  this  NHEJ-­‐‑based  approach  can  enable  efficient  correction  in  
proliferation-­‐‑limited  primary  cell  lines  that  may  not  be  amenable  to  homologous  
recombination  or  selection-­‐‑based  gene  correction.  For  example,  DMD  patient-­‐‑derived  
primary  dermal  fibroblasts  carrying  a  frame-­‐‑disrupting  deletion  of  exons  46-­‐‑50  (Δ46-­‐‑50)  
were  electroporated  with  plasmids  encoding  TN3/8,  resulting  in  high  frequency  gene  
modification  in  a  dose-­‐‑dependent  manner  (Figure  10a).  These  treated  fibroblasts  were  
then  transduced  with  a  lentivirus  expressing  MyoD  under  an  inducible  promoter  to  
stimulate  transdifferentiation  into  the  myogenic  lineage  and  dystrophin  expression  [157,  
158].  Expression  of  myogenin  (Figure  10b)  and  myosin  heavy  chain  (Figure  10c)  
confirmed  efficient  transdifferentiation  of  wild  type  and  DMD  patient  fibroblasts.  
Rescued  dystrophin  expression  was  detected  in  TALEN-­‐‑treated  MyoD-­‐‑induced  
fibroblasts  in  a  dose-­‐‑dependent  manner  at  the  predicted  size  of  approximately  400  kDa  
(Figure  10b),  similar  to  the  results  obtained  in  skeletal  myoblasts  (Figure  9c,  d).  
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Figure  10:  Dystrophin  reading  frame  restoration  in  primary  dermal  fibroblasts.  
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electroporated  with  increasing  doses  of  the  indicated  amount  of  each  TALEN  plasmid  
and  gene  modification  rates  were  quantified  with  the  Surveyor  assay.  Arrows  denote  
expected  cleavage  band  sizes  indicative  of  NHEJ  activity.  (b)  Analysis  of  myogenin  
and  dystrophin  expression  (MANDYS8)  in  wild-­‐‑type  and  DMD  fibroblasts  after  
treatment  with  TN3/8  and  15  days  of  forced  MyoD  expression.  Protein  from  wild-­‐‑type  
dermal  fibroblasts  is  included  as  a  positive  control  for  full-­‐‑length  dystrophin  
expression  (427  kDa)  relative  to  the  truncated  Δ46-­‐‑50  product  (400  kDa).  (c)  
Immunofluorescence  staining  to  detect  myosin  heavy-­‐‑chain  (MHC)  after  MyoD  
expression  by  lentiviral  gene  transfer.    
3.4.6. Analysis of off-target effects induced by TN3/8 
An  important  concern  for  all  genome  editing  strategies  is  the  potential  for  off-­‐‑
target  gene  modification  events.  TN3/8  does  not  show  significant  cytotoxicity  and  is  well  
tolerated  by  human  cells  (Figures  5b,  e,  f),  suggesting  specific  gene  targeting.  Potential  
off-­‐‑target  sites  were  assessed  in  silico  using  the  TALE-­‐‑NT  2.0  Paired  Target  Finder  
Prediction  webserver  [154]  to  scan  the  human  genome  for  sequences  containing  up  to  4  
mismatches  per  TALEN  half-­‐‑site  (up  to  8  total  mismatches  per  target  site)  separated  by  
spacers  of  any  length  between  12  and  23  bases.  Importantly,  this  analysis  did  not  
produce  any  potential  off-­‐‑target  sites  that  met  these  criteria.  To  further  examine  
unpredicted  off-­‐‑target  DNA  modifications,  we  sequenced  the  whole  exomes  of  clonally  
derived  DMD  myoblasts  that  we  had  previously  confirmed  to  contain  NHEJ  events  at  
the  on-­‐‑target  exon  51  locus  (Figure  7c,  d).  Notably,  the  only  insertion  or  deletion  events  
characteristic  of  NHEJ  were  detected  at  the  on-­‐‑target  exon  51  locus  of  the  dystrophin  
gene  in  all  four  clonal  lines  analyzed,  confirming  the  specificity  of  these  TALENs  (Table  
1,  Appendix  A).  Consistent  with  known  genomic  mutation  rates  that  normally  occur  
during  clonal  expansion,  the  exome  sequencing  revealed  several  single  nucleotide  
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variants  (SNVs)  in  each  clone  relative  to  the  parental  cell  line.  Using  the  TALE-­‐‑NT  2.0  
Paired  Target  Site  Prediction  webserver  [154],  the  immediate  region  around  each  
mutation  was  scanned  for  any  sequence  similarity  to  the  TN3/8  target  site  to  determine  
if  the  TALENs  could  be  responsible  for  the  observed  SNVs.  No  target  sites  with  
similarity  to  our  TALEN  target  site  with  spacers  of  1-­‐‑30  bases  were  found  in  the  flanking  
100  bp  of  any  SNV.  Because  NHEJ-­‐‑mediated  mutagenesis  rarely  results  in  substitutions  
relative  to  indels,  the  detected  SNVs  are  likely  to  have  arisen  during  clonal  expansion  as  
observed  in  other  studies  [80,  150].  In  summary,  there  was  no  apparent  off-­‐‑target  
activity  related  to  TALEN-­‐‑mediated,  NHEJ-­‐‑based  genetic  correction  in  these  clonally  
derived  cells.    
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Table  1:  Summary  of  clonal  sequence  variants  detected  by  exome  sequencing.    
Clone	   Mutation	  
Type	  




32	   Transition	   synonymous	  SNV	   S	   S	   ANKS1B	   12	   99201691	   C	   T	  
	   Transversion	   nonsynonymous	  SNV	   F	   L	   ZNF836	   19	   52659835	   G	   C	  
	   Transition	   synonymous	  SNV	   P	   P	   SASH1	   6	   148664242	   T	   C	  
	   Transversion	   synonymous	  SNV	   L	   L	   DAXX	   6	   33287597	   T	   G	  
	   Transversion	   synonymous	  SNV	   L	   L	   CDH7	   18	   63525175	   T	   A	  
	   Deletion	   frameshift	   -­‐	   -­‐	   DMD	   X	   31792285	   ACCAG	   -­‐	  
106	   Transition	   nonsynonymous	  SNV	   E	   G	   ENG	   9	   130582267	   T	   C	  
	   Transition	   nonsynonymous	  SNV	   N	   D	   CCDC36	   3	   49294344	   A	   G	  
	   Transition	   synonymous	  SNV	   V	   V	   TARBP1	   1	   234556520	   C	   T	  
	   Transition	   nonsynonymous	  SNV	   Q	   R	   UGT3A1	   5	   35988575	   T	   C	  
	   Transversion	   nonsynonymous	  SNV	   L	   I	   SOWAHB	   4	   77817679	   G	   T	  
	   Transversion	   nonsynonymous	  SNV	   Q	   P	   MEF2A	   15	   100252738	   A	   C	  
	   Transversion	   nonsynonymous	  SNV	   R	   L	   RFC1	   4	   39306505	   C	   A	  
	   Transition	   stopgain	  SNV	   Q	   X	   ELN	   7	   73474508	   C	   T	  
	   Deletion	   frameshift	   -­‐	   -­‐	   DMD	   X	   31792285	   ACCAG	   -­‐	  
127	   Transition	   nonsynonymous	  SNV	   A	   V	   PLEKHH1	   14	   68041071	   C	   T	  
	   Transition	   synonymous	  SNV	   P	   P	   RASAL2	   1	   178269222	   C	   T	  
	   Transversion	   nonsynonymous	  SNV	   S	   C	   IGDCC4	   15	   65676357	   G	   C	  
	   Transition	   synonymous	  SNV	   A	   A	   LMTK3	   19	   49001482	   G	   A	  
	   Transition	   stopgain	  SNV	   W	   X	   PLEKHS1	   10	   115526378	   G	   A	  
	   Transition	   nonsynonymous	  SNV	   V	   I	   FAM110C	   2	   45848	   C	   T	  
	   Transition	   nonsynonymous	  SNV	   G	   E	   TRAK1	   3	   42251610	   G	   A	  
	   Transversion	   synonymous	  SNV	   S	   S	   C15orf39	   15	   75499997	   A	   T	  
	   Transition	   synonymous	  SNV	   L	   L	   GPBAR1	   2	   219127549	   C	   T	  
	   Deletion	   nonframeshift	   -­‐	   -­‐	   DMD	   X	   31792284	   CAC	   -­‐	  
141	   Transition	   synonymous	  SNV	   L	   L	   MUC16	   19	   8999474	   T	   C	  
	   Transversion	   nonsynonymous	  SNV	   F	   C	   RP1	   8	   55538286	   T	   G	  
	   Transversion	   nonsynonymous	  SNV	   E	   A	   PPP1R10	   6	   30569808	   C	   G	  
	   Transition	   synonymous	  SNV	   T	   T	   CAMKV	   3	   49896829	   T	   C	  
	   Transition	   synonymous	  SNV	   F	   F	   AK2	   1	   33478842	   G	   A	  
	   Deletion	   nonframeshift	   -­‐	   -­‐	   DMD	   X	   31792287	   CAG	   -­‐	  
  
3.5. Discussion  
NHEJ-­‐‑exclusive  gene  correction  offers  several  potential  advantages  over  the  
HDR  pathway.  For  example,  NHEJ  does  not  require  a  donor  template,  which  may  cause  
nonspecific  insertional  mutagenesis.  In  contrast  to  HDR,  NHEJ  operates  efficiently  in  all  
stages  of  the  cell  cycle  and  therefore  can  be  effectively  exploited  in  both  cycling  and  
post-­‐‑mitotic  cells,  such  as  muscle  fibers.  This  provides  a  robust,  permanent  gene  
restoration  alternative  to  oligonucleotide-­‐‑based  exon  skipping  [4]  or  pharmacologic  
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forced  read-­‐‑through  of  stop  codons  [73]  and  could  theoretically  require  as  few  as  one  
drug  treatment.  NHEJ-­‐‑based  gene  correction  using  TALENs,  as  well  as  other  engineered  
nucleases  including  meganucleases  [89]  and  zinc  finger  nucleases  [159],  is  also  readily  
combined  with  other  existing  ex  vivo  and  in  vivo  platforms  for  cell-­‐‑  and  gene-­‐‑based  
therapies,  in  addition  to  the  plasmid  electroporation  approach  described  here.  For  
example,  delivery  of  TALENs  by  mRNA-­‐‑based  gene  transfer  or  as  purified  cell-­‐‑
permeable  proteins  [40]  could  enable  a  DNA-­‐‑free  genome  editing  approach  that  would  
circumvent  any  possibility  of  insertional  mutagenesis.    
Any  of  these  delivery  methods  could  be  utilized  with  a  myriad  of  cell  types  
currently  under  investigation  for  cell-­‐‑based  therapies  [36],  including  induced  
pluripotent  stem  cells  [29,  32],  bone  marrow-­‐‑derived  progenitors  [33],  skeletal  muscle  
progenitors  [34],  CD133+  cells  [35],  mesoangioblasts  [30],  and  dermal  fibroblasts  [36].  
Additionally,  advances  in  immortalization  of  human  myogenic  cells  may  greatly  
simplify  clonal  derivation  of  genetically  corrected  myogenic  cells  [37].  Significantly,  we  
modified  cells  ex  vivo  and  isolated  and  expanded  clonal  populations  of  immortalized  
DMD  myoblasts  that  contained  a  genetically  corrected  dystrophin  gene  and  were  free  of  
nuclease-­‐‑introduced  mutations  in  protein  coding  regions  of  the  genome.  Alternatively,  
transient  in  vivo  delivery  of  nucleases  by  non-­‐‑viral  or  non-­‐‑integrating  viral  gene  transfer  
[5,  48,  81]  or  by  direct  delivery  of  purified  proteins  [40]  containing  cell-­‐‑penetrating  
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motifs  may  enable  highly  specific  correction  in  situ  with  minimal  or  no  risk  of  exogenous  
DNA  integration.    
Future  studies  are  warranted  to  investigate  the  therapeutic  efficacy  of  this  
approach  and  similar  permanent  gene  editing  strategies  to  correct  endogenous  genes.  
For  example,  rescuing  dystrophin  expression  to  produce  these  “Becker-­‐‑like”  proteins  
theoretically  introduces  novel  epitopes  in  the  restored  C-­‐‑terminus.  Therefore  it  will  be  
important  to  consider  potential  immune  responses  following  permanent  genetic  
correction  of  the  reading  frame  [160],  though  current  exon  skipping  clinical  studies  
suggest  a  minimal  immune  response  to  the  restored  native  gene  product  [70,  71].  Any  
reduced  function  of  restored,  but  truncated,  protein  products  is  another  potential  hurdle  
to  this  strategy.  In  the  case  of  DMD,  naturally  occurring  mutations  and  their  
consequences  are  relatively  well  understood.  It  is  known  that  in-­‐‑frame  deletions  that  
occur  in  the  exon  45-­‐‑55  region  contained  within  the  rod  domain  can  produce  highly  
functional  dystrophin  proteins,  and  many  carriers  are  asymptomatic  or  display  mild  
symptoms  [4].  Theoretically,  greater  than  60%  of  patients  can  be  treated  by  targeting  
exons  in  this  region  of  the  dystrophin  gene  [161].  Collectively,  these  previous  studies  
indicate  that  the  restored  dystrophin  proteins  created  by  our  approach  will  be  highly  
functional  and  alleviate  disease  symptoms  when  expressed  in  skeletal  muscle  tissue.  
Genome  editing  is  a  powerful  approach  for  creating  custom  alterations  to  the  
genome,  as  evidenced  by  the  recent  entrance  of  zinc  finger  nucleases  into  clinical  trials  
  56  
for  disruption  of  the  HIV-­‐‑1  co-­‐‑receptor  CCR5  [12]  and  disruption  of  the  glucocorticoid  
receptor  in  T  cells  for  glioblastoma  treatment.  This  study  utilizes  NHEJ-­‐‑based  genome  
editing  to  restore  the  reading  frame  of  the  dystrophin  gene  in  patient  cells,  in  contrast  to  
the  conventional  use  of  NHEJ  for  gene  knockout.  Given  the  numerous  high-­‐‑throughput  
methods  to  engineer  new  TALENs  [8,  9,  134],  as  well  as  their  apparent  lack  of  
cytotoxicity  [9,  96],  it  should  be  possible  to  rapidly  extrapolate  this  NHEJ  correction  
method  to  other  regions  of  the  dystrophin  gene  as  well  as  other  diseases  that  are  caused  
by  a  loss  of  protein  function  introduced  by  intragenic  insertions,  deletions,  or  aberrant  
stop  codons  in  non-­‐‑essential  regions,  including  collagen  type  VII-­‐‑associated  dystrophic  
epidermolysis  bullosa,  Fukuyama  congenital  muscular  dystrophy,  and  limb-­‐‑girdle  
muscular  dystrophy  type  2B.  However,  the  resulting  functionality  of  these  proteins  
following  partial  gene  correction  remains  to  be  determined,  particularly  for  gene  
deletions  and  associated  phenotypes  that  are  not  as  well-­‐‑defined  as  the  region  targeted  
in  this  study.  Therefore  HDR-­‐‑based  genome  editing  for  complete  restoration  of  gene  
deletions  is  also  a  valuable  approach  to  pursue  in  parallel.  Nevertheless,  NHEJ-­‐‑based  
gene  correction  may  provide  a  versatile  therapy  for  DMD  when  frame  restoration  is  
predicted  to  permanently  correct  the  native  gene  and  restore  protein  function.   
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Chapter 4: Gene Correction of Duchenne Muscular 
Dystrophy by Genomic Excision of Exon 51 using Zinc-
Finger Nucleases 
  
Original  article  co-­‐‑authored  with  Ami  M.  Kabadi,  Pratiksha  I.  Thakore,  Pablo  Perez-­‐‑
Pinera,  Matthew  T.  Brown,  and  Charles  A.  Gersbach  
  
4.1. Synopsis 
Exon  skipping  using  oligonucleotides  has  been  shown  to  be  an  exciting  method  
to  restore  the  dystrophin  reading  frame  and  restore  dystrophin  protein  production.  
However,  these  methods  may  require  repeated  administration  for  the  lifetime  of  the  
patient  and  may  generate  incomplete  skipping  of  the  targeted  exon.  In  this  study,  we  
apply  recent  advances  in  genome  editing  to  permanently  exclude  exons  by  using  zinc-­‐‑
finger  nucleases  (ZFNs)  to  selectively  remove  sequences  important  in  specific  exon  
recognition.  ZFNs  were  designed  to  remove  essential  splicing  sequences  in  exon  51  of  
the  dystrophin  gene  and  thereby  exclude  exon  51  from  the  resulting  dystrophin  
transcript,  a  method  that  can  potentially  restore  the  dystrophin  reading  frame  in  up  to  
13%  of  DMD  patient  deletions.  Nucleases  were  assembled  by  extended  modular  
assembly  and  context-­‐‑dependent  assembly  methods  and  screened  for  activity  in  human  
cells.  Two  active  ZFN  pairs  flanking  the  exon  51  splice  acceptor  site  were  transfected  
into  DMD  patient  cells  and  a  clonal  population  was  isolated  with  this  region  deleted  
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from  the  genome.  Deletion  of  the  genomic  sequence  containing  the  splice  acceptor  
resulted  in  the  loss  of  exon  51  from  the  dystrophin  mRNA  transcript  and  restoration  of  
dystrophin  expression  in  vitro.  Furthermore,  transplantation  of  corrected  cells  into  the  
hind  limb  of  immunodeficient  mice  resulted  in  efficient  human  dystrophin  expression  
localized  to  the  sarcolemmal  membrane.  Finally,  the  toxicity  of  selected  ZFNs  was  
characterized  by  measuring  cytotoxicity  in  human  cells  and  by  quantifying  off-­‐‑target  
mutagenesis  at  predicted  chromosomal  sites.  This  study  demonstrates  a  powerful  
method  to  correct  the  dystrophin  reading  frame  by  permanently  deleting  exons  to  
restore  dystrophin  protein  expression.  
4.2. Introduction 
Designer  enzymes  have  rapidly  enabled  the  precise  manipulation  of  genomic  
sequences  of  interest  in  complex  genomes  [6,  162].  The  rapid  development  of  designer  
enzymes  such  as  ZFNs  [6],  TALENs  [75],  and  the  more  recently  described  RNA-­‐‑guided  
CRISPR/Cas9  system  [10]  has  enabled  the  possibility  of  genomic  therapy.  Nuclease-­‐‑
mediated  gene  editing  strategies  facilitate  site-­‐‑specific  changes  to  a  target  genome  by  
creating  double  strand  breaks  that  stimulate  cellular  DNA  repair  pathways.  These  
pathways  result  either  in  error-­‐‑prone  DNA  repair  through  non-­‐‑homologous  end-­‐‑joining  
in  the  absence  of  a  donor  DNA  molecule  or  in  specific  changes  guided  by  homology  
directed  repair  when  co-­‐‑delivered  with  a  repair  template.  Genome  editing  has  been  
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demonstrated  to  be  a  powerful  method  to  study  and/or  correct  monogenic  mutations  
associated  with  hereditary  disease  [31,  42,  77,  81,  150,  163,  164].  
The  severe  X-­‐‑linked  hereditary  disease  Duchenne  muscular  dystrophy  is  caused  
by  mutations  in  the  dystrophin  gene  [2]  that  prematurely  truncate  this  essential  
musculoskeletal  protein.  The  loss  of  functional  dystrophin  expression  causes  
progressive  muscle  wasting  leading  to  death  by  the  third  decade  of  life  in  these  patients.  
Oligonucleotide-­‐‑based  exon  skipping  is  a  powerful  method  to  exclude  specific  exons  
and  has  been  exploited  to  restore  the  dystrophin  gene  around  frame-­‐‑disrupting  
deletions  adjacent  to  exon  51,  thereby  addressing  potentially  up  to  13%  of  all  DMD  
patient  deletions  [4,  23,  24].  This  transient  restoration  requires  regular  administration  of  
the  exon  skipping  drug  for  the  life  of  the  patient.  In  contrast  to  transient  methods,  
genome  editing  creates  stable  changes  to  a  gene  in  a  modified  cell  that  persists  even  after  
cell  division.  Targeted  frameshifts  using  site-­‐‑specific  nucleases  has  been  demonstrated  to  
be  a  promising  method  to  correct  the  dystrophin  gene  [42,  90,  163].  However,  the  
introduction  of  random  small  insertions  and  deletions  in  the  dystrophin  gene  result  in  
heterogeneous  changes  to  the  final  protein  product  that  may  impact  the  predictability  
and  reliability  of  the  resulting  protein  function.  Thus,  it  would  be  advantageous  to  
explore  a  gene  correction  method  that  results  in  an  expected  protein  product  with  
predictable  functionality.  
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Zinc-­‐‑finger  nucleases  (ZFNs)  are  a  widely  studied  tool  to  create  targeted  genetic  
modifications.  ZFNs  are  polydactyl  proteins  that  recognize  DNA  by  linking  individual  
zinc-­‐‑finger  (ZF)  motifs,  with  each  motif  recognizing  3  bp  of  DNA,  in  tandem  [6].  Site-­‐‑
specific  double-­‐‑strand  breaks  are  created  when  two  independent  ZFN  monomers  bind  
to  adjacent  target  DNA  sequences,  thereby  permitting  dimerization  of  FokI  and  cleavage  
of  the  target  DNA.  Thus,  since  FokI  acts  as  a  dimer,  these  nucleases  are  designed  in  pairs  
to  guide  each  half  of  FokI  to  a  desired  target  site.  Several  improvements  have  been  made  
to  enhance  the  specificity  of  these  chimeric  nucleases  including  restriction  on  spacer  
length  between  ZFN  monomers  [165],  obligate  heterodimers  [114,  115],  generation  of  
autonomous  ZFN  pairs  [91],  and  enhancement  of  the  cleavage  activity  of  FokI  [118].  In  
the  past  decade,  numerous  preclinical  studies  have  descried  the  therapeutic  utility  of  
ZFNs  in  to  correct  several  other  human  genetic  mutations  associated  with  sickle  cell  
anemia  [78,  79],  X-­‐‑linked  SCID  [77],  and  alpha-­‐‑1-­‐‑antitrypsin  deficiency  [80],  and  
haemophilia  [81,  87].  Significantly,  ZFNs  are  now  being  tested  in  Phase  I/II  clinical  trials  
for  disruption  of  the  HIV-­‐‑1  co-­‐‑receptor  CCR5  [12,  144].    
Genome  editing  can  be  utilized  to  generate  precise  genomic  deletions  at  a  
targeted  genomic  locus  [91,  92].  In  this  study,  we  engineered  zinc-­‐‑finger  nucleases  
(ZFNs)  to  specifically  delete  exon  51  from  the  dystrophin  gene  to  generate  precise  and  
repeatable  frameshifts  in  the  resulting  transcript  in  DMD  patient  cells  by  the  loss  of  this  
exon.  The  advantage  of  this  method  is  that  the  resulting  changes  to  the  dystrophin  
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transcript  will  generate  restored  dystrophin  proteins  with  predictable  protein  sequence.  
First,  we  engineered  a  panel  of  zinc-­‐‑finger  nuclease  proteins  using  the  publicly  available  
extended  Modular  Assembly  (e-­‐‑MA)  [159]  or  Context-­‐‑Dependent  Assembly  (CoDA)  
[128]  methods.  Engineered  nucleases  were  screened  for  activity  by  reporter  assays  in  
human  cells  and  by  monitoring  gene-­‐‑editing  activities  at  the  intended  chromosomal  loci.  
Several  ZFN  pairs  demonstrated  measurable  activity  at  their  intended  chromosomal  
target,  including  two  ZFN  pairs  flanking  the  splice  acceptor  of  exon  51.  Active  ZFN  
pairs  were  observed  to  have  modest  levels  of  cytotoxicity  and  one  ZFN  pair  had  low  
levels  of  detectable  off-­‐‑target  mutagenesis  as  detected  by  the  Surveyor  assay.  Two  
selected  ZFN  pairs  were  transfected  into  DMD  patient  cells  and  a  clonal  cell  line  was  
isolated  harboring  the  intended  genetic  deletion.  After  differentiation,  we  demonstrate  
that  exon  51  is  lost  from  the  mRNA  transcript  and  dystrophin  protein  expression  was  
restored.  Furthermore,  these  cells  express  human  dystrophin  properly  localized  to  the  
sarcolemma  membrane  following  transplantation  into  the  hind  limb  of  immunodeficient  
mice.  Importantly,  this  study  demonstrates  a  general  method  to  delete  sequences  from  
the  genome  that  result  in  permanent  exclusion  of  a  specific  exon  from  the  resulting  
mRNA  transcript,  thereby  predictably  restoring  expression  of  the  dystrophin  protein.  
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4.3. Materials and Methods 
4.3.1. Plasmid constructs 
Extended  Modular  Assembly  ZFNs  were  constructed  using  standard  molecular  
biology  techniques  from  a  library  of  predefined  zinc  finger  modules  with  predefined  
specificity  [125]  as  described  [159]  in  expression  vectors  containing  the  wild-­‐‑type  FokI  
nuclease  domain.  In  some  cases,  this  library  was  supplemented  with  additional  ZFs  
targeting  TGC  or  TCT  by  grafting  a  recognition  helix  sequence  (Appendix  B)  obtained  
from  ZiFiT16  onto  the  Sp1C  zinc-­‐‑finger  motif  backbone  used  by  the  other  modular  
assembly  ZFs.  Coding  regions  for  Context-­‐‑Dependent  Assembly  [128]  ZFNs  were  
synthesized  by  BioBasic,  Inc.  (Ontario,  Canada)  and  cloned  by  standard  molecular  
biology  techniques.  The  linker  used  to  join  zinc-­‐‑finger  domains  to  the  FokI  domain  was  
dependent  on  the  spacer  size  between  the  half-­‐‑sites,  with  the  amino  acid  sequences  
HLRGS  for  5  base-­‐‑pair  spacers,  HTGAAARA  for  6  base-­‐‑pair  spacers,  and  
HTGPGAAARA  for  7  base-­‐‑pair  spacers  [165].  For  all  ZFN  assays  at  chromosomal  loci,  
FokI  domains  were  modified  using  both  the  ELD/KKR  obligate  heterodimer  mutations  
[115]  and  the  Sharkey  mutations  [118]  as  described  previously  [153].  Sequences  for  ZFN  
target  sites  Appendix  B.    
4.3.2. Cell culture and transfection 
HEK293T  cells  were  obtained  from  the  American  Tissue  Collection  Center  
(ATCC)  through  the  Duke  Cell  Culture  Facility  and  were  maintained  in  DMEM  
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supplemented  with  10%  fetal  bovine  calf  serum  and  1%  penicillin/streptomycin.  
Immortalized  myoblasts  [152]  from  a  DMD  patient  harboring  a  deletion  of  exons  48-­‐‑50  
(Δ48-­‐‑50)  in  the  dystrophin  gene  were  maintained  in  skeletal  muscle  media  (PromoCell)  
supplemented  with  20%  fetal  bovine  calf  serum  (Sigma),  50  µμg/ml  fetuin,  10  ng/ml  
human  epidermal  growth  factor  (Sigma),  1  ng/ml  human  basic  fibroblast  growth  factor  
(Sigma),  10  µμg/ml  human  insulin  (Sigma),  1%  GlutaMAX  (Invitrogen),  and  1%  
penicillin/streptomycin  (Invitrogen).  All  cell  lines  were  maintained  at  37°C  and  5%  CO2.  
For  screening  ZFN  activity  at  chromosomal  loci,  human  HEK293T  cells  were  transfected  
with  Lipofectamine  2000  (Invitrogen)  with  400  ng  of  each  expression  vector  according  to  
the  manufacturer’s  protocol  in  24  well  plates.  Immortalized  myoblasts  were  transfected  
with  10  micrograms  of  each  expression  vector  by  electroporation  using  the  Gene  Pulser  
XCell  (BioRad)  with  PBS  as  an  electroporation  buffer  using  optimized  conditions  [42].  
Transfection  efficiencies  were  measured  by  delivering  an  eGFP  expression  plasmid  
(pmaxGFP,  Clontech)  and  using  flow  cytometry.  These  efficiencies  were  routinely  ≥95%  
for  HEK293T  and  ≥70%  for  the  immortalized  myoblasts.    
4.3.3. Single-strand annealing assay 
For  this  assay,  extended  modular  assembly  ZFNs  were  constructed  in  vectors  
utilizing  the  wild-­‐‑type  FokI  domain.  Construction  of  the  SSA  luciferase  reporter  plasmid  
pSSA  Rep  3-­‐‑1  has  been  described  previously  [159].  Briefly,  ZFN  binding  sites  were  
introduced  into  the  left  and/or  right  arms  of  a  split  firefly  luciferase  gene  by  PCR,  and  
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cloned  into  the  BglII/EcoRI  sites  of  the  vector.  All  primers  used  for  SSA  construction  are  
listed  in  the  Appendix  B.  Human  HEK293T  cells  were  co-­‐‑transfected  with  25  ng  of  each  
ZFN  monomer  expression  plasmid  and  25  ng  of  SSA  reporter  plasmid  in  96  well-­‐‑plates  
using  Lipofectamine  2000  (Invitrogen)  according  to  the  manufacturer’s  instructions.  
Cells  were  lysed  directly  in  the  plate  and  30  microliters  of  each  lysate  was  transferred  to  
96  well  plates  for  analysis  using  the  Bright-­‐‑Glo  Luciferase  Assay  System  (Promega  
E2620)  and  a  luminescence  plate  reader  (1  second  integration).  
4.3.4. Surveyor assay for endogenous gene modification 
Genetic  modifications  were  quantified  using  the  Surveyor  nuclease  assay  [166],  
which  detects  mutations  characteristic  of  nuclease-­‐‑mediated  NHEJ.  After  transfection,  
cells  were  incubated  for  3  or  10  days  at  37°C  and  genomic  DNA  was  extracted  using  the  
DNeasy  Blood  and  Tissue  kit  (QIAGEN).  The  target  locus  was  amplified  by  35  cycles  of  
PCR  with  the  AccuPrime  High  Fidelity  PCR  kit  (Invitrogen)  using  primers  specific  to  
each  locus  (Appendix  B).  The  resulting  PCR  products  were  randomly  melted  and  
reannealed  in  a  thermal  cycler  with  the  program:  95°C  for  240  s,  followed  by  85°C  for  60  
s,  75°C  for  60s,  65°C  for  60s,  55°C  for  60  s,  45°C  for  60  s,  35°C  for  60  s,  and  25°C  for  60s  
with  a  -­‐‑0.3°C/s  rate  between  steps.  Following  reannealing,  8  µμl  of  PCR  product  was  
mixed  with  1  µμl  of  Surveyor  Nuclease  S  and  1  µμl  of  Enhancer  S  (Transgenomic)  and  
incubated  at  42°C  for  1  hour.  After  incubation,  6  µμl  of  digestion  product  was  loaded  onto  
a  10%  TBE  polyacrylamide  gel  and  run  at  200V  for  30  min.  The  gels  were  stained  with  
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ethidium  bromide  and  quantified  by  densitometry  using  the  ImageLab  software  suite  
(Bio-­‐‑Rad)  as  previously  described  [166].  
4.3.5. PCR-based assay to detect genomic deletions  
The  exon  51  locus  was  amplified  from  genomic  DNA  by  PCR  (Invitrogen  
AccuPrime  High  Fidelity  PCR  kit)  using  Cel-­‐‑I  primers  flanking  the  DZF-­‐‑1  (CelI-­‐‑
DZF1/2/10-­‐‑R)  and  DZF-­‐‑9  (CelI-­‐‑DZF9-­‐‑F)  target  sites  (Appendix  B).  PCR  products  were  
separated  on  TAE-­‐‑agarose  gels  and  stained  with  ethidium  bromide  for  analysis.  
4.3.6 Clone isolation procedure  
Immortalized  DMD  myoblasts  were  electroporated  with  5  µμg  of  each  ZFN  
plasmid  (10  µμg  total).  After  7  days,  isogenic  clones  were  isolated  by  clonal  density  
isolation.  Genomic  DNA  was  extracted  from  clones  using  the  QuickExtract  Kit  
(Epicentre)  and  the  target  locus  amplified  by  PCR  using  primers  to  detect  the  expected  
genomic  deletion  as  above  (Appendix  B).  The  resulting  PCR  products  were  analyzed  to  
identify  clones  carrying  the  expected  deletion  and  verified  by  Sanger  sequencing.  
4.3.7. mRNA analysis  
Immortalized  myoblasts  were  differentiated  into  myofibers  by  replacing  the  
growth  medium  with  DMEM  supplemented  with  1%  insulin-­‐‑transferrin-­‐‑selenium  
(Invitrogen  #51500056)  and  1%  penicillin/streptomycin  (Invitrogen  #15140)  for  6  days  
before  the  cells  were  trypsinized  and  collected.  Total  RNA  was  isolated  from  these  cells  
using  the  RNeasy  Plus  Mini  Kit  (QIAGEN)  according  to  the  manufacturer’s  instructions.  
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RNA  was  reverse  transcribed  to  cDNA  using  the  VILO  cDNA  synthesis  kit  (Life  
Technologies  #11754)  and  1.5  micrograms  of  RNA  for  2  hours  at  42°C  according  to  the  
manufacturer’s  instructions.  The  target  loci  were  amplified  by  35  cycles  of  PCR  with  the  
AccuPrime  High  Fidelity  PCR  kit  (Invitrogen)  using  primers  annealing  to  exons  44  and  
52  (Appendix  B).  PCR  products  were  run  on  TAE-­‐‑agarose  gels  and  stained  with  
ethidium  bromide  for  analysis.  
4.3.8. Western blot analysis  
To  assess  dystrophin  protein  expression,  immortalized  myoblasts  were  
differentiated  into  myofibers  as  above  for  6  days.  Cells  were  trypsinized,  collected  and  
lysed  in  RIPA  buffer  (Sigma)  supplemented  with  a  protease  inhibitor  cocktail  (Sigma)  
and  the  total  protein  amount  was  quantified  using  the  bicinchoninic  acid  assay  
according  to  the  manufacturer’s  instructions  (Pierce).  Samples  were  then  mixed  with  
NuPAGE  loading  buffer  (Invitrogen)  and  5%  β-­‐‑mercaptoethanol  and  heated  to  85°C  for  
10  minutes.  Twenty-­‐‑five  micrograms  of  protein  were  separated  on  4-­‐‑12%  NuPAGE  Bis-­‐‑
Tris  gels  (Invitrogen)  with  MES  buffer  (Invitrogen).  Proteins  were  transferred  to  
nitrocellulose  membranes  for  1-­‐‑2  hours  in  1X  tris-­‐‑glycine  transfer  buffer  containing  10%  
methanol  and  0.01%  SDS.  The  blot  was  then  blocked  for  1  hour  with  5%  milk-­‐‑TBST  at  
room  temperature.  Blots  were  probed  with  the  following  antibodies  in  5%  milk-­‐‑TBST:  
anti-­‐‑dystrophin  C-­‐‑terminus  (1:25  overnight  at  4°C,  Leica  NCL-­‐‑DYS2),  anti-­‐‑dystrophin  
rod  domain  (1:1000  one  hour  at  room  temperature,  Sigma  MANDYS8),  and  anti-­‐‑
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GAPDH  (1:5000  overnight  at  4°C,  Cell  Signal  2118S).  Blots  were  then  incubated  with  
horseradish  peroxidase-­‐‑conjugated  secondary  antibodies  (Santa  Cruz)  and  visualized  
using  the  ChemiDoc  chemilumescent  system  (BioRad)  and  Western-­‐‑C  ECL  substrate  
(BioRad).  
4.3.9. Transplantation into immunodeficient mice  
All  animal  experiments  were  conducted  under  protocols  approved  by  the  Duke  
Institutional  Animal  Care  &  Use  Committee.  Cells  were  trypsinized,  collected  and  
washed  in  1X  Hank’s  Balanced  Salt  Solution  (HBSS,  Sigma).  Two  million  cells  were  
pelleted  and  resuspended  in  five  µμL  1X  HBSS  (Sigma)  supplemented  with  cardiotoxin  
(Sigma  #C9759)  immediately  prior  to  injection.  These  cells  were  transplanted  into  the  
hind  limb  tibialis  anterior  (TA)  muscle  of  NOD.SCID.gamma  (NSG)  mice  (Duke  CCIF  
Breeding  Core)  by  intramuscular  injection.  Four  weeks  after  injection,  mice  were  
euthanized  and  the  TA  muscles  were  harvested.  
4.3.10. Immunofluorescence staining  
Harvested  TA  muscles  were  incubated  in  30%  glycerol  overnight  at  4°C  before  
mounting  and  freezing  in  Optimal  Cutting  Temperature  compound.  Serial  10  micron  
sections  were  obtained  by  cryosectioning  of  the  embedded  muscle  tissue  at  -­‐‑20°C.  
Cryosections  were  then  washed  in  PBS  to  remove  the  OCT  compound  and  subsequently  
blocked  for  30-­‐‑60  minutes  at  room  temperature  in  PBS  containing  10%  heat-­‐‑inactivated  
fetal  bovine  serum  for  spectrin  detection  or  5%  heat-­‐‑inactivated  fetal  bovine  serum  for  
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dystrophin  detection.  Cryosections  were  incubated  overnight  at  4°C  with  the  following  
primary  antibodies  that  are  specific  to  human  epitopes  only:  anti-­‐‑spectrin  (1:20,  Leica  
NCL-­‐‑SPEC1)  or  anti-­‐‑dystrophin  (1:10,  Leica  NCL-­‐‑DYS3).  After  primary  staining,  
spectrin  or  dystrophin  expression  was  detected  using  a  tyramide-­‐‑based  
immunofluorescence  signal  amplification  detection  kit  (Life  Technologies,  TSA  Kit  #22,  
catalog  #T-­‐‑20932,).  Briefly,  cryosections  were  incubated  with  1:200  goat  anti-­‐‑mouse  
biotin-­‐‑XX  secondary  (Life  Technologies  #B2763)  in  blocking  buffer  for  one  hour  at  room  
temperature.  The  signal  was  then  amplified  using  streptavidin-­‐‑HRP  conjugates  (1:100,  
from  TSA  Kit)  in  blocking  buffer  for  one  hour  at  room  temperature.  Finally,  cryosections  
were  incubated  with  tyramide-­‐‑AlexaFluor488  conjugates  (1:100,  TSA  kit)  in  
manufacturer-­‐‑provided  amplification  buffer  for  10  minutes  at  room  temperature.  
Stained  cryosections  were  then  mounted  in  ProLong  AntiFade  (Life  Technologies  
#P36934)  and  visualized  with  conventional  fluorescence  microscopy.  
4.3.11. Cytotoxicity assay 
  To  quantitatively  assess  nuclease-­‐‑associated  cytotoxicity,  HEK293T  cells  were  
transfected  with  10  ng  of  a  GFP  reporter  and  100  ng  of  each  ZFN  expression  vector  using  
Lipofectamine  2000  according  to  the  manufacturer’s  instructions  (Invitrogen).  The  
percentage  of  GFP  positive  cells  was  assessed  at  2  and  5  days  by  flow  cytometry.  The  
survival  rate  was  calculated  as  the  decrease  in  GFP  positive  cells  from  days  2  to  5  and  
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normalized  to  cells  transfected  with  an  empty  nuclease  expression  vector  as  described  
[155].  
4.3.12. Off-target analysis using the PROGNOS predictive algorithm 
Potential  off-­‐‑target  sites  were  scanned  for  off-­‐‑targets  using  the  recommended  
parameters  and  the  ZFN2.0  algorithm  [167].  Briefly,  the  maximum  number  of  
mismatches  allowed  were  considered  for  the  length  of  the  target  site  according  to  the  
software,  heterodimeric  and  homodimeric  target  sites  were  allowed,  and  the  top  sites  
were  binned  for  spacer  lengths  ideal  for  the  zinc-­‐‑finger  and  FokI  protein  linker  utilized  
in  each  monomer.  For  the  purposes  of  this  study,  DZF-­‐‑1  L6/R6  (linker:  HTGAAARA)  
was  assumed  to  have  optimal  activity  on  targets  with  6  or  7  base-­‐‑pair  spacers  between  
half-­‐‑sites  [165].  Similarly,  DZF-­‐‑9  (linker:  HLRGS)  was  assumed  to  have  ideal  activity  on  
5  or  6  base-­‐‑pair  spacers.  Ten  micrograms  of  each  monomer  was  electroporated  into  
human  DMD  patient  myoblasts  as  described  above  and  genomic  DNA  was  collected  3  
days  following  transfection.  Potential  off-­‐‑target  loci  were  PCR  amplified  using  primers  
were  generated  from  the  PROGNOS  output  (Appendix  B)  and  off-­‐‑target  activity  was  
quantified  using  the  Surveyor  assay  as  described  above.    
4.4. Results 
4.4.1. Design of ZFNs to target exon 51 
The  generation  of  ZFN  pairs  that  are  highly  active  at  chromosomal  loci  remains  a  
significant  challenge  in  using  this  technology.  Thus,  we  sought  to  create  a  large  panel  of  
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ZFN  pairs  with  targets  across  exon  51  of  the  dystrophin  gene  and  its  flanking  introns  
with  the  goal  of  finding  a  combination  of  ZFN  pairs  to  delete  the  entire  exon  or  
sequences  important  to  its  proper  splicing  in  the  resulting  mRNA  transcript  (Figure  11).  
Using  a  publicly  available  webserver  [168],  this  region  was  scanned  for  Context-­‐‑
Dependent  Assembly  (CoDA)  ZFN  targets  and  several  potential  ZFN  pairs  were  
assembled.  To  supplement  the  limited  number  of  available  CoDA  targets  at  this  locus,  
we  engineered  several  additional  ZFN  pairs  using  the  previously  described  extended  
Modular  Assembly  (e-­‐‑MA)  method  [159].  Together,  these  ZFN  pairs  are  designed  to  
flank  the  entire  exon  or  either  of  the  two  splice  junctions  on  the  5’  or  3’  end,  respectively.  
Deletion  of  one  or  more  of  these  conserved  splice  junctions  was  predicted  to  result  in  
loss  of  the  entire  exon  from  the  dystrophin  transcript.  
  
Figure  11:  Design  of  ZFNs  targeted  to  exon  51.  ZFN  pairs  (shown  as  blocks)  
were  designed  as  a  panel  of  targets  across  exon  51  and  the  flanking  introns.  
4.4.2. Screening for activity of extended Modular Assembly ZFNs 
Extended  modular  assembly  assumes  that  active  ZFNs  are  likely  to  have  three  to  
six  zinc  finger  motifs  in  tandem.  Accordingly,  a  panel  of  e-­‐‑MA  ZFNs  was  designed  
FIGURE 1 
Exon 51 
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against  exon  51  and  the  flanking  introns  in  silico  using  the  publicly  available  Zinc  Finger  
Tools  website  [124,  168]  to  construct  ZFNs  by  e-­‐‑MA.  We  generated  dozens  of  engineered  
proteins  consisting  of  three  to  six  zinc  fingers  per  target  site  across  six  target  sites.  We  
screened  these  e-­‐‑MA  ZFNs  for  activity  against  their  cognate  target  site  to  identify  
optimal  zinc  finger  composition  using  an  episomal  luciferase  reporter  assay  for  ZFN  
activity.  This  assay  utilizes  a  split  luciferase  gene  that  has  a  specific  target  site  separating  
a  flanking  region  of  luciferase  homology  that  will  recombine  to  form  active  luciferase  
when  the  target  site  is  correctly  recognized  and  cleaved  by  a  ZFN  pair  (Figure  12a).  
Following  transfection  into  human  cells,  nine  candidate  e-­‐‑MA  ZFNs  with  high  activity  
were  identified  for  further  analysis  (Figure  12b).  Notably,  similar  to  previous  studies  for  
extended  modular  assembly  ZFNs  [159],  increased  activity  was  observed  as  additional  
zinc-­‐‑finger  motifs  were  added  to  a  ZFN  monomer,  particularly  at  four  or  more  zinc-­‐‑
fingers  per  half  site.    
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Figure  12: Screening  for  active  extended  modular  assembly  ZFNs  using  an  
episomal  reporter  assay.  All  ZFNs  used  the  wild-­‐‑type  FokI  nuclease  domain.  (a)  
Schematic  of  single-­‐‑stranded  annealing  assay  to  detect  ZFN  activity.  Each  target  site  
was  cloned  between  a  split  luciferase  reporter  with  flanking  homology  on  either  side  
of  each  target  sequence.  Luciferase  expression  occurs  when  a  ZFN  pair  successfully  
recognizes  and  cleaves  its  cognate  site  in  the  reporter,  causing  single-­‐‑strand  annealing  
and  recombination  of  an  active  luciferase  gene.  (b)  Activity  of  different  combinations  
of  extended  modular  assembly  ZFN  pairs  compared  to  reporter  only  control  in  
HEK293T  cells.  Asterisks  indicate  ZFN  pairs  selected  for  further  testing.  
4.4.3. Evaluation of ZFN activity at endogenous targets 
An  alternative  method  of  ZFN  design,  termed  context-­‐‑dependent  assembly  
(CoDA)  [128],  creates  ZFNs  with  novel  DNA  recognition  by  recombining  a  library  of  
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previously  characterized  zinc  finger  arrays.  Initial  studies  suggested  that  this  method  
engineers  new  ZFNs  with  a  50%  success  rate  for  cleaving  a  chromosomal  target.  This  is  a  
significantly  higher  rate  than  previously  described  for  engineering  novel  modular  
assembly  ZFNs,  though  extended  modular  assembly  techniques  may  reach  similar  
success  rates  [159].  Seven  CoDA  ZFNs  were  selected  and  the  gene  constructs  encoding  
these  ZFNs  were  assembled.  Since  CoDA  ZFNs  have  an  established  high  success  rate  
[128],  each  ZFN  pair  was  immediately  tested  for  activity  at  chromosomal  loci.  Nine  
highly  active  e-­‐‑MA  ZFNs  (Figure  12b)  and  seven  designed  CoDA  ZFNs  were  
electroporated  into  human  myoblasts  to  test  their  ability  to  cleave  target  chromosomal  
loci.  Using  the  Surveyor  assay,  we  identified  three  e-­‐‑MA  ZFNs  and  three  CoDA  ZFNs  
that  had  activity  at  the  intended  chromosomal  locus  (Figure  13a).  Gene  modification  
was  still  detectable  for  4  out  of  6  ZFN  pairs  after  10  days,  and  remained  stable  (<25%  
signal  change)  for  all  tested  e-­‐‑MA  ZFNs  (Figure  13b).  Interestingly,  despite  efficient  
gene  editing  activity  at  3  days  post-­‐‑transfection,  all  three  CoDA  ZFNs  showed  a  
significant  or  complete  loss  of  signal  by  day  10  (Figure  13b).    
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Figure  13:  Evaluation  and  characterization  of  selected  ZFNs  in  human  cells.  (a)  
400ng  of  each  monomer  expression  plasmid  for  all  CoDA-­‐‑ZFNs  and  selected  eMA-­‐‑
ZFNs  were  transfected  into  HEK293Ts  and  endogenous  gene  editing  activity  
measured  at  3  days  post-­‐‑transfection  by  the  Surveyor  assay.  (b)  Activity  of  ZFN  pairs  
with  measurable  activity  in  (a)  at  10  days  post-­‐‑transfection.  The  ratio  of  gene  editing  
activity  at  3  and  10  days  was  calculated  from  the  data  in  (a)  and  (b).  n.d.:  not  detected.  
n.q.:  not  quantified.  (c)  Results  of  a  GFP  retention-­‐‑based  cytotoxicity  assay  in  
HEK293T  cells  after  transfection  with  the  indicated  nucleases  and  a  GFP  reporter.  
Percentage  survival  was  calculated  as  the  ratio  of  percent  GFP  cells  positive  at  days  2  
or  5  post-­‐‑transfection  and  normalized  to  mock  transfection  in  the  absence  of  
nucleases.  
FIGURE 3 
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4.4.4. Characterization of ZFN cytotoxicity 
To  further  assess  the  toxicity  of  designed  ZFNs,  we  transfected  human  cells  with  
constructs  carrying  the  six  ZFNs  with  detectable  chromosomal  gene  editing  activity  
(Figure  13a,b).  The  cytotoxicity  of  these  ZFNs  was  evaluated  using  a  flow  cytometry-­‐‑
based  GFP  retention  assay  that  measures  the  survival  of  highly  transfected  cells  in  a  
bulk  population  of  transfected  cells  [42].  All  of  the  ZFNs  tested  had  moderate  levels  of  
cytotoxicity  compared  to  I-­‐‑SceI,  a  known  non-­‐‑toxic  nuclease,  and  GZF3,  a  toxic  ZFN  pair  
(Figure  13c).  Interestingly,  a  modest  increase  in  cytotoxicity  was  observed  as  the  number  
of  ZF  motifs  was  increased  in  creating  an  e-­‐‑MA  ZFN  pair  targeted  to  DZF-­‐‑1  sequence.  
Despite  displaying  mildly  increased  cytotoxicity,  gene  editing  activity  appeared  stable  
for  all  DZF-­‐‑1  targeting  ZFN  pairs  (Figures  13a,b).  Overall,  the  ZFN  pairs  engineered  in  
this  study  had  measured  cytotoxicities  comparable  to  two  other  well-­‐‑characterized  ZFNs  
targeting  AAVS1  [169]  or  CCR5  [12]  loci.  
4.4.5. Restoration of the dystrophin gene by deleting exon 51 from the 
genome 
Co-­‐‑expression  of  two  nucleases  has  been  demonstrated  to  mediate  deletion  of  the  
intervening  chromosomal  sequence  between  the  two  nuclease  target  sites  [91,  92].  This  
could  be  exploited  to  permanently  delete  an  exon  at  the  genetic  level,  in  contrast  to  
current  methods  that  transiently  remove  the  exon  at  the  mRNA  level.  To  apply  this  to  
deleting  exon  51,  we  utilized  two  ZFNs,  DZF-­‐‑1  L6/R6  and  DZF-­‐‑9,  that  were  identified  to  
efficiently  cleave  chromosomal  targets  that  flank  the  exon  51  splice  acceptor  sequence  
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(Figures  13a  and  14a).  Co-­‐‑expression  of  these  ZFNs  is  intended  to  result  in  excision  of  
the  intervening  2.7  kb  segment  that  is  expected  to  contain  sequences  necessary  to  
include  exon  51  in  the  dystrophin  mRNA  transcript  (Figure  14a).  Constructs  encoding  
the  DZF-­‐‑1  L6/R6  and  DZF-­‐‑9  ZFN  pairs  were  electroporated  into  DMD  patient  
myoblasts.  We  verified  that  each  ZFN  pair  was  active  in  human  DMD  patient  cells  
(Figure  14b).  The  expected  genomic  deletions  were  detected  by  end-­‐‑point  PCR  only  in  
cell  populations  treated  with  both  combinations  of  ZFNs  (Figure  14c).  After  verifying  
the  presence  of  the  expected  genomic  deletion,  isogenic  clones  of  DMD  patient  cells  
were  derived  and  screened  for  this  deletion  event.  One  clone  of  interest  was  identified  
and  Sanger  sequencing  analysis  confirmed  a  new  junction  of  intron  50  and  intron  51  
sequences  flanking  the  target  sites  of  the  ZFN  pairs,  resulting  in  the  loss  of  the  2.7kb  
region  from  the  genome  (Figure  14d).  After  this  2.7kb  sequence  is  removed,  only  a  
partial  fragment  of  exon  51  remains  in  the  genome.  Since  the  deleted  segment  includes  
essential  splice  acceptor  sequences,  the  remaining  exon  51  fragment  is  unlikely  to  be  
incorporated  into  the  dystrophin  mRNA  transcript,  resulting  in  the  loss  of  exon  51  
entirely.  After  differentiating  this  clonal  population  into  myoblasts,  mRNA  RT-­‐‑PCR  
analysis  showed  that  exon  51  was  indeed  efficiently  removed  from  the  dystrophin  
transcript  (Figure  14e).  Furthermore,  genomic  deletion  and  removal  of  exon  51  from  the  
dystrophin  transcript  resulted  in  restored  dystrophin  expression  in  these  cells  (Figure  
14f),  detected  with  antibodies  targeting  upstream  (MANDYS8)  and  downstream  (NCL-­‐‑
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Dys2)  of  the  corrected  patient  mutation.  These  data  demonstrate  that  gene  editing  is  an  
effective  method  to  specifically  delete  exons  by  removing  essential  splicing  sequences  
from  the  genome.  
  
Figure  14:  Restoration  of  the  dystrophin  reading  frame  in  patient  cells.  (a)  
Schematic  of  strategy  to  delete  exon  51  from  the  dystrophin  gene  locus.  DZF-­‐‑1  and  
DZF-­‐‑9  flank  the  5’  splice  acceptor  site  of  exon  51,  which  is  removed  after  genomic  
FIGURE 4 
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deletion.  P1/P2:  Primers  used  for  genomic  deletion  PCR  in  (c).  (b)  Gene  modification  
activities  of  DZF-­‐‑1  L6/R6  and  DZF-­‐‑9  as  measured  by  the  Surveyor  assay  after  
electroporation  of  10  micrograms  of  each  monomer  expression  cassette  into  DMD  
patient  cells.  (c)  End-­‐‑point  genomic  PCR  across  deleted  locus  in  human  HEK293T  or  
DMD  patient  cells  after  treating  cells  with  the  indicated  pair  of  nucleases.  (d)  Sanger  
sequencing  result  of  PCR  product  from  genomic  DNA  of  a  genetically  corrected  
clonal  cell  population.  Underlined  sequences  show  target  half-­‐‑sites  for  the  indicated  
ZFN  target  site.  (e)  End-­‐‑point  RT-­‐‑PCR  analysis  of  mRNA  from  control  wild-­‐‑type  and  
untreated  or  a  genetically  corrected  clonal  population  (DMD/Δ51)  of  DMD  patient  
myoblasts  after  differentiation  into  myotubes.  (f)  Dystrophin  expression  as  detected  
by  western  blot  with  antibodies  to  detect  the  C-­‐‑terminus  (NCL-­‐‑DYS2)  or  rod  domain  
(MANDYS8)  in  each  of  the  indicated  cell  populations.  Different  exposure  times  for  
the  NCL-­‐‑Dys2  western  images  were  used  to  image  DMD  and  DMD/Δ51  or  control  
samples  to  compensate  for  overexposure  of  control  protein.  The  images  for  
MANDYS8  and  GAPDH  are  the  same  exposure  time  for  all  samples.  
4.4.6. Human dystrophin expression in vivo following transplantation 
of genetically corrected cells 
Transplantation  of  genetically  corrected  autologous  myoblasts  is  an  attractive  
method  to  introduce  functional  dystrophin  expression  to  skeletal  muscle  in  vivo  [36].  To  
demonstrate  the  feasibility  of  this  approach,  we  transplanted  a  clonally  derived  
population  of  DMD  patient  cells  with  a  corrected  dystrophin  gene  carrying  a  deletion  of  
exon  51  (Figures  14d-­‐‑f)  and  assessed  human  dystrophin  expression  in  vivo.  After  4  
weeks,  muscle  fibers  positive  for  human  spectrin,  which  is  expressed  by  both  corrected  
and  uncorrected  cells,  were  detected  in  cryosections  of  injected  muscle  tissue  (Figures  
15-­‐‑16).  A  significant  number  of  these  fibers  were  also  positive  for  human  dystrophin  
with  expression  localized  to  the  sarcolemma,  demonstrating  functional  protein  
correction  in  these  cells  (Figures  15-­‐‑16).  No  fibers  positive  for  human  dystrophin  were  
observed  in  sections  from  mice  injected  with  the  untreated  DMD  myoblasts  (Figures  15-­‐‑
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16),  indicating  that  the  genetically  corrected  cells  were  the  source  of  human  dystrophin  
expression.  
  
Figure  15: Untreated  or  genetically  corrected  (DMD/Δ51)  human  Δ48-­‐‑50  DMD  
myoblasts  carrying  a  background  deletion  of  exons  48-­‐‑50  were  injected  into  the  hind  
limbs  of  immunodeficient  mice  and  assessed  for  human-­‐‑specific  protein  expression  
in  muscle  fibers  after  4  weeks  post-­‐‑transplantation.  Cryosections  were  stained  with  
anti-­‐‑human  spectrin,  which  is  expressed  by  both  uncorrected  and  corrected  myoblasts  





























Figure  16:  Additional  immunofluorescence  images  probing  human  dystrophin  
expression.  Serial  sections  from  regions  stained  with  anti-­‐‑human  spectrin  are  shown  
inset  in  top  left.  (a-­‐‑c)  Sections  from  muscles  injected  with  untreated  human  DMD  
myoblasts.  (d-­‐‑f)  Sections  from  muscles  injected  with  clonally  derived  DMD  
myoblasts  carrying  a  deletion  of  exon  51  to  that  corrects  the  dystrophin  reading  frame.  





4.4.7. Analysis of genome integrity after editing the dystrophin gene 
Off-­‐‑target  activity  of  engineered  enzymes  is  a  primary  concern  for  gene  editing  
therapies.  To  predict  potential  off-­‐‑target  sites,  we  utilized  a  publicly  available  tool,  
PROGNOS,  that  compiles  and  ranks  potential  off-­‐‑target  sites  in  silico  [167].  Using  the  
ZFN2.0  detection  algorithm  in  PROGNOS,  we  selected  the  top  10  potential  off-­‐‑target  
sites  in  the  genome  for  both  DZF-­‐‑1  L6/R6  and  DZF-­‐‑9  ZFN  pairs.  Eight  of  the  ten  
identified  off-­‐‑target  sites  for  each  ZFN  pair  (Table  2)  were  successfully  amplified  and  
assessed  for  activity  by  the  Surveyor  assay  following  transfection  of  the  respective  ZFN  
pairs  into  human  DMD  patient  cells  (Figure  17).  DZF-­‐‑1  L6/R6  had  no  observed  off-­‐‑target  
activity  (0/8  loci,  Figure  17a),  while  DZF-­‐‑9  had  measurable  activity  at  2/8  loci  (Figure  
17b),  albeit  at  lower  levels  than  the  on-­‐‑target  locus.  Notably,  the  two  bona  fide  off-­‐‑target  
loci  with  observable  activity  for  the  DZF-­‐‑9  ZFN  pair  had  substantial  homology  to  the  
intended  target  site  (1  mismatch,  Table  2).  While  we  cannot  rule  out  activity  at  the  other  
off-­‐‑target  loci  that  may  exist  below  the  sensitivity  of  the  Surveyor  assay  or  off-­‐‑target  
activity  at  other  loci  that  were  not  assessed  here,  these  data  demonstrate  the  relative  
specificity  of  our  reagents  that  is  comparable  to  other  studies  utilizing  ZFNs  [87,  167,  
170,  171].    
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Table  2:  In  silico  prediction  of  putative  off-­‐‑target  sites  for  DZF-­‐‑1  or  DZF-­‐‑9  
predicted  by  the  online  PROGNOS  ZFN  v2.0  webtool.  
DZF-1 L6/R6 
Top ten with spacers of 6-7 (optimal for this linker) 
OT# HS Spacer MM Left Site Right Site Chr Chr Region Region Gene 
1 L/R 6 5/4 CcAACTtGAgATGCCAgC GgTGTgGGAGGTcgaTGC chr12 121465217 Intron OASL 
2 L/L 7 6/2 CtAgCaAGAAgTcCCtTC GATGGCATcTCTAcTTTG chr2 164675298 Intergenic - 
3 L/L 7 4/3 CAAACTAtAAgTGCCgTg GATGtCAaTTaTAGTTTG chr6 3268596 Intergenic - 
4 L/R 6 6/6 attACTtctAATGCCATC GATaTTGGAGaTAtaTtt chr11 73441555 Intron RAB6A 
5 L/R 7 6/6 CAAgaacctAATGCCATC GtcGgaGGAGGTACCccC chr12 349901 Intron SLC6A13 
6 L/L 7 6/4 CAAAggAGAAATGCCAag GATGGCtcTTaaAGTTgc chr14 87103919 Intergenic - 
7 R/R 7 6/6 GCAaactCCTCCAACAag GATGTTGGAaagACaaaC chr8 141637370 Intron EIF2C2 
8 R/L 6 6/5 cCAGaTACCaCCttaATC GcTGGCATgTCTcccTTG chr1 220550165 Intergenic - 
DZF-9 
Top ten with spacers of 5-6 (optimal for this linker) 
OT# HS Spacer MM Left Site Right Site Chr Chr Region Region Gene 
1 R/L 6 1/0 CCCTGCcCC TGGGCAGAT chr6 12015411 Intron HIVEP1 
2 L/R 6 1/0 ATCTGCCCA GGCGCAGtG chr4 58293132 Intergenic - 
3 R/L 6 1/0 CCCTGCGCC gGGGCAGAT chr18 76473917 Intergenic - 
4 L/R 5 1/0 ATCTGCCCA GGCGCAaGG chr17 8113802 Intron AURKB 
5 L/R 5 1/0 ATCTGCCCA GGCcCAGGG chr7 128034911 Intron IMPDH1 
6 R/L 6 1/0 CCCTGgGCC TGGGCAGAT chr10 80912948 Intron ZMIZ1 
7 R/L 5 1/0 CCCTGaGCC TGGGCAGAT chr4 1595869 Intergenic - 




Figure  17:  Evaluation  of  ZFN  off-­‐‑target  effects  in  human  cells.  Human  DMD  
myoblasts  were  electroporated  with  ten  micrograms  of  DNA  constructs  encoding  
either  DZF-­‐‑1  L6/R6  or  DZF-­‐‑9.  After  3  days,  genomic  DNA  was  analyzed  by  the  
Surveyor  to  measure  off-­‐‑target  activity  at  eight  different  loci  for  DZF-­‐‑1  L6/R6  (a)  or  
DZF-­‐‑9  (b).  Asterisks  indicate  detectable  Surveyor  cleavage  products.  
  
4.5. Discussion 
The  rapid  advancement  of  gene  editing  technologies  has  enabled  at-­‐‑will  
modification  and  correction  of  disease-­‐‑related  genes.  This  study  introduces  a  novel  
method  to  correct  the  dystrophin  gene  by  deleting  exons  from  the  genome,  thereby  
permanently  excluding  the  exons  in  the  dystrophin  transcript.  Importantly,  this  genome  
editing  method  will  likely  be  compatible  with  many  existing  gene-­‐‑  and  cell-­‐‑based  
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therapies  in  development  for  DMD.  Autologous,  genetically  corrected  myogenic  cells  
present  an  exciting  strategy  to  introduce  functional  dystrophin  in  vivo,  currently  a  major  
challenge  for  DMD  therapies.  Here,  we  demonstrate  that  a  clonally  derived,  genetically  
corrected  population  of  DMD  patient  cells  can  generate  human  dystrophin  expression  in  
vivo  that  is  properly  localized  to  the  sarcolemma  membrane.  Thus,  gene  correction  by  
excising  exons  from  the  genome  may  be  a  viable  method  for  creating  an  autologous  
population  of  corrected  cells.    
The  utility  of  this  approach  will  likely  require  enhancing  the  overall  efficiency  of  
deletions,  particularly  to  expand  this  strategy  to  in  vivo  delivery  of  gene  editing  enzymes  
to  correct  the  dystrophin  gene  in  situ.  Improving  the  activity  and  specificity  of  each  
nuclease  pair  may  also  further  enhance  the  efficiency  of  this  approach.  All  of  the  ZFNs  
engineered  in  this  study  displayed  moderate  cytotoxicity  in  human  cells  similar  to  two  
benchmark  ZFNs  targeting  AAVS1  and  CCR5.  One  ZFN  pair,  DZF-­‐‑9,  had  observable  
activity  in  2  of  8  tested  off-­‐‑target  loci  in  human  cells.  Notably,  all  eight  of  these  target  
sites  had  only  1  mismatch  to  the  intended  target  site.  It  may  be  possible  to  reduce  the  
observed  off-­‐‑target  activity  by  utilizing  recent  advances  in  ZFN  technology  that  have  
enabled  replacement  of  zinc  finger  modules  to  increase  specificity  and  decrease  off-­‐‑
target  toxicities  [172].  The  fidelity  of  this  approach  may  be  further  enhanced  by  
incorporating  highly  active  orthogonal  FokI  obligate  heterodimer  mutations  that  would  
increase  the  specificity  of  this  approach  by  limiting  or  eliminating  unintended  off-­‐‑target  
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pairings  between  monomers  from  each  ZFN  pair  [91].  This  may  reduce  the  potential  for  
generating  unintended  chromosomal  rearrangements  by  creating  simultaneous  DSBs  at  
unintended  chromosomal  loci.  Other  gene  editing  technologies,  such  as  CRISPR/Cas9  
[10,  11]  or  TALENs  [8,  113],  may  present  suitable  alternatives  to  introduce  similar  
genomic  deletions  with  potentially  reduced  toxicity  and/or  off-­‐‑target  activity.  
Based  on  these  results,  deletion  of  genetic  sequences  containing  splice  sites  for  
exon  51  results  in  the  complete  exclusion  of  the  exon  from  the  transcript  and  restoration  
of  dystrophin  protein  expression.  This  study  demonstrates  a  proof  of  principle  approach  
to  correcting  the  DMD  reading  frame  by  introducing  predictable  and  repeatable  changes  
to  the  genome  that  eliminate  exon  51  from  the  transcript.  Importantly,  genome  editing  
enables  permanent  changes  in  the  corrected  cell  and  its  progeny,  thereby  potentially  
eliminating  the  need  for  continuous  administration  of  a  therapeutic  agent.  In  contrast  to  
our  previous  study  [42],  the  genetic  changes  here  are  intended  to  remove  exon  51  and  
generate  expression  of  a  protein  that  is  predictable  based  on  the  patient  background  
deletion,  similar  to  the  changes  caused  by  oligonucleotide-­‐‑mediated  exon  skipping.  The  
advantage  of  this  method  is  that  it  reproducibly  generates  internally  deleted  proteins  
with  known  protein  sequences  and  predictable  functionality.  This  method  presents  a  
robust  gene  editing  approach  to  restore  the  dystrophin  gene  that  can  be  extended  to  
address  additional  patient  deletions  common  in  DMD  and  serves  as  a  blueprint  for  
correcting  the  genetic  basis  of  other  monogenic  hereditary  disorders.  
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Chapter 5: Correction of Duchenne Muscular Dystrophy 
by Multiplex CRISPR/Cas9-Based Genome Editing 
  
Co-­‐‑authored  with  Ami M. Kabadi, Pratiksha I. Thakore, and Charles A. Gersbach 
 
5.1. Synopsis  
The  recently  described  CRISPR/Cas9  gene  editing  platform  presents  a  novel  tool  
to  correct  the  genetic  basis  of  hereditary  diseases.  The  increased  versatility,  efficiency,  
and  multiplexing  capabilities  of  the  CRISPR/Cas9  system  enable  a  variety  of  otherwise  
challenging  gene  correction  strategies.  We  have  used  the  CRISPR/Cas9  system  to  restore  
the  expression  of  the  dystrophin  gene  that  is  mutated  in  Duchenne  muscular  dystrophy.  
Single  or  multiplexed  sgRNAs  were  designed  to  restore  the  dystrophin  reading  frame  by  
targeting  the  mutational  hotspot  at  exons  45-­‐‑55  and  introducing  either  intraexonic  small  
insertions  and  deletions,  or  large  deletions  of  one  or  more  exons.  Following  treatment  
with  Cas9  and  one  or  more  sgRNAs,  dystrophin  expression  was  restored  in  Duchenne  
patient  muscle  cells  in  vitro.  Human  dystrophin  was  detected  in  vivo  following  
transplantation  of  genetically  corrected  patient  cells  into  immunodeficient  mice.  
Significantly,  the  unique  multiplex  gene  editing  capabilities  of  the  CRISPR/Cas9  system  
enable  efficiently  generating  large  deletions  of  this  mutational  hotspot  region  that  can  
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correct  up  to  62%  of  patient  mutations  by  universal  or  patient-­‐‑specific  gene  editing  
approaches.  
5.2. Introduction 
Genome  editing  technologies  use  synthetic  nucleases  to  induce  cellular  DNA  
repair  mechanisms  and  introduce  site-­‐‑specific,  predefined  genetic  modifications  in  
complex  genomes  [162].  These  engineered  enzymes  are  commonly  based  on  zinc  finger  
nucleases  (ZFNs)  [6],  transcription  activator-­‐‑like  effector  nucleases  (TALENs)  [75],  
meganucleases  [7],  and  most  recently  the  RNA-­‐‑guided  CRISPR/Cas9  system  [10,  11,  99-­‐‑
101,  103,  173].  The  nucleases  create  site-­‐‑specific  double-­‐‑strand  breaks  (DSBs)  at  
predefined  genomic  sites  that  stimulate  either  non-­‐‑homologous  end  joining  (NHEJ)  for  
targeted  gene  disruption  or  homologous  recombination  for  highly  efficient  gene  
targeting.  The  simplicity  and  versatility  of  the  CRISPR/Cas9  genome  editing  system  has  
led  to  rapid  adoption  and  expansion  of  this  technology  that  has  proven  to  be  remarkably  
robust  for  manipulating  gene  sequences  in  human  cells.  This  has  enabled  new  
possibilities  such  as  efficient  multiplex  gene  editing  for  simultaneously  inactivating  
multiple  genes  [10,  11,  135].  In  this  study,  we  apply  the  CRISPR  system  to  repair  genes  
mutated  in  hereditary  disease,  including  capitalizing  on  the  unique  multiplex  capacity  
of  this  technology  to  create  large  genomic  deletions  that  restore  gene  expression.    
CRISPR/Cas9  systems  have  been  adapted  from  multiple  bacterial  species,  
including  S.  pyogenes,  S.  thermophilus,  and  N.  meningitidis,  to  efficiently  generate  targeted  
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gene  modifications  in  human  cells  [10,  11,  99-­‐‑101,  103,  136,  173].  These  systems  consist  of  
a  Cas9  nuclease  that  is  co-­‐‑expressed  with  a  single  guide  RNA  (sgRNA)  molecule.  Cas9  
forms  a  complex  with  the  3’  end  of  the  sgRNA,  and  the  protein-­‐‑RNA  pair  recognizes  its  
genomic  target  by  complementary  base  pairing  between  the  5’  end  of  the  sgRNA  
sequence  and  a  predefined  20  bp  DNA  sequence,  known  as  the  protospacer.  By  simply  
exchanging  the  20  bp  recognition  sequence  of  the  expressed  sgRNA,  the  Cas9  nuclease  
can  be  directed  to  new  genomic  targets.  The  only  restriction  for  protospacer  targeting  is  
that  the  sequence  must  be  immediately  followed  by  the  protospacer-­‐‑adjacent  motif  
(PAM),  a  short  sequence  recognized  by  the  Cas9  nuclease  that  is  required  for  DNA  
cleavage.  Several  studies  of  the  S.  pyogenes  CRISPR  system  have  defined  the  PAM  
sequence  for  this  Cas9  (SpCas9)  as  5’-­‐‑NRG-­‐‑3’,  where  R  is  either  A  or  G,  and  
characterized  the  specificity  of  this  system  in  human  cells  [137-­‐‑142,  174].  A  unique  
capability  of  the  CRISPR/Cas9  system  is  the  straightforward  ability  to  simultaneously  
target  multiple  distinct  genomic  loci  by  co-­‐‑expressing  a  single  Cas9  protein  with  two  or  
more  sgRNAs  [10,  11,  135].  
One  of  the  most  promising  applications  of  genome  editing  is  the  correction  of  
genetic  mutations  associated  with  hereditary  disease  [6,  7,  75,  162].  Duchenne  muscular  
dystrophy  (DMD)  is  the  most  common  hereditary  disease  and  no  effective  treatments  
exist  for  this  disorder.  DMD  is  a  severe  X-­‐‑linked  disease  that  presents  with  progressive  
muscle  wasting  that  typically  leads  to  loss  of  ambulation  in  the  second  decade  and  death  
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within  the  third  decade  of  life  due  to  respiratory  complications  or  heart  failure.  The  
molecular  basis  of  DMD  is  a  mutation  in  the  dystrophin  gene  [2]  that  leads  to  the  
complete  lack  of  function  of  this  essential  skeletal  muscle  protein.  These  mutations  are  
most  commonly  frameshifts  generated  by  large  intragenic  deletions  of  one  or  more  
exons.  DMD  is  the  prototypical  example  of  a  group  of  monogenetic  hereditary  diseases  
that  can  be  corrected  by  removing  internal,  but  unessential,  regions  of  the  mutated  gene  
to  restore  the  proper  reading  frame  [4,  175].  For  example,  there  is  a  class  of  common  
deletions  in  the  exon  45-­‐‑55  mutation  hotspot  region  of  the  dystrophin  gene  that  maintain  
the  correct  reading  frame  and  lead  to  the  expression  of  a  truncated,  but  functional,  
dystrophin  protein.  Patients  with  this  class  of  mutations  are  often  asymptomatic  or  
display  mild  symptoms  associated  with  Becker  muscular  dystrophy,  a  substantially  less  
severe  disease  than  DMD.  This  has  led  to  significant  interest  in  developing  an  
oligonucleotide-­‐‑mediated  exon  skipping  strategy  that  will  restore  the  dystrophin  
reading  frame  during  mRNA  processing  and  convert  DMD  to  a  Becker-­‐‑like  phenotype  
[4].  Whereas  early  clinical  trials  in  this  area  have  focused  on  skipping  only  exon  51  [70,  
71],  which  is  applicable  to  13%  of  DMD  patients,  other  preclinical  efforts  have  
demonstrated  multi-­‐‑exon  skipping  of  the  complete  exon  45-­‐‑55  coding  region  with  a  
combination  treatment  of  up  to  10  oligonucleotides  [176,  177]  that  could  potentially  
address  greater  than  60%  of  known  DMD  patient  mutations  [175].  However,  there  are  
significant  technical  and  practical  hurdles  to  designing  and  developing  this  type  of  
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complex  combination  therapy,  in  addition  to  the  general  challenges  of  developing  any  
oligonucleotide-­‐‑based  therapy  that  must  be  continuously  administered  for  the  lifetime  
of  the  patient.  In  contrast  to  these  transient  mRNA-­‐‑targeted  oligonucleotide-­‐‑mediated  
exon  skipping  strategies,  genome  editing  has  the  ability  to  make  precise  changes  to  gene  
sequences  that  will  be  permanent  in  treated  cells  and  persist  after  cell  division.  
Additionally,  only  two  nucleases  are  necessary  to  delete  a  genomic  region  of  any  length,  
in  contrast  to  exon  skipping  in  which  a  distinct  oligonucleotide  must  be  designed  for  
each  exon  to  be  removed  from  the  mRNA  transcript.  
Genome  editing  using  various  designer  nucleases  has  been  proposed  as  a  
promising  method  to  restore  the  native  dystrophin  gene  in  DMD  patient  cells  [42,  90,  
163].  However,  an  obstacle  to  implementing  this  approach  has  been  successfully  
engineering  the  multiple  nucleases  targeted  to  the  exons  and  introns  necessary  to  
address  a  large  fraction  of  the  DMD  patient  population.  In  this  study,  we  take  advantage  
of  the  versatility  of  the  S.  pyogenes  CRISPR/Cas9  system  to  rapidly  and  efficiently  
generate  targeted  frameshifts  and  large  deletions  to  address  commonly  occurring  
mutations  in  the  dystrophin  gene  across  exons  45-­‐‑55.  Skeletal  myoblasts  from  DMD  
patients  were  treated  with  sgRNAs  and  SpCas9  to  correct  patient-­‐‑specific  mutations  and  
edited  cells  were  enriched  by  fluorescence-­‐‑activated  cell  sorting.  Gene  editing  by  
CRISPR/Cas9  resulted  in  restored  dystrophin  mRNA  transcripts  and  protein  expression.  
Significantly,  we  generated  a  large  deletion  of  336  kb  across  a  mutational  hotspot  
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containing  exons  45-­‐‑55  that  is  applicable  to  correction  of  greater  than  60%  of  DMD  
patient  mutations.  This  genomic  deletion  resulted  in  the  loss  of  exons  45-­‐‑55  in  the  
corresponding  dystrophin  transcript  and  restored  dystrophin  expression  in  human  
DMD  cells.  Additionally,  an  enriched  pool  of  gene-­‐‑corrected  cells  demonstrated  
expression  of  human  dystrophin  in  vivo  following  engraftment  into  immunodeficient  
mice.  CRISPR/Cas9  gene  editing  did  not  have  significant  toxic  effects  in  human  
myoblasts  as  observed  by  stable  gene  editing  frequencies  and  minimal  cytotoxicity  of  
several  sgRNAs.  However,  gene  editing  activity  was  confirmed  at  three  out  of  50  
predicted  off-­‐‑target  sites  across  five  sgRNAs  and  CRISPR/Cas9-­‐‑induced  chromosomal  
translocations  between  on-­‐‑target  and  off-­‐‑target  sites  were  detectable,  indicating  a  need  
to  increase  the  specificity  of  this  technology.  Collectively,  this  study  demonstrates  that  
the  CRISPR/Cas9  technology  is  an  efficient  and  versatile  method  for  correcting  a  
significant  fraction  of  dystrophin  mutations  and  can  serve  as  a  general  platform  for  
treating  genetic  disease.  
5.3. Materials and Methods  
5.3.1. Plasmid constructs 
The  expression  cassettes  for  the  S.  pyogenes  sgRNA  and  human  codon  optimized  
Cas9  (hCas9)  nuclease  were  used  as  previously  described  [178].  In  order  to  create  a  
fluorescent  reporter  system  to  enrich  CRISPR/Cas9-­‐‑modified  cells,  a  GeneBlock  (IDT)  
was  synthesized  containing  a  portion  of  the  3’  end  of  the  Cas9  coding  sequence  fused  to  
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a  T2A  skipping  peptide  immediately  upstream  of  a  multiple  cloning  site  and  
subsequently  cloned  into  the  hCas9  expression  vector.  An  eGFP  reporter  gene  was  then  
cloned  into  the  T2A  vector  to  allow  co-­‐‑translation  of  Cas9  and  eGFP  proteins  from  the  
same  expression  vector.  
5.3.2. Cell culture and transfection 
HEK293T  cells  were  obtained  from  the  American  Tissue  Collection  Center  
(ATCC)  through  the  Duke  Cell  Culture  Facility  and  were  maintained  in  DMEM  
supplemented  with  10%  fetal  bovine  calf  serum  and  1%  penicillin/streptomycin.  
Immortalized  myoblasts  [152]  from  a  DMD  patient  harboring  a  deletion  of  exons  48-­‐‑50  
(Δ48-­‐‑50)  in  the  dystrophin  gene  were  maintained  in  skeletal  muscle  media  (PromoCell)  
supplemented  with  20%  fetal  bovine  calf  serum  (Sigma),  50  µμg/ml  fetuin,  10  ng/ml  
human  epidermal  growth  factor  (Sigma),  1  ng/ml  human  basic  fibroblast  growth  factor  
(Sigma),  10  µμg/ml  human  insulin  (Sigma),  1%  GlutaMAX  (Invitrogen),  and  1%  
penicillin/streptomycin  (Invitrogen).  All  cell  lines  were  maintained  at  37°C  and  5%  CO2.  
HEK293T  cells  were  transfected  with  Lipofectamine  2000  (Invitrogen)  with  400  ng  of  
each  expression  vector  according  to  the  manufacturer’s  protocol  in  24  well  plates.  
Immortalized  myoblasts  were  transfected  with  5  micrograms  of  each  expression  vector  
by  electroporation  using  the  Gene  Pulser  XCell  (BioRad)  with  PBS  as  an  electroporation  
buffer  using  optimized  conditions  [42].  Transfection  efficiencies  were  measured  by  
delivering  an  eGFP  expression  plasmid  (pmaxGFP,  Clontech)  and  using  flow  cytometry.  
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These  efficiencies  were  routinely  ≥95%  for  HEK293T  and  ≥70%  for  the  immortalized  
myoblasts.    
5.3.3. Surveyor assay for endogenous gene modification  
CRISPR/Cas9-­‐‑induced  lesions  at  the  endogenous  target  site  were  quantified  
using  the  Surveyor  nuclease  assay  [166],  which  detects  mutations  characteristic  of  
nuclease-­‐‑mediated  NHEJ.  After  transfection,  cells  were  incubated  for  3  or  10  days  at  
37°C  and  genomic  DNA  was  extracted  using  the  DNeasy  Blood  and  Tissue  kit  
(QIAGEN).  The  target  locus  was  amplified  by  35  cycles  of  PCR  with  the  AccuPrime  
High  Fidelity  PCR  kit  (Invitrogen)  using  primers  specific  to  each  locus  (Appendix  C).  
The  resulting  PCR  products  were  randomly  melted  and  reannealed  in  a  thermal  cycler  
with  the  program:  95°C  for  240  s,  followed  by  85°C  for  60  s,  75°C  for  60s,  65°C  for  60s,  
55°C  for  60  s,  45°C  for  60  s,  35°C  for  60  s,  and  25°C  for  60s  with  a  -­‐‑0.3°C/s  rate  between  
steps.  Following  reannealing,  8  µμl  of  PCR  product  was  mixed  with  1  µμl  of  Surveyor  
Nuclease  S  and  1  µμl  of  Enhancer  S  (Transgenomic)  and  incubated  at  42°C  for  1  hour.  
After  incubation,  6  µμl  of  digestion  product  was  loaded  onto  a  10%  TBE  polyacrylamide  
gel  and  run  at  200V  for  30  min.  The  gels  were  stained  with  ethidium  bromide  and  
quantified  by  densitometry  using  the  ImageLab  software  suite  (Bio-­‐‑Rad)  as  previously  
described  [166].  
  94  
5.3.4. Fluorescence-activated cell sorting of myoblasts 
DMD  myoblasts  were  electroporated  with  5  micrograms  each  of  hCas9-­‐‑T2A-­‐‑GFP  
and  sgRNA  expression  vectors  and  incubated  at  37°C  and  5%  CO2.  Three  days  after  
electroporation,  cells  were  trypsinized  and  collected  for  FACS  sorting  using  a  
FACSvantage  II  sorting  machine.  GFP-­‐‑positive  cells  were  collected  and  grown  for  
analysis.  
5.3.5. PCR-based assay to detect genomic deletions 
The  exon  51  or  exon  45-­‐‑55  loci  were  amplified  from  genomic  DNA  by  PCR  
(Invitrogen  AccuPrime  High  Fidelity  PCR  kit)  using  primers  flanking  each  locus.  The  
flanking  primers  were  CelI-­‐‑CR1/2-­‐‑F  and  CelI-­‐‑CR5-­‐‑R  for  exon  51  or  CelI-­‐‑CR6-­‐‑F  and  CelI-­‐‑
CR36-­‐‑R  for  exon  45-­‐‑55  analysis  (Appendix  C).  PCR  products  were  separated  on  TAE-­‐‑
agarose  gels  and  stained  with  ethidium  bromide  for  analysis.  
5.3.6. PCR-based detection of translocations 
Loci  with  predicted  possible  translocations  were  amplified  by  a  two-­‐‑step  nested  
PCR  (Invitrogen  AccuPrime  High  Fidelity  PCR  kit  for  each  step)  of  genomic  DNA  from  
cells  transfected  with  Cas9  alone  (control)  or  Cas9  with  sgRNA.  In  the  first  step,  
translocations  that  may  occur  at  each  on-­‐‑target  and  off-­‐‑target  sgRNA  target  site  were  
amplified  by  35  cycles  of  PCR  using  combinations  of  Surveyor  primers  for  each  locus  
that  were  modified  to  include  restriction  sites  to  facilitate  cloning  and  sequencing  
analysis  (Appendix  C).  One  microliter  of  each  PCR  reaction  was  subjected  to  a  second  
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round  of  amplification  by  35  rounds  of  PCR  using  nested  primer  sets  custom  designed  
for  each  individual  predicted  translocation  (Appendix  C).  Each  second  nested  PCR  
primer  binds  within  the  same  approximate  region  within  the  primary  amplicon;  
however,  each  pair  was  optimized  using  Primer3  online  bioinformatics  software  to  
ensure  specific  detection  of  each  translocation.  PCR  amplicons  corresponding  to  the  
expected  length  of  predicted  translocations  and  only  present  in  cells  treated  with  sgRNA  
were  purified  (QIAGEN  Gel  Extraction  kit)  and  analyzed  by  Sanger  sequencing.  
5.3.7. mRNA analysis 
Immortalized  myoblasts  were  differentiated  into  myofibers  by  replacing  the  
growth  medium  with  DMEM  supplemented  with  1%  insulin-­‐‑transferrin-­‐‑selenium  
(Invitrogen  #51500056)  and  1%  penicillin/streptomycin  (Invitrogen  #15140)  for  5  days  
before  the  cells  were  trypsinized  and  collected.  Total  RNA  was  isolated  from  these  cells  
using  the  RNeasy  Plus  Mini  Kit  (QIAGEN)  according  to  the  manufacturer’s  instructions.  
RNA  was  reverse  transcribed  to  cDNA  using  the  VILO  cDNA  synthesis  kit  (Life  
Technologies  #11754)  and  1.5  micrograms  of  RNA  for  2  hours  at  42°C  according  to  the  
manufacturer’s  instructions.  The  target  loci  were  amplified  by  35  cycles  of  PCR  with  the  
AccuPrime  High  Fidelity  PCR  kit  (Invitrogen)  using  primers  annealing  to  exons  44  and  
52  to  detect  exon  51  deletion  by  CR1/5  or  CR2/5  or  primers  annealing  to  exons  44  and  60  
to  detect  exon  45-­‐‑55  deletion  by  CR6/36  (Appendix  C).  PCR  products  were  run  on  TAE-­‐‑
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agarose  gels  and  stained  with  ethidium  bromide  for  analysis.  The  resolved  PCR  bands  
were  cloned  and  analyzed  by  Sanger  sequencing  to  verify  the  expected  exon  junctions.  
5.3.8. Western blot analysis  
To  assess  dystrophin  protein  expression,  immortalized  myoblasts  were  
differentiated  into  myofibers  as  above  for  6-­‐‑7  days.  Cells  were  trypsinized,  collected  and  
lysed  in  RIPA  buffer  (Sigma)  supplemented  with  a  protease  inhibitor  cocktail  (Sigma)  
and  the  total  protein  amount  was  quantified  using  the  bicinchoninic  acid  assay  
according  to  the  manufacturer’s  instructions  (Pierce).  Samples  were  then  mixed  with  
NuPAGE  loading  buffer  (Invitrogen)  and  5%  β-­‐‑mercaptoethanol  and  heated  to  85°C  for  
10  minutes.  Twenty-­‐‑five  micrograms  of  protein  were  separated  on  4-­‐‑12%  NuPAGE  Bis-­‐‑
Tris  gels  (Invitrogen)  with  MES  buffer  (Invitrogen).  Proteins  were  transferred  to  
nitrocellulose  membranes  for  1-­‐‑2  hours  in  1X  tris-­‐‑glycine  transfer  buffer  containing  10%  
methanol  and  0.01%  SDS.  The  blot  was  then  blocked  for  1  hour  with  5%  milk-­‐‑TBST  at  
room  temperature.  Blots  were  probed  with  the  following  primary  antibodies:  
MANDYS8  to  detect  dystrophin  (1:1000,  Sigma  D8168)  or  rabbit  anti-­‐‑GAPDH  (1:5000,  
Cell  Signaling  2118S).  Blots  were  then  incubated  with  mouse  or  rabbit  horseradish  
peroxidase-­‐‑conjugated  secondary  antibodies  (Santa  Cruz)  and  visualized  using  the  
ChemiDoc  chemilumescent  system  (BioRad)  and  Western-­‐‑C  ECL  substrate  (BioRad).  
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5.3.9. Transplantation into immunodeficient mice 
All  animal  experiments  were  conducted  under  protocols  approved  by  the  Duke  
Institutional  Animal  Care  &  Use  Committee.  Cells  were  trypsinized,  collected  and  
washed  in  1X  Hank’s  Balanced  Salt  Solution  (HBSS,  Sigma).  Two  million  cells  were  
pelleted  and  resuspended  in  five  µμL  1X  HBSS  (Sigma)  supplemented  with  cardiotoxin  
(Sigma  #C9759)  immediately  prior  to  injection.  These  cells  were  transplanted  into  the  
hind  limb  tibialis  anterior  (TA)  muscle  of  NOD.SCID.gamma  (NSG)  mice  (Duke  CCIF  
Breeding  Core)  by  intramuscular  injection.  Four  weeks  after  injection,  mice  were  
euthanized  and  the  TA  muscles  were  harvested.  
5.3.10. Immunofluorescence staining 
Harvested  TA  muscles  were  incubated  in  30%  glycerol  overnight  at  4°C  before  
mounting  and  freezing  in  Optimal  Cutting  Temperature  compound.  Serial  10  micron  
sections  were  obtained  by  cryosectioning  of  the  embedded  muscle  tissue  at  -­‐‑20°C.  
Cryosections  were  then  washed  in  PBS  to  remove  the  OCT  compound  and  subsequently  
blocked  for  30-­‐‑60  minutes  at  room  temperature  in  PBS  containing  10%  heat-­‐‑inactivated  
fetal  bovine  serum  for  spectrin  detection  or  5%  heat-­‐‑inactivated  fetal  bovine  serum  for  
dystrophin  detection.  Cryosections  were  incubated  overnight  at  4°C  with  the  following  
primary  antibodies  that  are  specific  to  human  epitopes  only:  anti-­‐‑spectrin  (1:20,  Leica  
NCL-­‐‑SPEC1)  or  anti-­‐‑dystrophin  (1:2,  Leica  NCL-­‐‑DYS3).  After  primary  staining,  spectrin  
or  dystrophin  expression  was  detected  using  a  tyramide-­‐‑based  immunofluorescence  
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signal  amplification  detection  kit  (Life  Technologies,  TSA  Kit  #22,  catalog  #T-­‐‑20932,).  
Briefly,  cryosections  were  incubated  with  1:200  goat  anti-­‐‑mouse  biotin-­‐‑XX  secondary  
(Life  Technologies  #B2763)  in  blocking  buffer  for  one  hour  at  room  temperature.  The  
signal  was  then  amplified  using  streptavidin-­‐‑HRP  conjugates  (1:100,  from  TSA  Kit)  in  
blocking  buffer  for  one  hour  at  room  temperature.  Finally,  cryosections  were  incubated  
with  tyramide-­‐‑AlexaFluor488  conjugates  (1:100,  TSA  kit)  in  manufacturer-­‐‑provided  
amplification  buffer  for  10  minutes  at  room  temperature.  Stained  cryosections  were  then  
mounted  in  ProLong  AntiFade  (Life  Technologies  #P36934)  and  visualized  with  
conventional  fluorescence  microscopy.  
5.3.11. Cytotoxicity assay 
To  quantitatively  assess  potential  sgRNA  or  SpCas9  nuclease-­‐‑associated  
cytotoxicity,  HEK293T  cells  were  transfected  with  10  ng  of  a  GFP  reporter  and  100  ng  
SpCas9  expression  vector  and  100  ng  sgRNA  expression  vector  using  Lipofectamine  
2000  according  to  the  manufacturer’s  instructions  (Invitrogen).  The  percentage  of  GFP  
positive  cells  was  assessed  at  2  and  5  days  by  flow  cytometry.  The  survival  rate  was  
calculated  as  the  decrease  in  GFP  positive  cells  from  days  2  to  5  and  normalized  to  cells  
transfected  with  an  empty  nuclease  expression  vector  as  described  [155].  
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5.4. Results 
5.4.1. Targeting CRISPR/Cas9 to Hotspot Mutations in the Human 
Dystrophin Gene 
To  utilize  the  CRISPR/Cas9  gene  editing  platform  for  correcting  a  wide  range  of  
dystrophin  mutations,  we  created  dozens  of  sgRNAs  targeted  to  the  hotspot  mutation  
region  between  exons  45-­‐‑55  (Figure  18).  We  selected  the  previously  described  S.  pyogenes  
system  that  utilizes  a  human-­‐‑codon  optimized  SpCas9  nuclease  [10,  11]  and  a  chimeric  
single-­‐‑guide  RNA  (sgRNA)  expression  vector  to  guide  efficient  site-­‐‑specific  gene  
editing.  Similar  to  our  previous  study  targeting  exon  51  with  TALENs  [42],  we  selected  
protospacers  to  target  the  5’  and  3’  ends  of  exons  45  through  55  which  meet  the  5’-­‐‑NRG-­‐‑
3’  PAM  requirement  of  SpCas9.  Small  insertions  or  deletions  created  by  NHEJ-­‐‑based  
DNA  repair  within  these  exons  can  generate  targeted  frameshift  mutations  that  address  
various  dystrophin  mutations  surrounding  each  exon  (Figure  18a-­‐‑b).  For  example,  CR3  
was  designed  to  correct  dystrophin  mutations  or  deletions  surrounding  exon  51  by  
introducing  small  insertions  or  deletions  in  the  5’  end  of  exon  51  to  restore  the  
downstream  dystrophin  reading  frame  (Figure  18b).  Additionally,  we  designed  sgRNAs  
to  employ  the  multiplex  capability  of  the  CRISPR/Cas9  system  and  specifically  delete  
individual  exons  or  a  series  of  exons  to  restore  the  dystrophin  reading  frame,  similar  to  
the  methods  of  oligonucleotide-­‐‑based  exon  skipping.  For  this  purpose,  sgRNAs  were  
targeted  to  the  intronic  regions  surrounding  exon  51  (Figure  18c)  or  exons  45-­‐‑55  (Figure  
18d).  These  sgRNAs  were  intentionally  targeted  to  sites  nearest  to  the  downstream  or  
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upstream  exon  intended  to  be  included  in  the  resulting  transcript  to  minimize  the  
likelihood  that  the  background  patient  deletion  would  include  the  intronic  sgRNA  
target  sites.  
  
Figure  18: CRISPR/Cas9  targeting  of  the  dystrophin  gene.  (a)  sgRNA  
sequences  were  designed  to  bind  sequences  in  the  exon  45-­‐‑55  mutational  hotspot  
A Exon 45-55 deletion 
(336,380bp) 
Exon 51 deletion 
(~800-1050bp) 




Panel of sgRNAs to create targeted 
frameshifts at  5’  or  3’  end  of  each  exon 
Exon 51 Exon 47 
E G P F D V Q GAAGGACCATTTGACGTTCAG L L L R L L L W * CTCCTACTCAGACTGTTACTCTGGTGA 
PAM 
Exon 47 
E G P F D V Q GAAGGACCATTTGACGTTCAG 
Exon 51 
L L L R L S   L V.. CTCCTACTCAGACTGT--CTCTGGTGA 
PAM 
Out-of-frame (Δ48-50) 
Frame restored by small 
targeted deletion 
Exon 47 Exon 51 Exon 52 
Exon 47 Exon 52 
sgRNA 1 sgRNA 2 
Out-of-frame (Δ48-50) 
Frame restored by genetic deletion 
of a specific exon 
Exon 44 Exons 45-55 Exon 56 
Exon 44 Exon 56 
sgRNA 1 sgRNA 2 
Out-of-frame (various deletions) 
Frame restored by genetic deletion 
of an entire region of exons 
56 
Figure 1 – CRISPR/Cas9 targeting of the dystrophin gene. (A) sgRNA sequences were designed to bind 
sequences in the exon 45-55 mutational hotspot region of the dystrophin gene, such that gene editing could 
restore dystrophin expression from a wide variety of patient-specific mutations. Arrows within introns indicate 
sgRNA targets designed to delete entire exons from the genome. Arrows within exons indicate sgRNA targets 
designed to create targeted frameshifts in the dystrophin gene. (B) Example of frame correction following 
introduction of small insertions or deletions by NHEJ DNA repair in exon 51 using the CR3 sgRNA. (C) 
Schematic of multiplex sgRNA targets designed to delete exon 51 and restore the dystrophin reading frame in a 
patient mutation with the deletion of exons 48-50. (D) Schematic of multiplex sgRNA targets designed to 
delete the entire exon 45-55 region to address a variety of DMD patient mutations. 
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region  of  the  dystrophin  gene,  such  that  gene  editing  could  restore  dystrophin  
expression  from  a  wide  variety  of  patient-­‐‑specific  mutations.  Arrows  within  introns  
indicate  sgRNA  targets  designed  to  delete  entire  exons  from  the  genome.  Arrows  
within  exons  indicate  sgRNA  targets  designed  to  create  targeted  frameshifts  in  the  
dystrophin  gene.  (b)  Example  of  frame  correction  following  introduction  of  small  
insertions  or  deletions  by  NHEJ  DNA  repair  in  exon  51  using  the  CR3  sgRNA.  (c)  
Schematic  of  multiplex  sgRNA  targets  designed  to  delete  exon  51  and  restore  the  
dystrophin  reading  frame  in  a  patient  mutation  with  the  deletion  of  exons  48-­‐‑50.  (d)  
Schematic  of  multiplex  sgRNA  targets  designed  to  delete  the  entire  exon  45-­‐‑55  region  
to  address  a  variety  of  DMD  patient  mutations.  
5.4.2. Screening of sgRNAs Targeted to the Dystrophin Gene in 
Human Cells 
We  initially  assessed  gene  editing  frequency  in  the  human  HEK293T  cell  line  to  
rapidly  determine  different  sgRNA  targeting  efficiencies.  As  quantified  by  the  Surveyor  
assay  3  days  post-­‐‑transfection,  we  found  that  29/32  (~90%)  of  sgRNAs  tested  were  able  
to  mediate  highly  efficient  gene  modification  at  the  intended  locus  (Table  3,  Appendix  
C).  The  gene  editing  frequencies  were  stable  for  almost  all  of  the  sgRNAs  (<25%  signal  
change  from  day  3  to  day  10,  Table  3,  Appendix  C),  indicating  that  gene  editing  
mediated  by  each  individual  sgRNA  was  well-­‐‑tolerated.  A  notable  exception  is  CR33,  
which  had  no  detectable  activity  at  day  10,  although  activity  may  be  below  the  
sensitivity  of  the  Surveyor  assay  (est.  ~1%).    
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Table  3: Measured  activity  of  sgRNAs  in  human  cells.  HEK293Ts  were  
transfected  with  constructs  encoding  human  codon-­‐‑optimized  SpCas9  and  the  
indicated  sgRNA.  Each  sgRNA  was  designed  to  modify  the  dystrophin  gene  as  
indicated.  The  frequency  of  gene  modification  at  day  3  or  day  10  post-­‐‑transfection  
was  determined  by  the  Surveyor  assay.  The  ratio  of  measured  Surveyor  signal  at  day  3  
and  day  10  was  calculated  to  quantify  the  stability  of  gene  editing  frequencies  for  
each  sgRNA  in  human  cells.  
Target   sgRNA  #  
%  modified  alleles  
at  day  3  
%  modified  alleles  
at  day  10  
%  change  
day  10/day  3  
Multiplex  deletion  of  exon  51  
Int  50   CR1   6.6   9.3   41.8  
Int  50   CR2   10.3   14.0   36.2  
Ex  51   CR4   11.9   14.4   21.3  
Int  51   CR5   12.4   13.3   7.8  
Multiplex  deletion  of  exons  45-­‐‑55  
Int  44   CR6   16.1   16.9   4.3  
Int  44   CR33   1.3   <1   n.d.  
Int  44   CR34   13.2   11.0   -­‐‑16.6  
Int  55   CR7   6.8   7.1   5.3  
Int  55   CR35   22.5   20.9   -­‐‑7.1  
Int  55   CR36   26.4   24.7   -­‐‑6.4  
Targeted  frameshifts  
Ex  45   CR10   14.9   16.3   9.3  
Ex  45   CR11   <1   <1   n.d.  
Ex  46   CR12   <1   <1   n.d.  
Ex  46   CR13   16.9   18.4   9.2  
Ex  47   CR14   17.2   17.6   2.9  
Ex  47   CR15   15.4   15.3   -­‐‑0.9  
Ex  48   CR16   11.5   10.9   -­‐‑5.0  
Ex  48   CR17   <1   <1   n.d.  
Ex  49   CR18   1.8   2.2   20.1  
Ex  49   CR19   33.7   38.4   13.9  
Ex  50   CR20   14.9   13.7   -­‐‑7.6  
Ex  50   CR21   24.1   20.8   -­‐‑13.5  
Ex  51   CR3   13.0   16.7   28.0  
Ex  51   CR31   18.9   16.9   -­‐‑10.2  
Ex  52   CR22   25.9   20.3   -­‐‑21.6  
Ex  52   CR23   25.2   24.0   -­‐‑4.8  
Ex  53   CR24   24.8   23.6   -­‐‑4.6  
Ex  53   CR25   2.6   2.9   9.5  
Ex  54   CR26   24.5   22.0   -­‐‑10.1  
Ex  54   CR27   13.4   12.6   -­‐‑5.9  
Ex  55   CR28   21.6   19.8   -­‐‑8.4  
Ex  55   CR29   19.2   19.6   2.2  
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5.4.3. Enrichment of Gene-Edited Cells Using a Fluorescence-Based 
Reporter System 
We  next  sought  to  use  selected  sgRNAs  to  correct  specific  mutations  in  DMD  
patient  myoblast  cell  lines.  After  transfection  into  DMD  myoblasts,  we  observed  
unexpectedly  low  or  undetectable  gene  modification  activity  as  measured  by  the  
Surveyor  assay  (Figure  19c,  bulk  population).  Therefore,  we  used  flow  cytometry  to  
select  for  transfected  cells  co-­‐‑expressing  GFP  through  a  2A  ribosomal  skipping  peptide  
linked  to  the  SpCas9  protein  (Figure  19a),  similar  to  previously  described  methods  to  
enrich  gene-­‐‑modified  cell  populations  using  fluorescent  reporters  [179,  180].  
Importantly,  the  addition  of  this  fluorescent  reporter  to  the  SpCas9  expression  vector  
did  not  seem  to  significantly  impact  gene  editing  activity  in  HEK293T  cells  (Figure  19b).  
A  low  percentage  of  transfected  myoblasts  (~0.5-­‐‑2%)  expressed  the  fluorescent  reporter  
at  3  days  after  electroporation,  despite  high  transfection  efficiencies  of  control  GFP  
expression  plasmids  (typically  >70%,  Figure  19d,  pmaxGFP).  Given  the  high  levels  of  
CRISPR/Cas9  activity  in  the  easily  transfected  HEK293T  line,  inefficient  transgene  
expression  after  electroporation  of  SpCas9-­‐‑T2A-­‐‑GFP  and  sgRNA  constructs  into  the  
DMD  cells  may  explain  the  low  observed  gene  editing  efficiencies  in  unsorted  cells.  
After  sorting  the  GFP-­‐‑positive  DMD  myoblasts,  we  observed  a  substantial  increase  in  
detectable  activity  at  most  sgRNA  target  loci  (Figure  19c).  Therefore,  all  subsequent  
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experiments  used  cells  sorted  for  SpCas9  expression  by  expression  of  this  fluorescent  
reporter.  
  
Figure  19:  Fluorescence-­‐‑activated  flow  sorting  to  enrich  genetically  modified  
DMD  myoblasts.  (a)  A  plasmid  expressing  a  human-­‐‑codon  optimized  SpCas9  protein  
linked  to  a  GFP  marker  using  a  T2A  ribosomal  skipping  peptide  sequence  was  co-­‐‑
electroporated  into  human  DMD  myoblasts  with  one  or  two  plasmids  carrying  
sgRNA  expression  cassettes.  (b)  The  indicated  sgRNA  expression  cassettes  were  
independently  co-­‐‑transfected  into  HEK293Ts  with  a  separate  plasmid  expressing  
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Figure 2 – luorescence-activated flow sorting to enrich genetically modified DMD myoblasts. (A) A 
plasmid expressing a human-codon optimized SpCas9 protein li ked to a GFP marker using a T2A ibosomal 
skipping peptide sequence was co-electroporated into human DMD myoblasts with one or two plasmids 
carrying sgRNA expression cassettes. (B) The indicated sgRNA expression cassettes were independently co-
transfected into HEK293Ts with a separate plasmid expressing SpCas9 with (bottom) or without (top) a GFP 
marker linked to SpCas9 by a T2A ribosomal skipping peptide sequence. Gene modification frequencies were 
assesse  at 3 days post-transfection by the Surveyor assay. (C) DMD myobl sts with deletions of exons 48-50 
in the dystrophin gene were treated ith sgRNAs that correct the dystrophin reading frame in these patient 
cells. Gene modification was assessed at 20 days post-electroporation in unsorted (bulk) or GFP+ sorted cells. 
(D) GFP expression in DMD myoblasts 3 days after electroporation with indicated expression plasmids. 
Transfection efficiencies and sorted cell populations are indicated by the gated region. 
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ribosomal  skipping  peptide  sequence.  Gene  modification  frequencies  were  assessed  
at  3  days  post-­‐‑transfection  by  the  Surveyor  assay.  (c)  DMD  myoblasts  with  deletions  
of  exons  48-­‐‑50  in  the  dystrophin  gene  were  treated  with  sgRNAs  that  correct  the  
dystrophin  reading  frame  in  these  patient  cells.  Gene  modification  was  assessed  at  20  
days  post-­‐‑electroporation  in  unsorted  (bulk)  or  GFP+  sorted  cells.  (d)  GFP  expression  
in  DMD  myoblasts  3  days  after  electroporation  with  indicated  expression  plasmids.  
Transfection  efficiencies  and  sorted  cell  populations  are  indicated  by  the  gated  
region.  
5.4.4. Restoration of Dystrophin Expression by Targeted Frameshifts 
We  have  shown  previously  that  small  insertions  and  deletions  created  by  NHEJ  
DNA  repair  can  be  used  to  create  targeted  frameshifts  to  correct  aberrant  reading  frames  
[42].  Similar  to  this  approach,  we  designed  a  sgRNA,  CR3,  to  restore  the  dystrophin  
reading  frame  by  introducing  small  insertions  and  deletions  within  exon  51  (Figures  
18b,  20a).  The  types  of  insertions  and  deletions  generated  by  CRISPR/Cas9  at  this  locus  
were  assessed  by  Sanger  sequencing  of  alleles  from  the  genomic  DNA  of  HEK293T  cells  
co-­‐‑transfected  with  expression  plasmids  for  SpCas9  and  the  CR3  sgRNA  (Figure  20b).  
Notably,  the  insertions  and  deletions  resulted  in  conversion  to  all  three  reading  frames  
(Figures  20b,c),  consistent  with  our  previous  results  using  TALENs  [42].  To  demonstrate  
genetic  correction  in  a  relevant  patient  cell  line,  expression  plasmids  for  SpCas9  and  the  
CR3  sgRNA  were  electroporated  into  a  DMD  myoblast  line  with  a  deletion  of  exons  48-­‐‑
50  that  is  correctable  by  creating  frameshifts  in  exon  51.  The  treated  cells  were  sorted,  
verified  to  have  gene  modification  activity  by  the  Surveyor  assay  (CR3,  Figure  20c  
sorted  population),  and  differentiated  into  myotubes  to  test  for  restored  dystrophin  
expression.  Expression  of  dystrophin  protein  was  observed  concomitant  with  the  
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detectable  nuclease  activity  (Figure  20d).  Taken  together  with  the  data  from  Table  3,  the  
S.  pyogenes  CRISPR/Cas9  system  presents  a  powerful  method  to  quickly  generate  
targeted  frameshifts  to  address  a  variety  of  patient  mutations  and  restore  expression  of  
the  human  dystrophin  gene.  
     
Figure  20:  Targeted  frameshifts  to  restore  the  dystrophin  reading  frame  using  
CRISPR/Cas9.  (a)  The  5’  region  of  exon  51  was  targeted  using  a  sgRNA,  CR3,  that  











TAGCTCCTACTCAGACTGTTACTCTGGTGACACAAC (x16)        Length Frame 
TAGCTCCTACTCAGACT--------GGTGACCCAAC             -8 +2 
TAGCTCCTAC------------TCTGGTGACACAAC -12 +3 
TAGCTCCTACTCAGAC--------TGGTGACACAAC (x2) -8 +2 
TAGCTCCTACTCAGAC--------------------  -21 +3 
TAGCTCCTACTCAGACTGTT---------ACACAAC  -9 +3 
TAGCTCCTACTCAGACTG------TGGTGAGGTGAC  -6 +3 
TAGCTCCTACTCAGAC----TCTCTGGTGACACAAC            -4 +1 
TAGCTCCTACTCAGA-----CCTCTGGTGACACAAC (x2)          -5 +2 
TAGCTCCTACTCAGGCTG----TCTGGTGACACAAC            -4 +1 
TAGCTCCTACTCAGACT---ACTCTGGTGACACAAC            -3 +3 
TAGCTCCTACTCAGAC--------TGTTGACACAAC             -8 +2 
-----------------------CTGGTGACACAAC -56 +2 
TAGCTCCTACTCAGACTGTTA-------GACACAAC -7 +1 
TAGCTCCTACTCAGACT---GCTCTGGTGACACAAC -3 +3 
CAGAC----------------TGTTACTCTGGTGAC (x16) Length Frame 
CAGACCACCTGTGGTCTCCTA-------CTGGTGAC +9 +3 
Total events: 17/33 (52%) 
+1 Frame: 3/17 (18%) 
+2 Frame: 7/17 (41%) 
+3 Frame: 7/17 (41%) 




Figure 3 – Targeted frameshifts to restore the dystrophin reading frame using CRISPR/Cas9. (A) The  5’  
region of exon 51 was targeted using a sgRNA, CR3, that binds immediately upstream of the first out-of-frame 
stop codon. PAM: protospacer-adjacent motif. (B) The exon 51 locus was PCR amplified from HEK293T 
cells treated with SpCas9 and CR3 expression cassettes. Sequences of individual clones were determined by 
Sanger sequencing. The top sequence (bolded, exon in red) is the native, unmodified sequence. The number of 
clones for each sequence is indicated in parentheses. (C) Summary of total gene editing efficiency and reading 
frame conversions resulting from gene modification shown in (B). (D) Western blot for dystrophin expression 
in human DMD myoblasts treated with SpCas9 and the CR3 sgRNA expression cassette (Figure 2C) to create 
targeted frameshifts to restore the dystrophin reading frame. Dystrophin expression was probed using an 
antibody against the rod-domain of the dystrophin protein after 6 days of differentation. 
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adjacent  motif.  (b)  The  exon  51  locus  was  PCR  amplified  from  HEK293T  cells  treated  
with  SpCas9  and  CR3  expression  cassettes.  Sequences  of  individual  clones  were  
determined  by  Sanger  sequencing.  The  top  sequence  (bolded,  exon  in  red)  is  the  
native,  unmodified  sequence.  The  number  of  clones  for  each  sequence  is  indicated  in  
parentheses.  (c)  Summary  of  total  gene  editing  efficiency  and  reading  frame  
conversions  resulting  from  gene  modification  shown  in  (b).  (d)  Western  blot  for  
dystrophin  expression  in  human  DMD  myoblasts  treated  with  SpCas9  and  the  CR3  
sgRNA  expression  cassette  (Figure  19c)  to  create  targeted  frameshifts  to  restore  the  
dystrophin  reading  frame.  Dystrophin  expression  was  probed  using  an  antibody  
against  the  rod-­‐‑domain  of  the  dystrophin  protein  after  6  days  of  differentation.  
5.4.5. Multiplex CRISPR/Cas9 Gene Editing Mediates Genomic 
Deletion of Exon 51 and Rescues Dystrophin Protein Expression 
The  multiplexing  capability  of  the  CRISPR/Cas9  system  presents  a  novel  method  
to  efficiently  generate  genomic  deletions  of  specific  exons  for  targeted  gene  correction.  
DMD  patient  myoblasts  with  background  deletions  correctable  by  exon  51  skipping  
were  treated  with  two  combinations  of  sgRNAs  flanking  exon  51  (CR1/CR5  or  CR2/CR5)  
and  sorted  to  enrich  for  gene-­‐‑edited  cells  as  in  Figure  19.  As  detected  by  end-­‐‑point  PCR  
of  the  genomic  DNA  from  these  treated  cells,  the  expected  genomic  deletions  were  only  
present  when  both  sgRNAs  were  electroporated  into  the  cells  with  SpCas9  (Figure  21a).  
Sanger  sequencing  confirmed  the  expected  junction  of  the  distal  chromosomal  segments  
(Figure  21b)  for  both  deletions.  After  differentiating  the  sorted  myoblasts,  a  deletion  of  
exon  51  from  the  mRNA  transcript  was  detected  only  in  the  cells  treated  with  both  
sgRNAs  (Figure  21c).  Finally,  restored  dystrophin  protein  expression  was  detected  in  
the  treated  cells  concomitant  with  observed  genome-­‐‑  and  mRNA-­‐‑level  deletions  of  exon  
51  (Figure  21d).  
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Figure  21: Deletion  of  exon  51  from  the  human  genome  using  multiplex  
CRISPR/Cas9  gene  editing.  (a)  End-­‐‑point  genomic  PCR  across  the  exon  51  locus  in  
human  DMD  myoblasts  with  a  deletion  of  exons  48-­‐‑50.  The  top  arrow  indicates  the  
expected  position  of  full-­‐‑length  PCR  amplicons  and  the  two  lower  arrows  indicate  the  
expected  position  of  PCR  amplicons  with  deletions  caused  by  the  indicated  sgRNA  
combinations.  (b)  PCR  products  from  (a)  were  cloned  and  individual  clones  were  





























PAM Intron 51 Intron 50 
Intron 50 Intron 51 
Intron 50 Intron 51 
CR2/5 treated 
genomic DNA 
Exon 47 Exon 52 
* * 
Figure 4 – Deletion of exon 51 from the human genome using multiplex CRISPR/Cas9 gene editing. (A) 
End-point genomic PCR across the exon 51 locus in human DMD yoblasts with a deletion of exons 48-50. 
The top arrow indicates the expected position of full-length PCR amplicons and the two l er arrows indicate 
the expected osition of PCR amplicons with deletions caused by the indicated sgRNA combinations. (B) PCR 
products from (A) were cloned and individual clones were sequenced to determine insertions and deletions 
present at the targeted locus. The top row shows the wild-type unmodified sequence and the triangles indicate 
SpCas9 cleavage sites. At the right are representative chromatograms showing the sequences of the expected 
deletion junctions. (C) End-point RT-PCR analysis of dystrophin mRNA transcripts in CRISPR/Cas9-modified 
human  Δ48-50 DMD myoblasts treated with the indicated sgRNAs. A representative chromatogram of the 
expected deletion PCR product is shown at the right. Asterisk: band resulting from hybridization of the deletion 
product strand to the unmodified strand. (D) Rescue of dystrophin protein expression by CRISPR/Cas9 genome 
editing was assessed by western blot for the dystrophin protein with GAPDH as a loading control. The arrow 
indicates the expected restored dystrophin protein band. 
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sequenced  to  determine  insertions  and  deletions  present  at  the  targeted  locus.  The  top  
row  shows  the  wild-­‐‑type  unmodified  sequence  and  the  triangles  indicate  SpCas9  
cleavage  sites.  At  the  right  are  representative  chromatograms  showing  the  sequences  
of  the  expected  deletion  junctions.  (c)  End-­‐‑point  RT-­‐‑PCR  analysis  of  dystrophin  
mRNA  transcripts  in  CRISPR/Cas9-­‐‑modified  human  Δ48-­‐‑50  DMD  myoblasts  treated  
with  the  indicated  sgRNAs.  A  representative  chromatogram  of  the  expected  deletion  
PCR  product  is  shown  at  the  right.  Asterisk:  band  resulting  from  hybridization  of  the  
deletion  product  strand  to  the  unmodified  strand.  (d)  Rescue  of  dystrophin  protein  
expression  by  CRISPR/Cas9  genome  editing  was  assessed  by  western  blot  for  the  
dystrophin  protein  with  GAPDH  as  a  loading  control.  The  arrow  indicates  the  
expected  restored  dystrophin  protein  band.  
5.4.6. Dystrophin Rescue by a Multi-Exon Large Genomic Deletion 
Although  addressing  patient-­‐‑specific  mutations  is  a  powerful  use  of  the  
CRISPR/Cas9  system,  it  would  be  advantageous  to  develop  a  single  method  that  can  
address  a  myriad  of  common  patient  deletions.  For  example,  a  promising  strategy  is  to  
exclude  the  entire  exon  45-­‐‑55  region  as  a  method  to  correct  up  to  62%  of  known  patient  
deletions  [4,  176,  177].  Therefore  we  tested  if  multiplex  CRISPR/Cas9-­‐‑based  gene  editing  
may  be  able  to  generate  efficient  deletion  of  the  exon  45-­‐‑55  locus  in  human  cells.  After  
transfection  into  HEK293T  cells,  we  detected  the  expected  deletion  of  ~336,000  bp  by  
PCR  of  the  genomic  DNA  (Figure  22a).  Similarly,  we  were  able  to  detect  this  deletion  by  
PCR  of  the  genomic  DNA  from  SpCas9/sgRNA-­‐‑treated  DMD  patient  cells  harboring  a  
background  deletion  of  exons  48-­‐‑50  of  unknown  length  (Figure  22a).  Sanger  sequencing  
of  this  deletion  band  from  the  genomic  DNA  of  treated  DMD  cells  revealed  the  expected  
junctions  of  intron  44  and  intron  55  immediately  adjacent  to  the  sgRNA  target  sites  
(Figure  22b).  After  differentiation  of  treated  DMD  cells,  the  expected  deletion  of  exons  
45-­‐‑55  was  detected  in  the  dystrophin  mRNA  transcript  and  verified  to  be  a  fusion  of  
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exons  44  and  56  by  Sanger  sequencing  (Figure  22c).  Restored  protein  expression  was  
observed  by  western  blot  in  the  sorted  cell  populations  containing  the  CRISPR/Cas9-­‐‑
induced  deletion  of  exons  45-­‐‑55  from  the  genome  and  resulting  mRNA  transcripts  
(Figure  22d).  These  data  demonstrate  that  multiplex  CRISPR/Cas9  editing  presents  a  
single  universal  method  to  restore  the  dystrophin  reading  frame  in  more  than  60%  of  
DMD  patient  mutations.  
  
Figure  22:  Deletion  of  the  entire  exon  45-­‐‑55  region  in  human  DMD  myoblasts  
by  multiplex  CRISPR/Cas9  gene  editing.  (a)  End-­‐‑point  genomic  PCR  of  genomic  DNA  
to  detect  deletion  of  the  region  between  intron  44  and  intron  55  after  treating  
HEK293Ts  or  DMD  myoblasts  with  the  indicated  sgRNAs.  (b)  Individual  clones  of  
PCR  products  of  the  expected  size  for  the  deletions  from  DMD  myoblasts  in  (a)  were  
analyzed  by  Sanger  sequencing  to  determine  the  sequences  of  genomic  deletions  
present  at  the  targeted  locus.  Below  is  a  representative  chromatograms  showing  the  
sequence  of  the  expected  deletion  junctions.  (c)  End-­‐‑point  RT-­‐‑PCR  analysis  of  
dystrophin  mRNA  transcripts  in  CRISPR/Cas9-­‐‑modified  human  Δ48-­‐‑50  DMD  
myoblasts  treated  with  the  indicated  sgRNAs.  A  representative  chromatogram  of  the  
expected  deletion  PCR  product  is  shown  at  the  right.  (d)  Analysis  of  restored  
dystrophin  protein  expression  by  western  blot  following  electroporation  of  DMD  
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Figure 5 – Deletion of the entire exon 45-55 region in human DMD myoblasts by multiplex 
CRISPR/Cas9 gene editing. (A) End-point genomic PCR of genomic DNA to detect deletion of the region 
between intron 44 and ntron 55 afte  treating HEK293Ts or DMD myoblasts wi h the indicated sgRNAs. (B) 
Individual clones of PCR products of the expected size for the deletions from DMD myoblasts in (A) were 
analyzed by Sanger sequencing to determine the sequences of genomic deletions present at the targeted locus. 
Below is a representative chromatograms showing the sequence of the expected deletion junctions. (C) End-
point RT-PCR analysis of dystrophi  mRNA transcripts in CRISPR/Cas9-modified  huma   Δ48-50 DMD 
myoblasts treated with the indicated sgRNAs. A representative chromatogram of the expected deletion PCR 
product is shown at the right. (D) Analysis of restored dystrophin protein expression by western blot 
following electroporation of DMD myoblasts with sgRNAs targeted to intron 44 and/or intron 55. 
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5.4.7. Transplantation of Corrected Myoblasts into Immunodeficient 
Mice 
A  promising  method  for  DMD  therapy  is  to  correct  a  population  of  autologous  
patient  muscle  progenitor  cells  that  can  be  engrafted  into  the  patient’s  skeletal  muscle  
tissue  to  rescue  dystrophin  expression  [19,  36,  181].  To  demonstrate  the  ability  of  the  
corrected  cells  to  express  human  dystrophin  in  vivo,  we  transplanted  a  population  of  
DMD  myoblasts  that  were  treated  with  sgRNAs  CR1  and  CR5,  which  flank  exon  51,  and  
sorted  for  expression  of  GFP  as  before  (Figure  23).  After  4  weeks,  muscle  fibers  positive  
for  human  spectrin,  which  is  expressed  by  both  corrected  and  uncorrected  cells,  were  
detected  in  cryosections  of  injected  muscle  tissue  (Figures  24-­‐‑25).  A  number  of  these  
fibers  were  also  positive  for  human  dystrophin  with  expression  localized  to  the  
sarcolemma,  demonstrating  functional  gene  correction  in  these  cells  (Figures  24-­‐‑25).  No  
fibers  positive  for  human  dystrophin  were  observed  in  sections  from  mice  injected  with  
the  untreated  DMD  myoblasts  (Figures  24-­‐‑25),  indicating  that  the  CRISPR/Cas9-­‐‑




Figure  23:  Verification  of  flow  cytometry-­‐‑based  enrichment  of  gene-­‐‑modified  
DMD  myoblasts  used  for  in  vivo  cell  transplantation  experiment.  DMD  myoblasts  
were  treated  with  Cas9  with  or  without  sgRNA  expression  vectors  for  CR1  and  CR5  
and  sorted  for  GFP+  cells  by  flow  cytometry.  Deletions  at  the  exon  51  locus  were  
detected  by  end-­‐‑point  PCR  using  primers  flanking  the  locus.  Neg  ctrl:  DMD  
myoblasts  treated  with  Cas9  only  and  sorted  for  GFP+  cells.  
6  
 
Supplementary Figure 3: Verification of flow cytometry-based enrichment of gene-modified 
DMD myoblasts used for in vivo cell transplantation experiment. DMD myoblasts were treated 
with Cas9 with or without sgRNA expression vectors for CR1 and CR5 and sorted for GFP+ cells 
by fl w cy ometry. Deletions at the exon 51 locus were detected by end-point PCR using primers 
flanking the locus. Neg ctrl: DMD myoblasts treated with Cas9 only and sorted for GFP+ cells. 
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Figure  24:  Expression  of  restored  human  dystrophin  in  vivo  following  
transplantation  of  CRISPR/Cas9-­‐‑treated  human  DMD  myoblasts  into  
immunodeficient  mice.  Human  Δ48-­‐‑50  DMD  myoblasts  were  treated  with  SpCas9,  
CR1,  and  CR5  to  delete  exon  51  and  sorted  for  GFP  expression  as  shown  in  Figure  19.  
These  sorted  cells  and  untreated  control  cells  were  injected  into  the  hind  limbs  of  
immunodeficient  mice  and  assessed  for  human-­‐‑specific  protein  expression  in  muscle  
fibers  after  4  weeks  post-­‐‑transplantation.  Cryosections  were  stained  with  anti-­‐‑human  
spectrin,  which  is  expressed  by  both  uncorrected  and  corrected  myoblasts  that  have  
fused  into  mouse  myofibers,  or  anti-­‐‑human  dystrophin  antibodies  as  indicated.  White  




























Figure 6 – Expression of restored human dystrophin in vivo following transplantation of 
CRISPR/Cas9-treated human DMD myoblasts into immunodeficient mice. Human Δ48-50 DMD 
myoblasts were treated with SpCas9, CR1, and CR5 to delete exon 51 and sorted for GFP expression as 
shown in Figure 2. These sorted cells and untreated control cells were injected into the hind limbs of 
immunodeficient mice and assessed for human-specific protein expression in muscle fibers after 4 weeks 
post-transplantation. Cryosections were stained with anti-human spectrin, which is expressed by both 
uncorrected and corrected myoblasts that have fused into mouse myofibers, or anti-human dystrophin 
antibodies as indicated. White arrows indicate muscle fibers positive for human dystrophin. 
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Figure  25: Additional  immunofluorescence  images  probing  human  dystrophin  
expression.  Serial  sections  from  regions  stained  with  anti-­‐‑human  spectrin  are  shown  
inset  in  top  left.  (a-­‐‑c)  Sections  from  muscles  injected  with  untreated  human  DMD  
myoblasts.  (d-­‐‑f)  Sections  from  muscles  injected  with  CR1/5  treated  human  DMD  





Supplementary Figure 4: Additional immunofluorescence images probing human dystrophin 
expression. Serial sections from regions stained with anti-human spectrin are shown inset in top 
left. (A-C) Sections from muscles injected with untreated human DMD myoblasts. (D-F) Sections 
from muscles injected with CR1/5 treated human DMD myoblasts enriched by flow cytometry. 
White arrows indicate dystrophin positive fibers. 
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5.4.8. Off-target and Cytotoxicity Analysis 
We  assessed  the  relative  cytotoxicity  of  the  CRISPR/Cas9  system  in  human  cells  
for  select  sgRNAs  by  adapting  a  flow  cytometry-­‐‑based  GFP  retention  assay  as  
previously  described  [42].  Minimal  cytotoxicity  was  observed  for  SpCas9  co-­‐‑expressed  
with  or  without  sgRNAs  after  transfection  into  human  cells  (Figure  26a).  Several  recent  
studies  have  documented  activity  of  the  CRIPSR/Cas9  system  at  off-­‐‑target  loci  in  human  
cells  [137-­‐‑142,  174].  Publicly  available  tools  are  available  to  assess  and  prioritize  
potential  CRISPR/Cas9  activity  at  off-­‐‑target  loci  based  on  predicted  positional  bias  of  a  
given  mismatch  in  the  sgRNA  protospacer  sequence  and  the  total  number  of  
mismatches  to  the  intended  target  site  [137].  We  used  this  public  webserver  to  predict  
the  most  likely  off-­‐‑target  sites  for  the  sgRNAs  used  to  correct  the  dystrophin  gene  in  this  
study  (Table  4).  The  top  ten  potential  off-­‐‑target  sites  were  assessed  by  the  Surveyor  
assay  in  HEK293T  cells  treated  with  SpCas9  and  individual  sgRNA  expression  cassettes  
for  CR1,  CR3,  CR5,  CR6,  or  CR36.  CR1,  CR3  and  CR36  each  had  one  of  these  ten  
predicted  off-­‐‑target  loci  demonstrate  significant  levels  of  gene  modification,  consistent  
with  other  studies  investigating  the  specificity  of  the  S.  pyogenes  CRISPR/Cas9  system  
[137-­‐‑142]  (Table  4  and  Appendix  C).  Interestingly,  the  CR3  off-­‐‑target  sequence  had  
substantial  homology  and  similar  modification  frequencies  to  the  intended  on-­‐‑target  
(9.3%  at  OT-­‐‑1  vs.  13.3%  at  intended  site  (Table  4  and  Appendix  C).  Notably,  CR3-­‐‑OT1  
was  the  only  one  of  these  three  off-­‐‑target  sites  to  show  significant  levels  of  activity  in  the  
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sorted  hDMD  cells  by  the  Surveyor  assay  (Figure  26b).  Thus,  our  selected  sgRNAs  have  
relatively  favorable  specificities,  however,  we  cannot  rule  out  activity  at  predicted  off-­‐‑
target  loci  that  may  exist  below  the  sensitivity  of  the  Surveyor  assay  or  off-­‐‑target  activity  




Figure  26: Evaluation  of  CRISPR/Cas9  toxicity  and  off-­‐‑target  effects  for  
CR1/CR5-­‐‑mediated  deletion  of  exon  51  in  human  cells.  (a)  Results  of  a  cytotoxicity  
assay  in  HEK293T  cells  treated  with  human-­‐‑optimized  SpCas9  and  the  indicated  
sgRNA  constructs.  Cytotoxicity  is  based  on  survival  of  GFP-­‐‑positive  cells  that  are  co-­‐‑
transfected  with  the  indicated  nuclease.  I-­‐‑SceI  is  a  well-­‐‑characterized  non-­‐‑toxic  
meganuclease  and  GZF3  is  a  known  toxic  zinc  finger  nuclease.  (b)  Surveyor  analysis  
at  off-­‐‑target  sites  in  sorted  hDMD  cells  treated  with  expression  cassettes  encoding  
Cas9  the  indicated  sgRNAs.  These  three  off-­‐‑target  sites  tested  in  hDMD  cells  were  
identified  from  a  panel  of  50  predicted  sites  tested  in  HEK293T  cells  (Table  4).  TGT:  
on-­‐‑target  locus  for  indicated  sgRNA.  OT:off-­‐‑target  locus.  (c,  d)  End-­‐‑point  nested  PCR  
to  detect  chromosomal  translocations  in  (c)  HEK293T  cells  treated  with  Cas9  and  CR1  
or  (d)  sorted  hDMD  cells  treated  with  Cas9,  CR1,  and  CR5.  The  schematic  depicts  the  
relative  location  of  nested  primer  pairs  customized  for  each  translocation  event.  The  
expected  size  of  each  band  was  estimated  based  on  the  primer  size  and  the  location  of  
the  predicted  sgRNA  cut  site  at  each  locus.  Asterisks  indicate  bands  detected  at  the  














Figure 7 – Evaluation of CRISPR/Cas9 toxicity and off-target effects for CR1/CR5-mediated deletion of exon 51 in 
human cells. (A) Results of a cytotoxicity assay in HEK293T cells treated with human-optimized SpCas9 and the indicated 
sgRNA constructs. Cytotoxicity is based on survival of GFP-positive cells that are co-transfected with the indicated nuclease. I-
SceI is a well-characterized non-toxic meganuclease and GZF3 is a known toxic zinc finger nuclease. (B) Surveyor analysis at 
off-target sites in sorted hDMD cells treated with expression cassettes encoding Cas9 the indicated sgRNAs. These three off-
target sites tested in hDMD cells were identified from a panel of 50 predicted sites tested in HEK293T cells (Supplementary 
Figure 5 and Supplementary Table 2). TGT: on-target locus for indicated sgRNA. OT:off-target locus. (C-D) End-point 
nested PCR to detect chromosomal translocations in (C) HEK293T cells treated ith Cas9 and CR1 or (D) sorted hDMD cells 
treated with Cas9, CR1, and CR5. The schematic depicts the relative location of nested primer pairs customized for each 
translocation event. The expected size of each band was estimated based on the primer size and the location of the predicted 
sgRNA cut site at each locus. Asterisks indicate bands detected at the expected size. The identities of the bands in (C) were 
verified by Sanger sequencing from each end (Supplementary Figure 8). A representative chromatogram for the P2/P5 
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from  each  end  (Figure  29).  A  representative  chromatogram  for  the  P2/P5  translocation  
in  HEK293T  cells  is  shown.  
Nuclease  activity  at  off-­‐‑target  sites  may  cause  unintended  chromosomal  
rearrangements  by  distal  re-­‐‑ligation  between  cleaved  target  and  off-­‐‑target  loci  on  
distinct  chromosomes  [174,  182].  This  presents  a  significant  concern  for  deletion-­‐‑based  
gene  correction  strategies  due  to  the  increased  potential  for  off-­‐‑target  activity  by  using  
two  or  more  nucleases,  such  as  in  multiplex  CRISPR/Cas9  gene  editing.  We  probed  for  
potential  translocations  using  a  highly  sensitive  nested  genomic  PCR  assay  to  detect  
translocations  at  the  validated  off-­‐‑target  loci  (Table  4)  during  both  single  and  multiplex  
CRISPR/Cas9  editing  strategies.  Using  this  assay,  we  readily  detected  translocations  
between  on-­‐‑target  and  off-­‐‑target  sites  in  the  model  HEK293T  cell  line  that  also  shows  
high  levels  of  off-­‐‑target  activity  (Figures  26c,  27-­‐‑29).  Sanger  sequencing  of  the  PCR  
amplicons  confirmed  the  identity  of  the  predicted  translocation  event  for  each  primer  
pair  (Figures  28-­‐‑29).  A  subset  of  the  translocations  detected  in  the  HEK293T  cells  were  
also  detectable  by  nested  PCR  in  the  sorted  hDMD  myoblasts,  although  the  signal  was  
considerably  weaker  and  we  were  unable  to  confirm  the  sequence  identity  due  to  low  
yield  of  product  (Figures  26d  and  27a,c).  Notably,  we  did  not  detect  translocations  using  
this  assay  in  HEK293T  or  sorted  hDMD  cells  treated  with  CR6  or  CR6/CR36,  
respectively  (Figure  27),  that  had  low  levels  of  off-­‐‑target  activity  at  CR6-­‐‑OT3  only  in  
HEK293T  cells  (Table  4).  These  results  underscore  the  importance  of  selecting  highly  
specific  sgRNAs,  particularly  for  multiplex  editing  applications,  and  show  that  this  
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approach  can  benefit  from  ongoing  efforts  to  improve  the  specificity  of  the  CRISPR/Cas9  
system  [139,  142,  143,  173,  174].  However,  taken  together  with  the  cytotoxicity  and  stable  
gene  editing  activities  observed  in  Table  3,  these  data  suggest  that  the  selected  sgRNAs  
are  able  to  correct  the  dystrophin  gene  without  significant  toxicity  and  with  only  a  single  
strongly  predicted  off-­‐‑target  site  with  detectable  levels  of  activity.  
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Table  4:  Summary  of  top  10  off  target  sites  predicted  in  silico  and  activity  at  
each  site  as  detected  by  the  Surveyor  assay  in  HEK293T  cells  transfected  with  Cas9  
and  the  indicated  sgRNA  expression  cassettes.  n.d.:  not  detected.  






CR3 Guide  GCCTACTCAGACTGTTACTC - - - - - - - 
Target tCCTACTCAGACTGTTACTC TGG - X DMD Exon 1 13.0 
OT1 tCCTACTCAcACTGTTACTC AGG 7.4 1 STRIP1 Intron 2 9.3 
OT2 aCCTgCTCAcACTGTTACTC CAG 2.5 2 ARHGAP25 Intron 3 n.d. 
OT3 GCaTtCTCAaACTGTTACTC AGG 2.4 13 None None 3 n.d. 
OT4 GgaTtCTCAcACTGTTACTC GGG 1.3 14 PGPEP1 Exon 4 n.d. 
OT5 aCaTACTtAtACTGTTACTC TAG 1.3 19 MDGA2 Intron 4 n.d. 
OT6 tatTcCTaAGACTGTTACTC AAG 0.9 8 LPPR1 Intron 5 n.d. 
OT7 aaggACTaAGACTGTTACTC GGG 0.9 9 RNF122 Intron 5 n.d. 
OT8 GagctCTCAtACTGTTACTC TAG 0.8 3 DNMBP Exon 5 n.d. 
OT9 GCaaAaTgAGACTGTTACTC CAG 0.8 5 SLC12A2 Intron 4 n.d. 
OT10 cCtcAtTCAGACTGTTACTC AAG 0.8 4 KCNIP4 Intron 4 n.d. 
CR1 Guide GATTGGCTTTGATTTCCCTA - - - - - - - 
Target cATTGGCTTTGATTTCCCTA GGG - X DMD Intron 1 8.3 
OT1 aATTGGCATTGATTTCCCTA GAG 7.1 16 None None 2 0.8 
OT2 cATTGGCTTTaATTTCCCTA TAG 4.8 4 None None 2 n.d. 
OT3 GATaGGCTgTGATTTCCCTA GAG 3.9 9 None None 2 n.d. 
OT4 GAaTaGCcTTGATTTCCCTA AAG 2.4 1 None None 3 n.d. 
OT5 aATTtGCTTTGATTTCCCTg AGG 1.5 1 TIMM17A Intron 3 n.d. 
OT6 GATgtGCTTTGATTTCCCTt GGG 1.4 17 MYO1D Intron 3 n.d. 
OT7 aATTGGtTTTaATTTCCCTA AAG 1.1 8 PIK1A Intron 3 n.d. 
OT8 aATTGGgTTTGATTTCCCTt TGG 1.1 11 MS4A1 Intron 3 n.d. 
OT9 GATgGGtTTTtATTTCCCTA GAG 1.0 11 None None 3 n.d. 
OT10 GAaTGGtTTTGATTTCCCTg GAG 1.0 11 None None 3 n.d. 
CR5 Guide GCAGTTGCCTAAGAACTGGT - - - - - - - 
Target aCAGTTGCCTAAGAACTGGT GGG - X DMD Intron 1 14.0 
OT1 cCAGTTGtCTAAGAACTGGg GAG 1.5 5 NRG1 Intron 3 n.d. 
OT2 GCAGTTGCCTgtGAACTGGT AGG 1.4  X None None 2 n.d. 
OT3 GCAGaTGCagAAGAACTGGT GAG 1.4 19 SMIM7 Intron 3 n.d. 
OT4 GCAGTTcCagAAGAACTGGT GAG 0.9 11 GLB1L2 Intron 3 n.d. 
OT5 caAcTTGCCTAtGAACTGGT AGG 0.7 8 ASAP1 Intron 4 n.d. 
OT6 aCAccTGCCTAAGAACTGGa GGG 0.7 11 None None 4 n.d. 
OT7 tCAGgTGgCTAAGAACTGGg TGG 0.7 14 NIN Intron 4 n.d. 
OT8 GaAGTTGgCcAAGAACTGGa GAG 0.6 7 None None 4 n.d. 
OT9 GCtGcTGCCcAAGAACTGGc AGG 0.6 11 AMOTL1 Intron 4 n.d. 
OT10 tCAGcTGgCTAAGAACgGGT AAG 0.6 7 ACTR3C Intron 4 n.d. 
CR6 Guide GGGGCTCCACCCTCACGAGT - - - - - - - 
Target aGGGCTCCACCCTCACGAGT GGG - X DMD Intron 1 19.9 
OT1 GcaGCTCagCCCTCACGAGT CAG 0.8 3 None None 4 n.d. 
OT2 GGGGCTtCAgCaTCACGAGT GAG 0.8 8 None None 3 n.d. 
OT3 GGGGCTCtcCCCTCACtAGT GAG 0.6 8 None None 3 n.d. 
OT4 GGGGaTCCACCtTCACcAGT CAG 0.6 2 None None 3 n.d. 
OT5 aGGGCTggACCCTCACaAGT AAG 0.4 16 AXIN1 Intron 4 n.d. 
OT6 tGGtCTCCtCCCcCACGAGT GGG 0.4 2 None None 4 n.d. 
OT7 aGGGCTCCcaCCcCACGAGT GAG 0.3 5 None None 4 n.d. 
OT8 GaGGCTCCAtaCTCACcAGT GAG 0.3 11 None None 4 n.d. 
OT9 GGaGCTgCcCCtTCACGAGT GGG 0.3 3 None None 4 n.d. 
OT10 atGaCTCCACCCTCAaGAGT AAG 0.3 8 AGPAT5 None 4 n.d. 
CR36 Guide GCCTTCTTTATCCCCTATCG - - - - - - - 
Target GCCTTCTTTATCCCCTATCG AGG - X DMD Intron 0 20.6 
OT1 GtCTgCTgTgTCCCCTATCG GGG 1.3 21 None None 4 n.d. 
OT2 cCCTTCTcTATCCCCTgTCG TGG 1.3 8 None None 3 n.d. 
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OT3 GCCTTCTTTATCCCCTcTCt TGG 0.9 10 None None 2 0.5 
OT4 GCgcTCTTTtTCCCCTATCt TAG 0.6 16 None None 4 n.d. 
OT5 GCCcTCTgTcTCCCCTgTCG CAG 0.5 1 NFASC None 4 n.d. 
OT6 tCCATCTtTgTCCCCTATtG AGG 0.5 10 None None 4 n.d. 
OT7 aCCtTCTCTcTCCCCTATaG AGG 0.5 5 LOC10099
6485 
Intron 4 n.d. 
OT8 GttTTCTTTtTCCCCTATgG GAG 0.5 3 None None 4 n.d. 
OT9 tgCTTCTTaATCCCCTATCa AAG 0.4 7 None None 4 n.d. 




Figure  27:  End-­‐‑point  nested  PCR  to  detect  chromosomal  translocations  caused  
by  CRISPR/Cas9  off-­‐‑target  activity  for  CR3  and  CR6/CR36  in  human  cells.  Nested  
end-­‐‑point  PCR  analysis  was  used  to  detect  translocations  in  (a)  HEK293T  or  sorted  
hDMD  cells  treated  with  Cas9  and  CR3  as  indicated,  (b)  HEK293T  cells  treated  with  
Cas9  and  CR36  alone,  or  (c)  sorted  hDMD  cells  treated  with  Cas9,  CR6,  and  CR36  
expression  cassettes.  The  second  nested  PCR  reaction  for  translocation  was  amplified  
using  custom  primers  for  each  predicted  translocation  locus  to  maximize  specificity  
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Supplementary Figure 6 – End-point nested PCR to detect chromosomal translocations 
caused by CRISPR/Cas9 off-target activity for CR3 and CR6/CR36 in human cells. Nested 
end-point PCR analysis was used to detect translocations in (A) HEK293T or sorted hDMD cells 
treated with Cas9 and CR3 as indicated, (B) HEK293T cells treated with Cas9 and CR36 alone, 
or (C) sorted hDMD cells treated with Cas9, CR6, and CR36 expression cassettes. The second 
nested PCR reaction for transloc tion was amplified using custom primers for ach predicted 
translocation locus to maximize specificity (See Supplementary Table 2). The schematic depicts 
the relative location of nested primer pairs used to probe for the presence of translocations. Each 
possible translocation event was first amplified from genomic DNA isolated from cells treated 
with or without the indicated sgRNA(s). A second nested PCR reaction was performed using 
primers within the predicted PCR amplicons that would result from translocations. Expected size 
was estimated based on the indicated primer binding site and the predicted sgRNA cut site at each 
locus. *indicates bands detected at the expected size and verified by Sanger sequencing from each 
end. #indicates amplicons in which Sanger sequencing showed sequences other than the predicted 
translocation, likely a result of mispriming during the nested PCR. 
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(See  Appendix  C).  The  schematic  depicts  the  relative  location  of  nested  primer  pairs  
used  to  probe  for  the  presence  of  translocations.  Each  possible  translocation  event  
was  first  amplified  from  genomic  DNA  isolated  from  cells  treated  with  or  without  the  
indicated  sgRNA(s).  A  second  nested  PCR  reaction  was  performed  using  primers  
within  the  predicted  PCR  amplicons  that  would  result  from  translocations.  Expected  
size  was  estimated  based  on  the  indicated  primer  binding  site  and  the  predicted  
sgRNA  cut  site  at  each  locus.  *indicates  bands  detected  at  the  expected  size  and  
verified  by  Sanger  sequencing  from  each  end.  #indicates  amplicons  in  which  Sanger  
sequencing  showed  sequences  other  than  the  predicted  translocation,  likely  a  result  




Figure  28:  Sanger  sequencing  chromatograms  for  bands  detected  in  Figure  27  
resulting  from  translocations  between  CR3  and  CR3-­‐‑OT1,  on  chromosomes  X  and  1,  




Supplementary Figure 7- Sanger s que cing chromatograms f r ds detected in 
Suppleme tary Figu e 6 resul ng from translocations between CR3 and CR3-OT1, on 
chromosomes X and 1, respectively, in HEK293T cells treated with Cas9 and CR3 gene cassettes. 
Arrows show regions of homology to the indicated chromosome nearby the expected break points 
caused by the appropriate sgRNAs. Note that sequencing reads become out of phase near the 
break point due to the error-prone nature of DNA repair by non-homologous end-joining. 
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show  regions  of  homology  to  the  indicated  chromosome  nearby  the  expected  break  
points  caused  by  the  appropriate  sgRNAs.  Note  that  sequencing  reads  become  out  of  





Figure  29:  Sanger  sequencing  chromatograms  for  bands  detected  in  Figure  26c  
resulting  from  translocations  between  CR1  and  CR1-­‐‑OT1,  on  chromosomes  X  and  16,  
respectively,  in  HEK293T  cells  treated  with  Cas9  and  CR1  gene  cassettes.  Arrows  
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Supplementary Figure 8- Sanger sequencing chromatograms for bands detected in Figure 7C 
resulting from translocations between CR1 and CR1-OT1, on chromosomes X and 16, 
respectively, in HEK293T cells treated with Cas9 nd CR1 gene cassettes. Arrows show regions 
of homolo y t  the indicated chromosome earby the expected break points caused by the 
appropriate sgRNAs. Note that sequencing reads become out of phase near the break point due to 




show  regions  of  homology  to  the  indicated  chromosome  nearby  the  expected  break  
points  caused  by  the  appropriate  sgRNAs.  Note  that  sequencing  reads  become  out  of  
phase  near  the  break  point  due  to  the  error-­‐‑prone  nature  of  DNA  repair  by  non-­‐‑
homologous  end-­‐‑joining.  
5.5. Discussion 
Genome  editing  is  a  powerful  tool  for  correcting  genetic  disease  and  the  recent  
development  of  the  CRISPR/Cas9  system  is  dramatically  accelerating  progress  in  this  
area.  Here  we  demonstrate  the  correction  of  DMD,  the  most  common  genetic  disease  
that  also  currently  has  no  approved  therapeutic  options.  Many  gene-­‐‑  and  cell-­‐‑based  
therapies  for  DMD  are  in  preclinical  development  and  clinical  trials,  and  genome  editing  
methods  are  compatible  with  many  of  these  approaches.  For  example,  genome  editing  
may  be  combined  with  patient-­‐‑specific  cell-­‐‑based  therapies  for  DMD  [19,  36,  181].  The  
CRISPR/Cas9  system  has  been  previously  demonstrated  to  function  in  human  
pluripotent  stem  cells  [100,  103]  and  other  human  cell  lines  [10,  11,  99,  101],  as  well  as  
human  skeletal  myoblasts  in  this  study.  Furthermore,  genome  editing  of  autologous  
primary  T  cells  with  ZFNs  is  currently  in  clinical  trials  (NCT01252641,NCT00842634  and  
NCT01044654)  [13].  Importantly,  gene  editing  with  CRISPR/Cas9  did  not  abolish  the  
myogenic  capacity  of  these  cells,  as  demonstrated  by  efficient  dystrophin  expression  in  
vitro  and  in  vivo  after  transplantation  into  immunodeficient  mice.  Thus,  this  strategy  
should  be  compatible  with  cell-­‐‑based  therapies  for  DMD  that  are  under  development,  
although  achieving  efficient  cell  engraftment  is  still  a  challenge  [19,  36,  181].  
Additionally,  direct  transfection  of  the  sgRNA  and  Cas9  mRNA,  in  contrast  to  the  
  128  
plasmid-­‐‑based  delivery  method  used  here,  may  increase  specificity  and  safety  by  
reducing  the  duration  of  Cas9  expression  and  eliminating  the  possibility  of  random  
plasmid  integration.  Alternatively,  delivery  of  the  CRISPR/Cas9  system  directly  to  
skeletal  and/or  cardiac  muscle  by  viral,  plasmid,  or  RNA  delivery  vectors  is  a  promising  
strategy  for  in  vivo  genome  editing  and  translation  of  this  approach  [5,  19,  183].  The  large  
size  of  S.  pyogenes  Cas9  gene  (~4.2  kilobases)  presents  a  challenge  to  its  use  in  size-­‐‑
restricted  adeno-­‐‑associated  viral  vectors.  However,  Cas9  genes  from  other  species  [136],  
such  as  N.  meningitidis  and  S.  thermophilus,  are  short  enough  to  efficiently  package  both  
Cas9  and  sgRNA  expression  cassettes  into  single  AAV  vectors  for  in  vivo  gene  editing  
applications,  as  has  been  done  with  the  smaller  ZFNs  [81,  87].  
The  S.  pyogenes  CRISPR/Cas9  system  enabled  efficient  modification  of  nearly  90%  
of  tested  targets,  consistent  with  other  reports  of  robust  activity  of  this  system  at  diverse  
loci.  The  robustness  and  versatility  of  this  technology  is  a  significant  advancement  
towards  at-­‐‑will  creation  of  patient-­‐‑specific  gene  editing.  However,  further  enhancing  
gene  editing  frequencies  and  minimizing  off-­‐‑target  activity  remain  as  major  challenges  
to  customized  clinical  applications.  Notably,  recent  studies  have  shown  that  low  levels  
of  dystrophin,  including  as  little  as  4%  of  wild-­‐‑type  expression,  are  sufficient  to  improve  
survival,  motor  function,  and  cardiac  function  in  a  mouse  model  [184-­‐‑186].  Therefore  the  
levels  of  CRISPR/Cas9  activity  reported  in  this  study  may  be  sufficient  for  therapeutic  
benefit,  although  we  suspect  that  optimized  delivery  and  expression  vehicles,  as  well  as  
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ongoing  improvements  to  the  CRISPR/Cas9  system  [173],  will  lead  to  significant  
enhancements  of  gene  correction  levels.    
The  use  of  multiplexing  with  CRISPR/Cas9  to  delete  exons  also  presents  a  unique  
set  of  opportunities  and  challenges.  While  Chapter  4  explores  deletion  of  essential  exon  
splicing  sequences,  this  is  the  first  study  to  report  the  deletion  of  entire  exons  from  the  
genome  to  restore  dystrophin  expression.  Previous  efforts  restored  the  reading  frame  of  
the  dystrophin  gene  with  small  indels  generated  by  NHEJ-­‐‑based  DNA  repair  following  
the  action  of  a  single  nuclease  [42,  90].  A  primary  benefit  of  this  new  approach  is  that  the  
protein  product  of  the  edited  gene  is  predictable  and  already  characterized  in  Becker  
muscular  dystrophy  patients  with  the  naturally  occurring  deletion,  in  contrast  to  the  
random  indels  created  by  intraexonic  action  of  a  single  nuclease  that  will  lead  to  the  
creation  of  novel  epitopes  from  each  DNA  repair  event.  Furthermore,  the  product  
resulting  from  the  exon  deletions  will  lead  to  restored  dystrophin  for  every  successful  
gene  editing  event,  whereas  modifying  the  gene  with  random  indels  within  exons  will  
only  restore  the  reading  frame  in  the  one-­‐‑third  of  editing  events  that  leads  to  the  correct  
reading  frame.  Additional  studies  on  enhancing  and/or  biasing  gene  repair  towards  
distal  chromosomal  re-­‐‑ligation  will  be  helpful,  particularly  for  long  deletions  such  as  the  
excision  of  the  336  kb  containing  exons  45-­‐‑55  demonstrated  in  this  study.  Moreover,  the  
introduction  of  multiple  DSBs  increases  the  requirement  for  stringent  specificity  of  the  
gene  editing  reagents  in  order  to  minimize  the  opportunity  for  the  unintended  
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chromosomal  rearrangements  that  were  readily  detected  in  the  treated  HEK293T  cells  
(Figures  26c  and  27-­‐‑29).  
We  observed  that  all  of  the  sgRNAs  tested  were  not  associated  with  significant  
cytotoxic  effects  in  human  cells.  We  identified  three  potential  off-­‐‑target  sites  out  of  50  
total  tested  sites  for  the  five  sgRNAs  used  here  to  restore  dystrophin  expression.  
Furthermore,  chromosomal  translocations  between  the  intended  on-­‐‑target  sites  and  
these  off-­‐‑target  sites  were  detectable  by  highly  sensitive  nested  PCR  assays  in  HEK293T  
cells  expressing  high  levels  of  Cas9  and  sgRNAs.  This  is  consistent  with  previous  work  
showing  translocations  with  two  nucleases  intentionally  targeted  to  distinct  
chromosomes  [182].  These  results  are  also  consistent  with  other  studies  that  have  
characterized  off-­‐‑target  activity  and  translocations  generated  by  SpCas9  [137-­‐‑142,  174]  
and  compare  favorably  with  other  gene  editing  systems,  including  ZFNs  and  TALENs,  
which  are  sometimes  cytotoxic  [187]  and  are  known  to  also  act  at  off-­‐‑target  sites  [12].  
Notably,  the  off-­‐‑target  activity  and  translocations  identified  in  HEK293T  cells,  which  is  
an  immortalized  and  aneuploid  cell  line  that  expresses  very  high  levels  of  Cas9  and  
sgRNA,  did  not  occur  at  as  high  a  level  and  in  some  cases  were  undetectable  in  the  
hDMD  myoblasts.  This  corroborates  previous  studies  showing  that  lower  levels  of  Cas9  
and  sgRNA  can  reduce  off-­‐‑target  effects  [137,  140].  Importantly,  this  level  of  specificity  
may  be  tolerable  given  the  severity  of  DMD,  the  lack  of  an  apparent  cytotoxic  effect  in  
human  cells,  and  the  absence  of  adverse  events  in  ongoing  clinical  trials  for  genome  
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editing  with  ZFNs  (NCT01252641,  NCT00842634  and  NCT01044654)  [13].  Furthermore,  
improvements  to  the  specificity  of  the  CRISPR/Cas9  system,  including  the  use  of  dual  
nickases,  truncated  sgRNAs,  and  careful  sgRNA  selection  methods  [139,  142,  143,  174],  
are  also  under  development.  CRISPR/Cas9  specificity  may  be  further  enhanced  by  
rational  design  or  directed  evolution  of  the  S.  pyogenes  sgRNA  and/or  Cas9  nuclease,  or  
characterization  of  novel  Cas9  nucleases  from  other  species  with  more  stringent  sgRNA  
or  PAM  requirements  [136].    
This  study  demonstrates  that  CRISPR/Cas9  genome  editing  is  a  robust,  easily  
programmable  method  to  rapidly  generate  targeted  frameshifts  or  genomic  deletions  
that  can  address  a  variety  of  dystrophin  mutations.  Importantly,  this  method  can  
reproducibly  modify  the  dystrophin  gene  by  deleting  exons  45-­‐‑55,  thereby  addressing  
more  than  half  of  DMD  patient  deletions  with  a  single  genome  editing  strategy.  Further  
advancements  in  the  delivery,  specificity,  and  efficiency  of  these  reagents  will  enhance  
the  utility  of  this  method  for  correcting  the  dystrophin  gene  and  creating  other  custom  
genetic  modifications.  Thus,  CRISPR/Cas9  genome  editing  offers  an  exciting  new  avenue  




Chapter 6: Summary and Future Studies 
6.1. Overview 
This  thesis  capitalizes  on  the  rapid  advancement  of  genome  editing  tools  to  
create  novel  molecular  therapies  for  Duchenne  muscular  dystrophy.  Genetic  correction  
of  the  native  dystrophin  gene  is  a  powerful  method  to  permanently  restore  dystrophin  
expression  that  is  compatible  with  many  leading  cell  and  gene  therapies  for  this  
disorder.  Presently,  there  is  still  a  need  to  find  effective  therapies  for  DMD  and  gene  
correction  at  the  genomic  level  is  a  promising  alternative  to  transient  methods  such  as  
AAV  gene  transfer  of  minidystrophin  genes  or  small  oligonucleotides  to  rescue  the  
reading  frame  of  the  dystrophin  gene.  
Chapter  3  explores  the  use  of  TALEN  technologies  to  generate  intraexonic  small  
insertions  and  deletions  that  restore  the  dystrophin  reading  frame.  First,  several  
combinations  of  TALEN  pairs  were  generated  and  tested  for  efficient  gene  modification  
in  human  cells.  An  optimal  TALEN  pair  was  then  transfected  into  several  human  cell  
lines  derived  from  DMD  patients.  These  cell  lines  included  myoblasts  and  fibroblasts,  
two  clinically  relevant  cell  sources  for  cell-­‐‑based  therapies  for  DMD.  TALEN  gene  
modification  was  able  to  restore  the  expression  of  dystrophin  in  clonally  derived  patient  
myoblasts,  and  in  treated  bulk  populations  of  myoblasts  as  well  as  fibroblasts  that  were  
reprogrammed  into  the  myogenic  lineage  by  forced  overexpression  of  the  master  
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myogenic  transcription  factor,  MyoD.  Importantly,  exome  sequencing  of  clonally  
derived  DMD  myoblasts  revealed  no  off-­‐‑target  effects  caused  by  these  TALENs.  
Building  on  this  work,  we  also  wanted  to  create  homogeneous  changes  to  the  
corrected  dystrophin  protein.  Chapter  4  describes  a  strategy  to  generate  genetic  
deletions  of  sequences  essential  to  exon  splicing  as  a  method  to  delete  exon  51  and  
restore  the  dystrophin  reading  frame.  To  do  this,  ZFNs  were  generated  and  screened  for  
chromosomal  activity.  Two  ZFN  pairs  were  transfected  into  DMD  patient  derived  
myoblasts  and  a  single  clonal  population  was  isolated  containing  the  expected  genetic  
deletion.  This  genetic  deletion  resulted  in  the  loss  of  exon  51  from  the  mRNA  transcript  
and  restoration  of  dystrophin  expression.  Furthermore,  these  corrected  cells  were  able  to  
engraft  in  vivo  following  transplantation  into  immunodeficient  mice  and  express  human  
dystrophin  that  is  correctly  localized  to  the  sarcolemma  membrane.  Thus,  this  study  
demonstrates  that  genetic  corrections  can  result  in  restored  dystrophin  functionality  and  
that  ZFN-­‐‑mediated  gene  modification  can  be  achieved  without  a  significant  impact  of  
the  myogenic  capabilities  of  targeted  cells.  
In  Chapter  5,  we  expanded  on  this  approach  using  the  recently  described  
CRISPR/Cas9  system  to  rapidly  generate  intraexonic  small  insertions  and  deletions,  
single  exon  deletions,  and  multiple  exon  deletions  across  a  mutational  hotspot  in  the  
dystrophin  gene.  Importantly,  the  S.  pyogenes  CRISPR/Cas9  gene  editing  platform  is  able  
to  generate  gene  modifications  with  a  high  rate  of  success,  thereby  allowing  expansion  
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of  the  proof-­‐‑of-­‐‑principle  studies  in  Chapters  3  and  4.  Thus,  we  were  able  to  generate  
unique  nucleases  targeting  the  5’  and  3’  ends  of  nearly  every  exon  between  the  
mutational  hotspot  of  exons  45-­‐‑55,  enabling  a  patient-­‐‑specific  therapeutic  strategy  that  is  
otherwise  difficult  and  time-­‐‑consuming  to  achieve  with  other  gene  editing  technologies.  
Furthermore,  we  utilized  the  unique  multiplex  editing  capabilities  of  this  system  to  
rapidly  and  efficiently  delete  exon  51  or  exons  45-­‐‑55.  Using  these  approaches,  we  were  
able  to  restore  dystrophin  expression  in  vitro  in  human  DMD  patient  myoblasts  and  in  
vivo  after  transplantation  of  a  bulk  corrected  population  of  hDMD  myoblasts.  Taken  
together,  these  approaches  can  address  over  60%  of  patient  mutations.  Notably,  
multiplex  deletion  of  exons  45-­‐‑55  presents  a  universal  approach  to  correct  these  >60%  of  
mutations  and  generate  a  predictable  protein  product  that  is  known  to  have  high  
functionality  in  some  Becker  muscular  dystrophy  patients  [176,  188],  a  less  severe  form  
of  DMD.  We  also  show  that  there  is  a  need  to  improve  the  specificity  of  these  
approaches,  as  we  were  able  to  readily  detect  off-­‐‑target  cleavage  at  unintended  genomic  
loci  that  resulted  in  chromosomal  rearrangements  in  human  cells.  
Nuclease-­‐‑mediated  gene  correction  is  an  effective  method  to  restore  the  
dystrophin  gene.  This  thesis  demonstrates  that  the  reading  frame  of  the  dystrophin  gene  
can  be  corrected  in  a  variety  of  methods,  including  small  insertions  and  deletions  and  
large  deletions  of  one  or  more  exons.  We  show  that  ZFNs,  TALENs,  and  CRISPR/Cas9  
are  efficient  systems  for  generating  genetic  modifications  in  complex  genomes.  
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However,  the  large  size  and  repetitive  sequence  composition  of  TALENs  presents  a  
significant  challenge  for  delivering  these  gene-­‐‑editing  tools  in  vivo.  Therefore,  ZFNs  and  
CRISPR/Cas9  are  excellent  candidates  for  clinical  translation  as  genetic  tools  to  cure  
DMD.  A  recent  clinical  trial  established  that  ZFN-­‐‑modified  cells  met  safety  criteria  gene  
editing  platform  after  ex  vivo  gene  modification  and  transplantation  of  autologous  ZFN-­‐‑
modified  cells  [13].  Chapter  5  demonstrates  that  CRISPR/Cas9  can  efficiently  delete  one  
or  more  entire  exons,  thereby  restoring  a  clinically  relevant,  predictable  protein.  The  
multiplexing  capability  and  straightforward  sgRNA  design  of  CRISPR/Cas9  gene  
editing  is  a  highly  efficient  method  to  introduce  genetic  deletions.  In  particular,  genetic  
deletion  of  exon  51  is  attractive  due  to  the  high  efficiency  of  deletion  with  CRISPR/Cas9  
and  the  positive  results  in  ongoing  oligonucleotide-­‐‑based  transient  exon  51  skipping  
clinical  trials.  Further  work  remains  to  increase  the  specificity  of  these  gene  editing  
platforms  and  to  develop  strategies  for  cell-­‐‑based  therapies  or  gene  transfer  of  gene  
editing  tools  to  restore  dystrophin  in  vivo.  
6.2. Improving the efficiency of gene correction 
A  major  factor  that  will  influence  the  therapeutic  efficacy  of  genomic  
intervention  in  DMD  is  the  percentage  of  muscle  fibers  expressing  restored  dystrophin  
protein.  A  notable  set  of  studies  have  investigated  the  effect  of  dystrophin  expression  
levels  on  phenotypic  outcome  in  a  mosaic  mouse  model  of  DMD  that  expresses  variable  
levels  of  dystrophin  to  explore.  From  these  studies,  it  has  been  suggested  that  
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dystrophin  levels  greater  than  4-­‐‑12%  of  normal  can  ameliorate  skeletal  muscle  
histopathology  and  cardiomyopathic  symptoms  in  mosaic  mice  that  randomly  express  
normal  or  mutant  dystrophin  [184,  186],  while  dystrophin  levels  of  greater  than  20%  are  
necessary  to  protect  muscle  from  exercise-­‐‑induced  damage  [189].  A  study  investigating  
phenotypic  severity  in  Becker  muscular  dystrophy  patients,  which  have  variable  levels  
of  expressed  dystrophin,  demonstrates  that  10%  or  less  of  normal  dystrophin  levels  
universally  results  in  a  high  disease  severity,  including  early  onset  of  loss  of  ambulation,  
cardiac  involvement,  and  death  [21].  Thus,  genetic  correction  strategies  that  correct  >4%  
of  genomes  will  provide  therapeutic  benefit  and  protection,  with  a  secondary  goal  of  
achieving  optimal  gene  correction  rates  of  >20%  of  treated  nuclei  to  ensure  complete  
therapeutic  protection.  
In  Chapter  3,  TALENs  mediated  in  situ  modification  in  6.8-­‐‑39.3%  of  DMD  
myoblasts,  of  which  1/3  of  total  events  are  expected  to  result  in  frame  correction,  thereby  
creating  an  effective  correction  rate  of  2.2-­‐‑13.1%  of  cells.  In  Chapter  4,  we  were  able  to  
generate  an  isogenic  genetically  corrected  population  that  can  engraft  into  host  muscle  
tissue  to  restore  human  dystrophin  expression.  A  limitation  of  this  study  is  that  clonally  
corrected  cell  populations  must  be  efficiently  delivered  to  dystrophic  muscle  in  vivo.  
This  is  a  significant  challenge,  requiring  numerous  injections  in  each  muscle  and  would  
be  particularly  difficult  for  engrafting  corrected  cells  in  the  heart.  However,  as  discussed  
in  Chapter  2,  there  have  been  significant  advances  in  iPSC  and  dystrophic  muscle  
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homing  progenitors  that  may  be  compatible  with  this  approach.  Finally,  Chapter  5  
demonstrates  a  variety  of  gene  modifications,  including  efficient  deletion  of  exon  51  in  
10.5-­‐‑13.6%  of  DMD  myoblasts  (each  deletion  event  is  expected  to  result  in  genetic  
correction)  and  modification  of  intraexonic  targets  in  1.8-­‐‑33.7%  of  treated  human  cells  
(0.6-­‐‑11.2%  total  corrective  events).  Together,  the  methods  presented  in  Chapters  3-­‐‑5  are  
able  to  generate  in  situ  genetic  correction  rates  of  0.6-­‐‑13.6%  in  vitro  in  well  controlled  
conditions.  Future  studies  will  need  to  explore  the  efficiency  of  gene  modifications  in  
vivo  following  delivery  of  targeted  nucleases  to  skeletal  and  cardiac  muscle.  
The  genome  editing  strategies  presented  in  this  work  mediate  highly  efficient  
correction,  easily  surpassing  the  4%  of  treated  genomes  needed  for  therapeutic  effect.  
However,  improving  specificity  of  these  approaches  will  be  important  to  minimize  
unintended  genotoxicity  that  may  be  caused  by  engineered  nucleases.  Currently,  ZFNs,  
TALENs,  and  CRISPR/Cas9  are  capable  of  generating  single-­‐‑site  double-­‐‑strand  breaks  in  
>50%  of  treated  cells,  but  this  is  heavily  locus-­‐‑  or  reagent-­‐‑dependent.  Moving  forward,  
the  discovery  or  engineering  of  improved  gene  editing  systems  and  approaches  can  be  
used  to  increase  single-­‐‑site  gene  editing  as  well  as  genetic  deletions  to  >20%  correction  
levels  that  will  provide  complete  protection,  particularly  for  large  deletions  such  as  the  
330kb  deletion  of  exons  45-­‐‑55  in  Chapter  5.  For  example,  there  have  been  a  number  of  
recent  studies  improving  the  delivery,  activity,  and/or  specificity  of  ZFNs  [172],  TALENs  
[103],  and  CRISPR/Cas9  [142,  190].  Furthermore,  next  generation  gene  editing  tools,  such  
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as  recombinases  [109-­‐‑111,  191],  may  improve  genome  editing  efficiencies  as  well.  
Finally,  efficient  delivery  methods  to  deliver  gene  editing  enzymes,  such  as  adeno-­‐‑
associated  virus,  or  novel  cell-­‐‑based  methods  such  as  dystrophic  muscle-­‐‑homing  
progenitors  or  iPSC-­‐‑derived  progenitors  [29]  will  need  to  be  optimized  to  reach  
protective  levels  of  restored  dystrophin  expression.  AAV  is  of  significant  interest  for  
gene  transfer  to  muscle  and  there  has  been  significant  progress  in  engineering  novel  
AAV  serotypes  with  improved  tropism  to  skeletal  and  cardiac  muscle  [53,  192-­‐‑196].  
Importantly,  these  studies  demonstrate  that  customized  AAV  vectors  can  be  developed  
to  evade  pre-­‐‑existing  vector  immunity  and  optimize  vector  biodistribution  to  muscle.  
Despite  this,  genome  editing  is  an  exciting  method  to  generate  autologous  cell  therapies  
for  DMD,  and  could  be  realized  as  a  custom  therapeutic  that  allows  extensive  ex  vivo  
characterization  and  safety  profiling  before  administration  to  the  patient.  
6.3. Functional analysis of restored dystrophin proteins  
DMD  patient  mutations  that  disrupt  the  dystrophin  reading  frame  are  commonly  
deletions  of  one  or  more  non-­‐‑essential  exons.  Chapters  3-­‐‑5  explore  restoration  of  the  
dystrophin  reading  frame  around  these  mutational  hotspot  of  the  dystrophin  gene  that  
accounts  for  >60%  of  patient  mutations.  Additional  work  is  needed  to  characterize  the  
resulting  proteins  generated  by  these  methods.  As  shown  in  Chapter  5,  genome  editing  
offers  the  exciting  possibility  of  deleting  large  regions  of  the  dystrophin  gene  at  will,  
thereby  creating  the  possibility  to  characterize  of  the  function  of  a  range  of  predefined,  
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internally  deleted  dystrophin  proteins  through  generation  of  isogenic  myoblast  cell  
lines.  These  modified  isogenic  cell  populations  could  be  combined  with  novel  in  vitro  
analyses  [197]  to  assess  the  effect  of  internal  dystrophin  deletions  on  skeletal  muscle  
functions  such  as  passive  and  contractile  force  as  well  as  calcium  regulation.  Moreover,  
genome  editing  can  be  used  to  rapidly  create  animal  models  [162]  that  could  be  applied  
to  investigate  phenotypic  outcomes,  such  as  reduction  in  centrally  nucleated  fibers,  
increased  muscle  contractility,  and  reduction  of  creatine  kinase  levels,  in  whole  
organisms  with  genetically  modified  dystrophin  genes,  including  mouse  models  
engineered  to  express  the  entire  2.4  megabase  human  dystrophin  gene  [198].    
While  this  information  will  be  valuable,  it  is  known  that  there  are  variable  
phenotypic  outcomes  in  Becker  muscular  dystrophy  (BMD)  patient  siblings  with  the  
same  underlying  mutations  in  the  dystrophin  gene  [21,  22].  This  observation  suggests  
that  there  is  uncertain  functionality  in  internally  deleted  dystrophin  proteins  that  will  be  
patient-­‐‑dependent.  However,  analysis  of  BMD  patients  with  mutations  similar  to  those  
created  by  exon  skipping,  and  by  extension  genome  editing,  suggests  that  restoration  of  
internally  deleted  dystrophin  proteins  alone  will  have  significant  therapeutic  benefit  
[22].  Thus,  in  vitro  analysis  in  human  DMD  patient  cells  and  in  vivo  analysis  in  model  
organisms  will  provide  significant  insight  into  protein  function,  but  may  not  fully  
elucidate  absolute  phenotypic  outcomes.  Nevertheless,  these  efforts  will  help  identify  
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optimal  genomic  editing  outcomes  with  strongly  predicted  functionality  of  the  corrected  
dystrophin  proteins.  
6.4. In vivo genetic correction of native dystrophin gene in mdx 
and humanized DMD mouse models 
One  of  the  most  promising  gene  therapy  strategies  for  DMD  is  to  introduce  
functional  dystrophin  expression  in  dystrophic  tissue  using  the  small  nonpathogenic  
adeno-­‐‑associated  virus.  AAV  serotype  8  (AAV8)  vectors  have  demonstrated  high  
efficiency  genome  editing  in  in  vivo  applications  to  deliver  ZFNs  to  liver  tissue  [81,  87].  
AAV  serotypes,  such  as  AAV1,  6,  8,  or  9,  have  high  muscle-­‐‑specific  tropism  that  can  be  
exploited  to  direct  in  situ  genetic  correction  by  delivering  engineered  nucleases  directly  
to  muscle  tissue  in  vivo.  Thus,  there  is  an  opportunity  to  deliver  gene  editing  nucleases  
directly  to  muscle  tissue  in  vivo  to  restore  dystrophin  expression  by  in  situ  correction.  
The  canonical  mdx  animal  model  of  DMD  carries  a  premature  stop  codon  in  exon  23  of  
the  dystrophin  gene.  Importantly,  this  exon  can  be  skipped  from  the  transcript  without  
disrupting  the  reading  frame  [199],  and  is  therefore  an  excellent  proof-­‐‑of-­‐‑principle  
model  to  test  genetic  deletion  strategies  to  delete  exons  and  restore  dystrophin  
expression  similar  to  the  approaches  in  Chapters  4  and  5.  To  expand  on  this  approach,  a  
humanized  DMD  animal  model  has  also  been  developed  that  carries  the  entire  2.4  
megabase  human  dystrophin  gene  [198]  and  will  be  useful  in  studies  investigating  gene  
targeting  of  the  human  dystrophin  gene.  However,  at  present,  these  animal  models  
express  only  functional  human  dystrophin  genes  and  do  not  recapitulate  the  mutations  
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or  phenotype  of  DMD.  Thus,  humanized  DMD  animal  models  are  currently  useful  only  
to  investigate  gene  modification  of  the  human  dystrophin  gene  in  vivo  rather  than  
serving  as  a  therapeutic  model  of  the  human  disease.  
Further  work  should  focus  on  identifying  optimal  conditions  for  creating  genetic  
modifications  in  skeletal  and  cardiac  tissue.  Two  major  parameters  to  investigate  are  the  
impact  of  AAV  serotype  and  dose  on  gene  corrections  in  muscle  and  non-­‐‑muscle  types.  
An  important  consideration  for  these  studies  will  be  to  monitor  the  ratio  of  on-­‐‑target  to  
off-­‐‑target  activity  to  balance  safety  and  efficacy.  The  use  of  muscle-­‐‑specific  promoters  
will  be  useful  in  limiting  non-­‐‑muscle  gene  correction  and  off-­‐‑target  effects,  however  
these  promoters  will  need  to  retain  activity  in  all  dystrophin-­‐‑expressing  cell  types,  
including  skeletal  and  cardiac  tissue.  Preliminary  work  suggests  evidence  that  NHEJ-­‐‑
like  gene  repair  is  evident  in  non-­‐‑dividing  skeletal  muscle  (see  Figure  30c,  Chapter  6.5).  
Further  studies  will  be  necessary  to  evaluate  the  overall  robustness  of  NHEJ  repair  
pathways  and  also  to  investigate  if  homology-­‐‑directed  repair  (HDR)  DNA  repair  
pathways  are  functional  in  non-­‐‑dividing  muscle  fibers.  Finally,  it  is  presently  not  known  
if  AAV  can  efficiently  transduce  muscle  progenitors  to  create  a  self-­‐‑renewing  pool  that  
can  repopulate  genetically  corrected  muscle  fibers  following  damage  and  repair.  Gene  
editing  offers  a  novel  method  to  probe  the  ability  of  AAV  to  efficiently  transduce  muscle  
progenitors  in  vivo  because  it  leaves  behind  a  permanent  genetic  imprint  after  expression  
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of  the  engineered  nuclease.  While  not  comprehensive,  these  studies  will  be  critical  to  
translate  engineered  nucleases  as  effective  genomic  therapies  to  treat  DMD.  
6.5. Targeted addition of dystrophin to predefined safe harbor 
genomic loci 
Our  work  demonstrates  efficient  restoration  of  the  mutant  dystrophin  reading  
frames  within  a  mutational  hotspot  that  represents  >60%  of  patient  mutations.  However,  
other  patient  mutations  can  result  in  the  loss  of  essential  exons  or  large  regions  of  the  
dystrophin  gene  that  impair  any  functionality  of  a  frame  restored  dystrophin  gene.  In  
these  cases,  restoration  of  the  reading  frame  would  be  predicted  to  have  little  or  no  effect  
on  restoring  the  functionality  of  dystrophin  in  DMD  patients.  Functional  replacement  of  
the  dystrophin  gene  by  expression  of  exogenous  dystrophin  protein  may  be  an  attractive  
complementary  method  to  address  these  rare  mutations.  To  date,  these  efforts  include  
expression  of  functional  miniaturized  or  reassembled  full-­‐‑length  dystrophin  genes  by  
transient  adeno-­‐‑associated  virus  gene  transfer  [48,  60,  200]  and  by  permanent  knock-­‐‑in  
to  the  CCR5  safe  harbor  locus  [31],  or  by  genomic  integration  of  full-­‐‑length  dystrophin  
gene  cassettes  using  the  ΦC31  integrase  [107,  201].  Other  useful  avenues  to  explore  
could  focus  on  high  efficiency  integration  of  the  entire  dystrophin  gene  into  predefined  
genomic  loci  using  engineered  site-­‐‑specific  recombinases  [109,  111,  112,  191,  202]  and  
transposases  [203,  204].  These  strategies  remain  difficult  to  implement  due  to  the  low  
efficiency  of  integration  of  large  gene  constructs  by  nuclease-­‐‑mediated  homologous  
recombination  and  difficulty  in  engineering  highly  specific  recombinases  and  
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transposases  to  ensure  high  fidelity  integration.  Thus,  the  continued  development  of  
new,  highly  specific  genome  editing  technologies,  in  combination  with  novel  gene  
transfer  vectors  specific  to  muscle  tissue,  will  be  a  valuable  component  towards  creating  
a  single,  universal,  highly  functional  correction  of  all  types  of  dystrophin  genetic  defects  
that  cause  DMD.  
Minidystrophin  proteins  have  been  designed  to  retain  maximum  functionality  
while  reducing  the  overall  size  of  the  coding  region  to  enable  efficient  gene  transfer  
using  adeno-­‐‑associated  virus  and  thus  are  of  interest  to  in  vivo  gene  correction  strategies.  
Our  preliminary  work  demonstrates  the  feasibility  of  two  genome  editing  methods  to  
introduce  minidystrophin  expression  by  promoterless  knock-­‐‑in  of  a  gene  cassette  to:  (1)  
the  safe  harbor  Rosa26  locus  in  mice  or  (2)  the  5’UTR  of  the  skeletal  muscle  isoform  
Dp427m  of  human  dystrophin.    
The  Rosa26  locus  is  an  attractive  site  to  knock-­‐‑in  a  minidystrophin  gene  cassette  
because  it  expresses  a  long  non-­‐‑coding  RNA  with  no  known  essential  functions  and  
permits  ubiquitous  expression  of  a  knocked-­‐‑in  gene  without  needing  an  exogenous  
promoter  to  drive  expression.  Previously,  we  engineered  a  highly  active  zinc-­‐‑finger  
nuclease  pair  targeting  the  Rosa26  locus  [153].  AAV-­‐‑based  gene  transfer  of  a  bicistronic  
gene  cassette  expressing  this  ZFN  pair  (AAV-­‐‑ROSA)  was  able  to  efficiently  modify  
proliferating  and  differentiated  skeletal  myoblasts  (Figures  30a,  b).  Local  injection  of  
AAV-­‐‑ROSA  into  the  tibialis  anterior  of  mice  resulted  in  efficient  gene  modification  
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(Figure  30c),  demonstrating  that  NHEJ  based  gene  repair  is  possible  in  skeletal  muscle.  
As  mentioned  in  6.4,  further  studies  are  needed  to  characterize  tissue-­‐‑specific  gene  
modification  using  systemic  delivery  methods.  As  discussed  above,  some  critical  
parameters  to  be  assessed  will  be  the  dose  and  AAV  capsid  used  to  deliver  nuclease  and  
donor  template  and  expression  levels  of  minidystrophin  from  the  Rosa26  locus.  
Ultimately,  future  studies  will  aim  to  determine  if  AAV-­‐‑delivery  of  the  Rosa26  ZFN  and  
a  minidystrophin  gene  cassette  can  restore  functional  dystrophin  expression  in  vivo  and  
improve  the  DMD  phenotype  in  the  canonical  mdx  animal  model.    
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Figure  30:  Surveyor  analysis  of  Rosa26  ZFN  activities  in  skeletal  muscle  in  
vitro  and  in  vivo  following  delivery  of  AAV-­‐‑SASTG-­‐‑ROSA.  Arrows  indicate  
expected  bands  resulting  from  Surveyor  cleavage.  n.d.:  not  detected.  (a)  Proliferating  
C2C12s  were  transduced  with  the  indicated  amount  of  virus  and  harvested  at  4  days  
% indels:    n.d.           n.d.           n.d.           n.d.           n.d.             <1            7.6 
4E9 4E8 4E7 4E6 4E5 4E4 NT 
Day 0: 
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post-­‐‑infection.  Arrows  indicate  expected  bands  sizes  resulting  from  Surveyor  
cleavage.  (b)  C2C12s  were  incubated  in  differentiation  medium  for  5  days  and  then  
transduced  with  the  indicated  amount  of  AAV-­‐‑SASTG-­‐‑ROSA  virus  in  24  well  plates.  
Samples  were  collected  at  10  days  post-­‐‑transduction.  (c)  The  indicated  amount  of  
AAV-­‐‑SASTG-­‐‑ROSA  was  injected  directly  into  the  tibialis  anterior  of  C57BL/6J  mice  
and  muscles  were  harvested  4  weeks  post-­‐‑infection.  The  harvested  TA  muscles  were  
partitioned  into  8  separate  pieces  for  genomic  DNA  analysis,  each  shown  in  a  separate  
lane.  
Using  TALENs,  we  were  able  to  isolate  monoclonal  cell  lines  expressing  a  
minidystrophin  gene  cassette  from  the  native  dystrophin  promoter  (Figure  31).  
However,  in  order  to  expand  this  as  a  viable  therapeutic  platform,  several  factors  must  
be  improved.  First,  the  overall  efficiency  of  integration  is  presently  high  but  requires  
antibiotic  selection.  Investigation  of  AAV-­‐‑based  delivery  in  vitro  and  in  vivo  will  be  
important  to  demonstrate  efficient  in  situ  knock-­‐‑in  of  minidystrophin  without  selection.  
Second,  we  observed  highly  variable  expression  levels  of  minidystrophin  in  different  
clones  (Figure  31c).  Further  studies  may  investigate  including  promoter  enhancement  




Figure  31:  TALEN  mediated  integration  of  minidystrophin  at  the  5’UTR  of  the  
Dp427m  skeletal  muscle  isoform  of  dystrophin  in  skeletal  myoblast  cell  lines  derived  
from  human  DMD  patients  carrying  different  deletions  in  the  dystrophin  gene.  DMD  
patient  cells  were  electroporated  with  constructs  encoding  a  TALEN  pair  active  at  the  
5’UTR  locus  and  a  donor  template  carrying  the  minidystrophin  gene.  (a)  Schematic  
showing  how  minidystrophin  is  integrated  into  the  5’UTR.  (b)  Hygromycin-­‐‑resistant  
clonal  cell  lines  were  isolated  and  screened  by  PCR  for  successful  site-­‐‑specific  
integrations  at  the  5’UTR  using  the  primers  shown  in  (a).  Asterisks  indicate  clones  
selected  for  further  analysis  in  (c).  (c)  Clonally  isolated  DMD  myoblasts  with  detected  
integration  events  were  differentiated  for  6  days  and  assessed  for  expression  of  an  HA  
tag  fused  to  the  C  terminus  of  minidystrophin.  
Ultimately,  these  studies  will  need  to  be  expanded  to  humanized  animal  models  
to  determine  the  efficacy  of  these  approaches  in  more  human-­‐‑like  genomic  contexts.  The  
AAVS1  locus  is  a  non-­‐‑coding  safe  harbor  locus  in  the  human  genome  similar  to  Rosa26,  
for  which  animal  models  [205]  as  well  as  well-­‐‑characterized  ZFN  pairs  [169]  exist.  
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Notably,  the  strategy  outlined  above  does  not  utilize  homology  arms  to  integrate  
minidystrophin  to  the  Rosa26  locus,  therefore  only  the  ZFN  utilized  would  need  to  be  
changed  to  adapt  this  study.  As  discussed  in  Chapter  6.3,  a  humanized  DMD  animal  
model  [198]  will  also  be  useful  in  studies  investigating  gene  targeting  of  minidystrophin  
to  the  5’UTR  in  an  animal  model.  Thus,  there  are  exciting  and  available  opportunities  to  
expand  on  the  studies  presented  in  this  thesis  to  introduce  functional  dystrophin  
expression  to  address  nearly  any  DMD  patient  deletion.  
6.6. Immunity to restored dystrophin protein products 
Rescuing  native  dystrophin  expression  will  generate  novel  protein  epitopes  at  
the  site  of  gene  correction,  as  well  as  expression  of  the  absent  C-­‐‑terminus  of  the  
dystrophin  protein.  Therefore  it  will  be  important  to  consider  potential  immune  
responses  to  restored  dystrophin  proteins  [160,  206]  following  permanent  genetic  
correction  of  the  reading  frame.  For  example,  one  clinical  study  found  pre-­‐‑existing  
dystrophin  immunity  in  approximately  29%  of  enrolled  patients  [206].  Interestingly,  this  
study  also  showed  that  commonly  used  steroid  treatments  for  DMD  may  attenuate  
potential  anti-­‐‑dystrophin  responses.  Additionally,  exon  skipping  clinical  studies  
observed  a  minimal  immune  response  to  the  restored  native  gene  product  in  DMD  
patients  with  restored  dystrophin  protein  expression  [70,  71].  The  methods  described  in  
Chapters  3-­‐‑5  result  in  modification  of  the  native  dystrophin  gene  that  may  further  
reduce  potential  immune  responses  as  compared  to  the  addition  of  foreign  components  
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contained  in  exogenous  expression  cassettes,  such  as  in  minidystrophin  gene  transfer.  
Finally,  it  may  be  possible  to  introduce  tolerance  to  restored  dystrophin  protein  
products  by  immunomodulation  [207-­‐‑209],  and  may  be  enhanced  by  transient  T-­‐‑cell  
suppression  therapy  [210].  Thus,  future  studies  will  need  to  account  for  dystrophin  





Table  5:  Exome  capture  statistics.  DOWT  is  the  parent  DMD  myoblast  cell  line  used  
as  the  reference  sample  for  analysis.  DO32,  DO106,  DO127,  and  DO141  are  the  four  
clonally  derived  DMD  myoblast  lines  carrying  predetermined  on-­‐‑target  NHEJ  events  
at  the  exon  51  dystrophin  locus.  
 
Table  6: Target  sequences  and  RVDs  for  TALENs  in  this  study.  All  target  
sequences  are  preceded  by  a  prerequisite  5’-­‐‑T.  
 Target sequence (5'-3') RVDs 
TN1 attttagctcctact NI NG NG NG NG NI NN HD NG HD HD NG NI HD NG 
TN2 tttagctcctactcaga NG NG NG NI NN HD NG HD HD NG NI HD NG HD NI NN NI 
TN3 agctcctactcagact NI NN HD NG HD HD NG NI HD NG HD NI NN NI HD NG 
TN4 cctactcagactgtt HD HD NG NI HD NG HD NI NN NI HD NG NN NG NG 
TN5 aaccacaggttgtgtca NI NI HD HD NI HD NI NN NN NG NG NN NG NN NG HD NI 
TN6 agtaaccacaggttgt NI NN NG NI NI HD HD NI HD NI NN NN NG NG NN NG 




Table  7:  Summary  of  target  sites  for  ZFNs  targeted  in  Chapter  5.  
ZFN  target   Target  site   Spacer  length  
(bp)  
DZF-­‐‑1   5'ʹ-­‐‑CAA  ACT  AGA  AAT  GCC  ATC  TTCCTT  GAT  GTT  GGA  GGT  ACC  TGC   6  
     3'ʹ-­‐‑GTT  TGA  TCT  TTA  CGG  TAG  AAGGAA  CTA  CAA  CCT  CCA  TGG  ACG       
DZF-­‐‑2   5'ʹ-­‐‑ATG  ATC  ATC  AAG  CAG  AAG  GTATGA  GAA  AAA  ATG  ATA  AAA  GTT   6  
     3'ʹ-­‐‑TAC  TAG  TAG  TTC  GTC  TTC  CATACT  CTT  TTT  TAC  TAT  TTT  CAA       
DZF-­‐‑3   5'ʹ-­‐‑GAC  TGT  TAC  TCT  GGT  GAC  ACAACCT  GTG  GTT  ACT  AAG  GAA  ACT   7  
     3'ʹ-­‐‑CTG  ACA  ATG  AGA  CCA  CTG  TGTTGGA  CAC  CAA  TGA  TTC  CTT  TGA       
DZF-­‐‑4   5'ʹ-­‐‑CTT  TAC  CAC  TTC  CAC  AAT  GTATATG  ATT  GTT  ACT  GAG  AAG  GCT   7  
     3'ʹ-­‐‑GAA  ATG  GTG  AAG  GTG  TTA  CATATAC  TAA  CAA  TGA  CTC  TTC  CGA       
DZF-­‐‑5   5'ʹ-­‐‑CAC  ATT  CAC  ATT  CAC  AATATA  GTT  ATG  GAT  ATG  GAT  GTA   6  
     3'ʹ-­‐‑GAG  TAA  GTG  TAA  GTG  TTATAT  CAA  TAC  CTA  TAC  CTA  CAT       
DZF-­‐‑6   5'ʹ-­‐‑AAC  TTC  ACC  AAT  TCCATA  GGA  ATA  AAA  GTA  ATT  TGA   6  
     3'ʹ-­‐‑TTG  AAG  TGG  TTA  AGGTAT  CCT  TAT  TTT  CAT  TAA  ACT       
DZF-­‐‑7   5'ʹ-­‐‑AAC  CCC  ATC  AAAAAGT  GGG  GGA  AGG   7  
     3'ʹ-­‐‑TTG  GGG  TAG  TTTTTCA  CCC  CCT  TCC       
DZF-­‐‑8   5'ʹ-­‐‑ATC  ATC  TCC  TCTGGTG  GAT  GAG  GCT   7  
     3'ʹ-­‐‑TAG  TAG  AGG  AGACCAC  CTA  CTC  CGA       
DZF-­‐‑9   5'ʹ-­‐‑ATC  TGC  CCA  TGACT  GGC  GCA  GGG   5  
     3'ʹ-­‐‑TAG  ACG  GGT  ACTGA  CCG  CGT  CCC       
DZF-­‐‑10   5'ʹ-­‐‑GCC  ATC  TTC  CTTGAT  GTT  GGA  GGT   6  
     3'ʹ-­‐‑CGG  TAG  AAG  GAACTA  CAA  CCT  CCA       
DZF-­‐‑11   5'ʹ-­‐‑TGC  TTC  AGC  CTCCTGA  GTA  GCT  GGG   7  
     3'ʹ-­‐‑ACG  AAG  TCG  GAGGACT  CAT  CGA  CCC       
DZF-­‐‑12   5'ʹ-­‐‑GCC  TCA  GCC  TCCCAAA  GTG  GTG  GGA   7  
     3'ʹ-­‐‑CGG  AGT  CGG  AGGGTTT  CAC  CAC  CCT       
DZF-­‐‑13   5'ʹ-­‐‑CTC  AGC  CTC  CCAAA  GTG  GTG  GGA   5  
     3'ʹ-­‐‑GAG  TCG  GAG  GGTTT  CAC  CAC  CCT       
  
Table  8:  Sequences  of  zinc-­‐‑finger  recognition  helices  to  supplement  Barbas  
modular  assembly  kit.  
Triplet  target   Helix  sequence   Source  
TGC   QRNALAG   ZiFiT  F3  ID  #631  
TCT   QQRSLVG   ZiFiT  F3  ID  #790  
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Table  9:  Primers  used  in  the  study  in  Chapter  4.  
Primer  name   Primer  sequence   Notes  
CelI-­‐‑DZF-­‐‑1/3/10-­‐‑F   GAGTTTGGCTCAAATTGTTACTCTT   Forward  Surveyor  primer  for  DZF-­‐‑1,  
DZF-­‐‑3  and  DZF-­‐‑10  
CelI-­‐‑DZF-­‐‑1/3/10-­‐‑R   GGGAAATGGTCTAGGAGAGTAAAGT   Reverse  Surveyor  primer  for  DZF-­‐‑1,  
DZF-­‐‑3  and  DZF-­‐‑10  
CelI-­‐‑DZF-­‐‑4/5/6-­‐‑F   CCTCAGTGTAATCCATTTGGTAAAA   Forward  Surveyor  primer  forDZF-­‐‑4,  
DZF-­‐‑5  and  DZF-­‐‑6  
CelI-­‐‑DZF-­‐‑4-­‐‑R   CTGCTACTTACTGGGAATTTGACAT   Reverse  Surveyor  primer  for  DZF-­‐‑4  
CelI-­‐‑DZF-­‐‑5/6-­‐‑R   CAAAGTTGTGCTGAAGGTATTTAGG   Reverse  Surveyor  primer  for  DZF-­‐‑5  
and  DZF-­‐‑6  
CelI-­‐‑DZF-­‐‑7-­‐‑F   AACCATTGGAATTTACAGGATGAT   Forward  Surveyor  primer  for  DZF-­‐‑7  
CelI-­‐‑DZF-­‐‑7-­‐‑R   GGCTGAGTTAAATGGTATTTCTGG   Reverse  Surveyor  primer  for  DZF-­‐‑7  
CelI-­‐‑DZF-­‐‑8-­‐‑F   ACTTGCACCTCATTCTAATTGTGA   Forward  Surveyor  primer  for  DZF-­‐‑8  
CelI-­‐‑DZF-­‐‑8-­‐‑R   CCTCCTACCTGAATGTTAGAGACAA   Reverse  Surveyor  primer  for  DZF-­‐‑8  
CelI-­‐‑DZF-­‐‑9-­‐‑F   GATGCAAGAGATAGAGCAGTGAGA   Forward  Surveyor  primer  for  DZF-­‐‑9  
CelI-­‐‑DZF-­‐‑9-­‐‑R   GTTTGGAAAAAGACAGAAAGGAAG   Reverse  Surveyor  primer  for  DZF-­‐‑9  
CelI-­‐‑DZF-­‐‑11-­‐‑F   CCAATGACTTAAGGTTTCTTCACA   Forward  Surveyor  primer  for  DZF-­‐‑11  
CelI-­‐‑DZF-­‐‑11-­‐‑R   CTGAATCATTGATGAAAAAGACCA   Reverse  Surveyor  primer  for  DZF-­‐‑11  
CelI-­‐‑DZF-­‐‑12/13-­‐‑F   CCAACATGAGACTTTCTTTTTGTTT   Forward  Surveyor  primer  for  DZF-­‐‑12  
and  DZF-­‐‑13  
CelI-­‐‑DZF-­‐‑12/13-­‐‑R   AGCTGGAATATGCTTTTACTTTCC   Reverse  Surveyor  primer  for  DZF-­‐‑12  
and  DZF-­‐‑13  
Dys-­‐‑E44-­‐‑F   TGGCGGCGTTTTCATTAT   Forward  RT-­‐‑PCR  primer  binding  in  
exon  44  
Dys-­‐‑E52-­‐‑R   TTCGATCCGTAATGATTGTTCTAGCC   Reverse  RT-­‐‑PCR  primer  binding  in  
exon  52  






























Reverse  primer  to  construct  SSA  
luciferase  
DZF1-­‐‑OT-­‐‑1-­‐‑F   CATGCTAGCTCCTACAAAGCACTG   Forward  Surveyor  primer  for  DZF-­‐‑1  
off-­‐‑target  site  1  
DZF1-­‐‑OT-­‐‑1-­‐‑R   GGGAAATGGGTACTGAAGAAGACG   Reverse  Surveyor  primer  for  DZF-­‐‑1  
off-­‐‑target  site  1  
DZF1-­‐‑OT-­‐‑2-­‐‑F   CTGTGCTGCCTATTGCTTTCTGTC   Forward  Surveyor  primer  for  DZF-­‐‑1  
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off-­‐‑target  site  2  
DZF1-­‐‑OT-­‐‑2-­‐‑R   CTGGTTGTGTGCCTAGTGATGG   Reverse  Surveyor  primer  for  DZF-­‐‑1  
off-­‐‑target  site  2  
DZF1-­‐‑OT-­‐‑3-­‐‑F   CCCATTACTGCATTTGCGGTCTTG   Forward  Surveyor  primer  for  DZF-­‐‑1  
off-­‐‑target  site  3  
DZF1-­‐‑OT-­‐‑3-­‐‑R   TCAACCTTGCCTGCACGGAG   Reverse  Surveyor  primer  for  DZF-­‐‑1  
off-­‐‑target  site  3  
DZF1-­‐‑OT-­‐‑4-­‐‑F   CCTCTTCTCTTGGGATCTGTGAGT   Forward  Surveyor  primer  for  DZF-­‐‑1  
off-­‐‑target  site  4  
DZF1-­‐‑OT-­‐‑4-­‐‑R   GAGAACCCAATGTAATGTGTTCACTGAGC   Reverse  Surveyor  primer  for  DZF-­‐‑1  
off-­‐‑target  site  4  
DZF1-­‐‑OT-­‐‑5-­‐‑F   AAAGACACCTTTTCTGCCCTCACG   Forward  Surveyor  primer  for  DZF-­‐‑1  
off-­‐‑target  site  5  
DZF1-­‐‑OT-­‐‑5-­‐‑R   GTGCCCAGCCCAATTCTTTCTTGC   Reverse  Surveyor  primer  for  DZF-­‐‑1  
off-­‐‑target  site  5  
DZF1-­‐‑OT-­‐‑6-­‐‑F   GGTCCTGGTCCAAAGCAATTCTG   Forward  Surveyor  primer  for  DZF-­‐‑1  
off-­‐‑target  site  6  
DZF1-­‐‑OT-­‐‑6-­‐‑R   CGCCCGGCCAGATTTGTCTA   Reverse  Surveyor  primer  for  DZF-­‐‑1  
off-­‐‑target  site  6  
DZF1-­‐‑OT-­‐‑7-­‐‑F   CCACACACACAGGACACTGATC   Forward  Surveyor  primer  for  DZF-­‐‑1  
off-­‐‑target  site  7  
DZF1-­‐‑OT-­‐‑7-­‐‑R   CCAGAAGGCAGCCACTAGAAAC   Reverse  Surveyor  primer  for  DZF-­‐‑1  
off-­‐‑target  site  7  
DZF1-­‐‑OT-­‐‑8-­‐‑F   CTAGAATTACAGGCGTGAGCCACT   Forward  Surveyor  primer  for  DZF-­‐‑1  
off-­‐‑target  site  8  
DZF1-­‐‑OT-­‐‑8-­‐‑R   GCAGCTGAGTTGCAGGCATAAG   Reverse  Surveyor  primer  for  DZF-­‐‑1  
off-­‐‑target  site  8  
DZF9-­‐‑OT-­‐‑1-­‐‑F   ACGTTCCTGGGAAACACAGGG   Forward  Surveyor  primer  for  DZF-­‐‑9  
off-­‐‑target  site  1  
DZF9-­‐‑OT-­‐‑1-­‐‑R   CCACCAAAAGGCAGCTCCATAAAC   Reverse  Surveyor  primer  for  DZF-­‐‑9  
off-­‐‑target  site  1  
DZF9-­‐‑OT-­‐‑2-­‐‑F   GCACAGGGTACACACCCATTAAC   Forward  Surveyor  primer  for  DZF-­‐‑9  
off-­‐‑target  site  2  
DZF9-­‐‑OT-­‐‑2-­‐‑R   AGTCTCTCCATCCCCGAGGT   Reverse  Surveyor  primer  for  DZF-­‐‑9  
off-­‐‑target  site  2  
DZF9-­‐‑OT-­‐‑3-­‐‑F   CTGGTTTCTGCACCACATATTGCC   Forward  Surveyor  primer  for  DZF-­‐‑9  
off-­‐‑target  site  3  
DZF9-­‐‑OT-­‐‑3-­‐‑R   CACATGGCCGGCAGGAGAAA   Reverse  Surveyor  primer  for  DZF-­‐‑9  
off-­‐‑target  site  3  
DZF9-­‐‑OT-­‐‑4-­‐‑F   AAAAGGGAGCAGGTCAGCACAC   Forward  Surveyor  primer  for  DZF-­‐‑9  
off-­‐‑target  site  4  
DZF9-­‐‑OT-­‐‑4-­‐‑R   GGGGGAATTTGGGGAAACTTTCCT   Reverse  Surveyor  primer  for  DZF-­‐‑9  
off-­‐‑target  site  4  
DZF9-­‐‑OT-­‐‑5-­‐‑F   TGAGTCAGATGGCCCAGGGA   Forward  Surveyor  primer  for  DZF-­‐‑9  
off-­‐‑target  site  5  
DZF9-­‐‑OT-­‐‑5-­‐‑R   CTTGGAGCCTCCACAGGTGA   Reverse  Surveyor  primer  for  DZF-­‐‑9  
off-­‐‑target  site  5  
DZF9-­‐‑OT-­‐‑6-­‐‑F   TGGACTGAGGGAACCCCTCT   Forward  Surveyor  primer  for  DZF-­‐‑9  
off-­‐‑target  site  6  
DZF9-­‐‑OT-­‐‑6-­‐‑R   CAGATTCCCAGGGAAGCTCG   Reverse  Surveyor  primer  for  DZF-­‐‑9  
off-­‐‑target  site  6  
DZF9-­‐‑OT-­‐‑7-­‐‑F   GCGCGCTCGGGTGAAAAAATTAAG   Forward  Surveyor  primer  for  DZF-­‐‑9  
off-­‐‑target  site  7  
DZF9-­‐‑OT-­‐‑7-­‐‑R   TCCCCTTCTTCCACCTCCAG   Reverse  Surveyor  primer  for  DZF-­‐‑9  
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off-­‐‑target  site  7  
DZF9-­‐‑OT-­‐‑8-­‐‑F   GGCTCCCCTCCTTGTTAATGTTG   Forward  Surveyor  primer  for  DZF-­‐‑9  
off-­‐‑target  site  8  
DZF9-­‐‑OT-­‐‑8-­‐‑R   AGTGAGGACGATGACCAGCG   Reverse  Surveyor  primer  for  DZF-­‐‑9  





Table  10:  List  of  sgRNA  targets  in  Chapter  5.  PAM:  protospacer-­‐‑adjacent  motif.  
Name   Target   Strand   19bp  protospacer   PAM   Target  Finder  
CR1   Intron  50   +   GATTGGCTTTGATTTCCCTA   GGG   Manual  Inspection  
CR2   Intron  50   -­‐‑   GTGTAGAGTAAGTCAGCCTA   TGG   Manual  Inspection  
CR3   Exon  51-­‐‑5'ʹ   +   GCCTACTCAGACTGTTACTC   TGG   Manual  Inspection  
CR4   Exon  51-­‐‑3'ʹ   +   GTTGGACAGAACTTACCGAC   TGG   Manual  Inspection  
CR5   Intron  51   -­‐‑   GCAGTTGCCTAAGAACTGGT   GGG   Manual  Inspection  
CR6   Intron  44   -­‐‑   GGGGCTCCACCCTCACGAGT   GGG   UCSC  Browser  (Cong  et  al.  Science  
2013)  
CR7   Intron  55   +   GTTTGCTTCGCTATAAAACG   AGG  
UCSC  Browser  (Cong  et  al.  Science  
2013)  
CR10   Exon  45   +   GCCAGGATGGCATTGGGCAG   CGG   Manual  Inspection  
CR11   Exon  45   +   GCTGAATCTGCGGTGGCAGG   AGG   Manual  Inspection  
CR12   Exon  46   -­‐‑   GTTCTTTTGTTCTTCTAGCC   TGG   Manual  Inspection  
CR13   Exon  46   +   GGAAAAGCTTGAGCAAGTCA   AGG   Manual  Inspection  
CR14   Exon  47   +   GGAAGAGTTGCCCCTGCGCC   AGG   Excel  File  from  Mali  et  al.  Science  
2013  
CR15   Exon  47   +   GACAAATCTCCAGTGGATAA   AGG   Manual  Inspection  
CR16   Exon  48   -­‐‑   GTGTTTCTCAGGTAAAGCTC   TGG   Manual  Inspection  
CR17   Exon  48   +   GGAAGGACCATTTGACGTTA   AGG   Manual  Inspection  
CR18   Exon  49   -­‐‑   GAACTGCTATTTCAGTTTCC   TGG   Manual  Inspection  
CR19   Exon  49   +   GCCAGCCACTCAGCCAGTGA   AGG   Manual  Inspection  
CR20   Exon  50   +   GGTATGCTTTTCTGTTAAAG   AGG   Manual  Inspection  
CR21   Exon  50   +   GCTCCTGGACTGACCACTAT   TGG   Manual  Inspection  
CR22   Exon  52   +   GGAACAGAGGCGTCCCCAGT   TGG   Manual  Inspection  
CR23   Exon  52   +   GGAGGCTAGAACAATCATTA   CGG   Manual  Inspection  
CR24   Exon  53   +   GACAAGAACACCTTCAGAAC   CGG   Manual  Inspection  
CR25   Exon  53   -­‐‑   GGGTTTCTGTGATTTTCTTT   TGG   Manual  Inspection  
CR26   Exon  54   +   GGGCCAAAGACCTCCGCCAG   TGG   Manual  Inspection  
CR27   Exon  54   +   GTTGGAGAAGCATTCATAAA   AGG   Manual  Inspection  
CR28   Exon  55   -­‐‑   GTCGCTCACTCACCCTGCAA   AGG   Manual  Inspection  
CR29   Exon  55   +   GAAAAGAGCTGATGAAACAA   TGG   Manual  Inspection  
CR31   Exon  51   +   GGAGATGATCATCAAGCAGA   AGG   Manual  Inspection  
CR33   Intron  44   -­‐‑   GCACAAAAGTCAAATCGGAA   TGG  
UCSC  Browser  (Cong  et  al.  Science  
2013)  
CR34   Intron  44   -­‐‑   GATTTCAATATAAGATTCGG   AGG  
UCSC  Browser  (Cong  et  al.  Science  
2013)  
CR35   Intron  55   -­‐‑   GCTTAAGCAATCCCGAACTC   TGG  
UCSC  Browser  (Cong  et  al.  Science  
2013)  
CR36   Intron  55   -­‐‑   GCCTTCTTTATCCCCTATCG   AGG  




Figure  32:  Images  of  TBE-­‐‑PAGE  gels  used  to  quantify  Surveyor  assay  results  to  
measure  day  3  gene  modification  in  Table  3.  Asterisks  mark  expected  sizes  of  bands  
indicative  of  nuclease  activity.  
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Supplementary Figure 1: Images of TBE-PAGE gels used to quantify Surveyor assay results to 




Figure  33:  Images  of  TBE-­‐‑PAGE  gels  used  to  quantify  Surveyor  assay  results  to  
measure  day  10  gene  modification  in  Table  3.  Asterisks  mark  expected  sizes  of  bands  
indicative  of  nuclease  activity.  
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Supplementary Figure 2: Images of TBE-PAGE gels used to quantify Surveyor assay results to 
measure day 10 gene modification in Table 1. Asterisks mark expected sizes of bands indicative 




Figure  34:  Images  of  TBE-­‐‑PAGE  gels  used  to  quantify  Surveyor  assay  results  to  
measure  on-­‐‑target  and  off-­‐‑target  gene  modification  in  Table  4.  Asterisks  mark  




Supplementary Figure 5 - Images of TBE-PAGE gels used to quantify Surveyor assay results to 
easure on-target and off-target gene modification in Supplementary Table 2. Asterisks mark 
expected sizes of bands indicative of nuclease activ ty.
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